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Abstract 
The dysregulation of RNAs has global effects on all cellular pathways. The regulation 
of RNA metabolism is thus tightly controlled. Terminal RNA nucleotidyltransferases 
(TENTs) regulate RNA stability and activity through the addition of non-templated 
nucleotides to the 3′-end. TENT-catalyzed adenylation and uridylation have opposing 
effects; adenylation stabilizes while uridylation silences or degrades RNA. All TENT 
homologs were initially characterized as adenylyltransferases; the identification of 
caffeine-induced death suppressor protein 1 (Cid1) in Schizosaccharomyces pombe as an 
uridylyltransferase led to the reclassification of many TENTs as uridylyltransferases. 
Cid1 uridylates mRNAs that are subsequently degraded by the exonuclease Dis-like 3′-5′ 
exonuclease 2 (Dis3L2), while the human homolog germline-development 2 (Gld2) has 
been associated with adenylation of mRNAs and miRNAs and uridylation of Group II 
pre-miRNAs. Mechanisms regulating these enzymes and the extent of TENT activity on 
cellular RNA homeostasis remain largely unknown. In this thesis, the regulation of 
human Gld2 and the role of the yeast Cid1/Dis3L2-mediated RNA decay pathway were 
investigated. An enzyme kinetic study revealed that Gld2 is a true adenylyltransferase 
with only weak activity for UTP. A detailed phylogenetic analysis revealed that 
uridylyltransferases arose multiple times during evolution through a single histidine 
insertion in the active site of adenylyltransferases. Insertion of the critical histidine into 
Gld2 changed its nucleotide preference from ATP to UTP. Next, the regulation of Gld2 
through site-specific phosphorylation in the predicted disordered N-terminal domain was 
investigated using phosphomimetic substitutions at specific serine (S) residues. Two sites 
(S62, S110) increased Gld2 activity while one site (S116) drastically reduced 3′-
adenylation activity. Mass spectrometry and in vitro activity assays identified protein 
kinases A (PKA) and B (Akt1) as kinases that specifically phosphorylate Gld2 at S116 to 
obliterate nucleotide addition activity similarly to the S116E phosphomimetic mutant. 
Finally, RNA deep sequencing of cid1 and dis3L2 S. pombe deletion strains revealed that 
the role of Cid1 is redundant in uridylation-dependent mRNA decay while Dis3L2 is the 
bottleneck to RNA decay. Deletion of either gene increases the accumulation of 
misfolded proteins but only the dis3L2 deletion up-regulates stress response proteins. 
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Overall, this thesis demonstrates how terminal nucleotidyltransferases regulate RNA 
stability.  
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Summary for Lay Audience 
Ribonucleic acids (RNAs) play important roles in protein production and regulating 
cellular processes such as cell proliferation. Dysregulation of RNA expression, 
maturation, and/or degradation is associated with multiple human diseases such as cancer 
and cardiovascular disease. RNAs can be regulated through the addition of adenine or 
uridine nucleotides to its 3’-end. The proteins that perform these additions are known as 
terminal RNA nucleotidyltransferases (TENTs). All TENTs were initially thought to add 
adenine residues (adenylyltranferases), but more extensive studies revealed that some 
TENTs preferred to add uridine residues (uridylyltransferases). The addition of adenine is 
associated with stability while uridine addition is associated with silencing/degradation. 
Thus, the simple addition of different nucleotides can change the fate of an RNA 
molecule. The yeast TENT uridylates RNAs which are recognized and degraded by the 
exonuclease Dis-like 3′-5′ exonuclease 2 (Dis3L2). On the other hand, its human 
counterpart, germline-development 2 (Gld2), has been associated with RNA adenylation 
and uridylation. Mechanisms regulating these proteins and the extent of TENT activity on 
cellular RNA homeostasis remain largely unknown. In this thesis, the regulation of 
human Gld2 and the role of the yeast Cid1/Dis3L2-mediated RNA decay pathway were 
investigated. First, Gld2 was shown to be a true adenylyltransferase. The simple insertion 
or deletion of the amino acid histidine in the active site was shown to change the 
nucleotide preference of TENTs. Secondly, Gld2 was shown to be regulated through 
phosphorylation of specific serine residues (S). Two sites (S62, S110) increased Gld2 
activity while one site (S116) drastically reduced activity. Two cancer-related kinases, 
protein kinases A (PKA) and B (Akt1), were identified to phosphorylate Gld2 at S116 to 
obliterate nucleotide addition activity. This discovery provided the first link between 
cancer-related kinases and RNA regulation. Finally, deletion of either the Cid1 or Dis3L2 
genes in yeast revealed that Cid1 is redundant in uridylation-dependent mRNA decay 
while Dis3L2 is the bottleneck to RNA decay. Deletion of the Dis3L2 gene elicited a 
larger change in the RNA population. Overall, this thesis demonstrates how terminal 
nucleotidyltransferases regulate RNA stability.  
 
v 
 
Co-Authorship Statement 
Chapter 1 
 Sections of the text and some figures were adapted from the published review titled 
“Tipping the balance of RNA stability by 3′ editing of the transcriptome.” The review is 
co-authored by Christina Z. Chung, Lauren E. Seidl, and Mitchell R. Mann. All authors 
contributed to creating the figures and writing the manuscript. 
Chung CZ*, Seidl LE*, Mann MR*, & Heinemann IU. 2017. Tipping the balance of 
RNA stability by 3′ editing of the transcriptome. Biochimica et Biophysica Acta. 1861: 
2971-2979 (*These authors contributed equally). 
Chapter 2 
Text and figures are from the published paper titled “Nucleotide specificity of the human 
terminal nucleotidyltransferase Gld2 (TUT2).” David H.S. Jo constructed the wildtype 
Gld2 expression plasmid and contributed to the phylogenetic analysis. Ilka U. Heinemann 
performed the phylogenetic analysis and sequence alignment. All other experiments were 
carried out by Christina Z. Chung. Both I.U. Heinemann and C.Z. Chung contributed to 
the writing of the manuscript.                                           
Chung CZ, Jo DHS, & Heinemann IU. 2016. Nucleotide specificity of the human 
terminal nucleotidyltransferase Gld2 (TUT2). RNA N. Y. N. 22(8): 1239-1249. 
Chapter 3 
Text and figures are from the published paper titled “Gld2 activity is regulated by 
phosphorylation in the N-terminal domain.” Patrick O’Donoghue performed the multiple 
sequence alignment and Xuguang Liu carried out the mass spectrometry analysis. Nileeka 
Balasuriya cloned, expressed, and purified all the Akt1 variants and performed the dot 
plot kinase activity assays. All other experiments were carried out by Christina Z. Chung. 
C.Z. Chung, N. Balasuriya, X. Liu, P. O’Donoghue, and I.U. Heinemann contributed to 
the writing of the manuscript. 
 
vi 
 
Chung CZ, Balasuriya N, Manni E, Liu X, Li SSC, O’Donoghue P, & Heinemann IU. 
2019. Gld2 activity is regulated by phosphorylation in the N-terminal domain. RNA Biol. 
doi:10.1080/15476286.2019.1608754. 
Chapter 4 
Text and figures are from the published paper titled “RNA surveillance by uridylation-
dependent RNA decay in Schizosaccharomyces pombe.” David H.S. Jo cloned the Cid1 
expression plasmid and performed the cRACE experiment. D.H.S. Jo, Julia E. Jaramillo, 
Lauren E. Seidl, Matthew A. Turk, and Christina Z. Chung purified Cid1. The Cid1 
activity assay was performed by C.Z. Chung and L.E. Seidl and the yeast spotting assays 
were performed by Daniel Y.N. Bour. The Northern blots were performed by J.E. 
Jaramillo and Yumin Bi and the RT-qPCR by C.Z. Chung and J.E. Jaramillo. C.Z. Chung 
performed the sedimentation assay and western blot and Ilka U. Heinemann carried out 
the RNA sequencing and data analysis. Michael J. Ellis contributed to the analysis of the 
sequencing data. All authors contributed to the writing of the manuscript. 
Chung CZ*, Jaramillo JE*, Ellis MJ, Bour DYN, Seidl LE, Jo DHS, Turk MA, Mann 
MR, Bi Y, Haniford DB, Duennwald ML, & Heinemann IU. 2018. RNA surveillance by 
uridylation-dependent RNA decay in Schizosaccharomyces pombe. Nucleic Acids Res. 
47(6): 3045-3057 (*These authors contributed equally). 
 
 
vii 
 
Dedication 
 
 
 
For my loving and supportive parents, Betsy and Lawrence Chung. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
Acknowledgements 
I would like to thank my supervisor Dr. Ilka U. Heinemann for her support and 
guidance. Her enthusiasm and optimism have continuously pushed me forward and I am 
grateful for all the opportunities she has given me.  
Many thanks to my advisory committee, Dr. Murray Junop, Dr. Stanley Dunn, and 
Dr. David Haniford, for their guidance and suggestions. 
All members of the Heinemann lab, past and present, have my thanks for making my 
time there enjoyable and all the amazing discussions. Special thanks to Dr. Patrick 
O’Donoghue and all the past and present members of the O’Donoghue lab for all the 
support over the years.   
Finally, many people in the Biochemistry department have helped me from my time 
there as an undergraduate student. I would like to extend my thanks to all of you. 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
Table of Contents 
Abstract ............................................................................................................................... ii 
Summary for Lay Audience ............................................................................................... iv 
Co-Authorship Statement.................................................................................................... v 
Dedication ......................................................................................................................... vii 
Acknowledgements .......................................................................................................... viii 
Table of Contents ............................................................................................................... ix 
List of Tables .................................................................................................................... xv 
List of Figures .................................................................................................................. xvi 
List of Appendices ......................................................................................................... xviii 
List of Abbreviations ........................................................................................................ xx 
Chapter 1 ............................................................................................................................. 1 
1 Introduction .................................................................................................................... 1 
1.1 Central Dogma of Molecular Biology .................................................................... 1 
1.2 Regulation of mRNA .............................................................................................. 3 
1.2.1 mRNA transcription in eukaryotes ............................................................. 3 
1.2.2 Role of the poly(A) tail ............................................................................... 5 
1.2.3 5′-3′ and 3′-5′ degradation of mRNAs ........................................................ 6 
1.3 miRNAs: Functions in Gene Expression .............................................................. 10 
1.3.1 Role of miRNAs in regulating gene expression ....................................... 10 
1.3.2 miRNA maturation pathway ..................................................................... 11 
1.3.3 Regulation of miRNA through untemplated nucleotide addition ............. 12 
1.4 Terminal RNA Nucleotidyltransferases ................................................................ 15 
1.4.1 Adenylation vs. uridylation ....................................................................... 16 
1.4.2 Human uridylyltransferases ...................................................................... 18 
 
x 
 
1.4.3 Gld2, the minimal human nucleotidyltransferase ..................................... 20 
1.4.4 The founder uridylyltransferase Cid1 ....................................................... 21 
1.5 Scope of Thesis ..................................................................................................... 22 
1.6 References ............................................................................................................. 24 
Chapter 2 ........................................................................................................................... 34 
2 Nucleotide specificity of the human terminal nucleotidyltransferase Gld2 (TUT2) ... 34 
2.1 Introduction ........................................................................................................... 34 
2.2 Materials and Methods .......................................................................................... 37 
2.2.1 Gld2 cloning and site-directed mutagenesis ............................................. 37 
2.2.2 Gld2 expression and purification .............................................................. 38 
2.2.3 Size exclusion chromatography ................................................................ 38 
2.2.4 RNA substrate preparation ........................................................................ 39 
2.2.5 Determination of enzymatic activity and substrate range ......................... 40 
2.2.6 Determination of enzyme kinetics ............................................................ 40 
2.2.7 Phylogenetic analysis ................................................................................ 41 
2.3 Results ................................................................................................................... 41 
2.3.1 Gld2 displays RNA substrate promiscuity ................................................ 41 
2.3.2 Nucleotide preference of recombinant Gld2 ............................................. 43 
2.3.3 Gld2 is an adenylyltransferase .................................................................. 44 
2.3.4 Nucleotidyltransferase specificity arose multiple times during 
evolution ................................................................................................... 46 
2.3.5 Insertion of a histidine residue confers UTP specificity ........................... 48 
2.4 Discussion ............................................................................................................. 51 
2.4.1 Gld2 is an adenylyltransferase .................................................................. 51 
2.4.2 Gld2 monoadenylates small RNA substrates ............................................ 53 
 
xi 
 
2.4.3 Convergent evolution of Tutase activity by histidine insertion in the 
PAP active site .......................................................................................... 54 
2.5 Acknowledgements ............................................................................................... 56 
2.6 References ............................................................................................................. 56 
Chapter 3 ........................................................................................................................... 60 
3 Gld2 activity is regulated by phosphorylation in the N-terminal domain .................... 60 
3.1 Introduction ........................................................................................................... 60 
3.2 Materials and Methods .......................................................................................... 63 
3.2.1 Multiple sequence alignment .................................................................... 63 
3.2.2 Plasmids .................................................................................................... 64 
3.2.3 Gld2 protein production and purification ................................................. 64 
3.2.4 Western blotting ........................................................................................ 64 
3.2.5 Nucleotide addition assay ......................................................................... 65 
3.2.6 Fluorescence anisotropy............................................................................ 65 
3.2.7 Identification of potential kinases ............................................................. 66 
3.2.8 Dot plot kinase activity assays .................................................................. 66 
3.2.9 Kinase activity assays using SDS gels ...................................................... 66 
3.2.10 Isolation of phosphorylated Gld2 for downstream assays ........................ 67 
3.2.11 Phosphorylation of Gld2 using HEK 293 cell extract .............................. 67 
3.2.12 Mass spectrometry .................................................................................... 68 
3.3 Results ................................................................................................................... 68 
3.3.1 Phosphorylation of the Gld2 N-terminal domain by HEK 293 cells ........ 69 
3.3.2 Gld2 N-terminal domain phosphomimetic variants regulate catalytic 
activity....................................................................................................... 71 
3.3.3 Gld2 phosphomimetic substitutions impact RNA substrate affinity ........ 73 
3.3.4 PKA and Akt1 site-specifically phosphorylate Gld2 at S116 ................... 75 
 
xii 
 
3.3.5 Phosphorylation of Gld2 at S116 abolishes nucleotide addition activity . 78 
3.4 Discussion ............................................................................................................. 79 
3.4.1 Gld2 activity is regulated by phosphorylation .......................................... 79 
3.4.2 Oncogenic protein kinases signal to miRNA regulation........................... 82 
3.4.3 Relevance of Akt1-dependent regulation of miRNAs to disease ............. 83 
3.4.4 Conclusion ................................................................................................ 84 
3.5 Acknowledgements ............................................................................................... 85 
3.6 References ............................................................................................................. 85 
Chapter 4 ........................................................................................................................... 90 
4 RNA surveillance by uridylation-dependent RNA decay in Schizosaccharomyces 
pombe ........................................................................................................................... 90 
4.1 Introduction ........................................................................................................... 90 
4.2 Materials and Methods .......................................................................................... 93 
4.2.1 Yeast strains and growth conditions ......................................................... 93 
4.2.2 Spotting assays .......................................................................................... 94 
4.2.3 Cid1 cloning, purification, and activity assays ......................................... 94 
4.2.4 Circular rapid amplification of cDNA ends (cRACE) and Northern 
blotting ...................................................................................................... 95 
4.2.5 RT-qPCR................................................................................................... 96 
4.2.6 Yeast sedimentation assay and Western blot ............................................ 96 
4.2.7 RNA sequencing and data analysis ........................................................... 97 
4.3 Results ................................................................................................................... 97 
4.3.1 Recombinant Cid1 displays ambiguous substrate specificity in vitro ...... 97 
4.3.2 RNA uridylation is prominent in wildtype S. pombe and a cid1 
deletion strain ............................................................................................ 99 
4.3.3 Deletion of the Dis3L2 exonuclease elicits changes in the 
transcriptome........................................................................................... 100 
 
xiii 
 
4.3.4 Deletion of dis3L2 confers resistance to hydroxyurea, whereas deletion 
of cid1 increases sensitivity to protein misfolding stress........................ 106 
4.3.5 Deletion of dis3L2 and cid1 causes the accumulation of misfolded 
proteins .................................................................................................... 108 
4.4 Discussion ........................................................................................................... 109 
4.4.1 mRNA uridylation does not exclusively depend on Cid1 ...................... 109 
4.4.2 Mixed mRNA A/U tails .......................................................................... 110 
4.4.3 Uridylation-dependent RNA decay is linked to stress response and 
telomere maintenance ............................................................................. 110 
4.4.4 Dis3L2 depletion increases resistance to hydroxyurea-induced stress ... 112 
4.5 Acknowledgements ............................................................................................. 114 
4.6 References ........................................................................................................... 114 
Chapter 5 ......................................................................................................................... 118 
5 Summary and Perspectives ........................................................................................ 118 
5.1 The evolution of adenylyl- and uridylyltransferase nucleotide specificities ...... 119 
5.2 Regulation of Gld2 activity by post-translational phosphorylation .................... 120 
5.3 The role of the Cid1/Dis3L2 pathway in global RNA decay.............................. 121 
5.4 Future Directions and Perspectives ..................................................................... 122 
5.4.1 The role of post-translational modifications in regulating Gld2 ............. 122 
5.4.2 Regulating miR-122 through Gld2 in health and disease ....................... 124 
5.4.3 Identifying new cellular roles of Gld2 .................................................... 124 
5.4.4 Impact of Cid1 and Dis3L2 on Schizosaccharomyces pombe RNA 
metabolism .............................................................................................. 125 
5.5 Conclusion .......................................................................................................... 127 
5.6 References ........................................................................................................... 127 
Appendices ...................................................................................................................... 131 
Appendix A ..................................................................................................................... 131 
 
xiv 
 
Appendix B ..................................................................................................................... 136 
Curriculum Vitae ............................................................................................................ 157 
 
xv 
 
List of Tables 
Table 2.1: Nucleotide addition kinetics of Gld2. .............................................................. 46 
Table 3.1: Activity and RNA-binding of wildtype (WT) and phosphomimetic Gld2 
variants. ............................................................................................................................. 75 
Table 4.1: Select genes up- or down-regulated in either S. pombe ∆cid1 deletion strain or 
S. pombe ∆dis3L2 deletion compared to wildtype S. pombe. ......................................... 104 
Table 4.2: Functional enrichments in genes >1.8-fold up-regulated in S. pombe Δdis3L2 
compared to wildtype. ..................................................................................................... 106 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvi 
 
List of Figures 
Figure 1.1: Central Dogma of Molecular Biology. ............................................................. 3 
Figure 1.2: Transcription of mRNA.................................................................................... 5 
Figure 1.3: mRNA degradation pathways. ......................................................................... 9 
Figure 1.4: Maturation pathway of miRNAs. ................................................................... 12 
Figure 1.5: miRNA modifications. ................................................................................... 15 
Figure 1.6: Domain organization of selected TENTs. ...................................................... 16 
Figure 1.7: Overview of mRNA modifications by adenylation and uridylation in humans.
........................................................................................................................................... 18 
Figure 2.1: Proposed catalytic activities and domain organization of Gld2. .................... 37 
Figure 2.2: RNA substrates of Gld2. ................................................................................ 42 
Figure 2.3: In vitro transcription of pre-let-7 RNA. ......................................................... 43 
Figure 2.4: Nucleotide substrates of Gld2. ....................................................................... 44 
Figure 2.5: Dependence of the reaction rate on nucleotide concentration. ....................... 45 
Figure 2.6: Phylogeny of the Tutase/PAP superfamily. ................................................... 48 
Figure 2.7: Nucleotide preference is defined by a histidine residue. ................................ 50 
Figure 2.8: Insertion of an active site histidine into Gld2 alters nucleotide specificity. ... 51 
Figure 3.1: Pathways regulated by Gld2 and Gld2 domain architecture. ......................... 63 
Figure 3.2: Multiple sequence alignment of mammalian Gld2 sequences. ...................... 69 
 
xvii 
 
Figure 3.3: Gld2 is phosphorylated at S62 when incubated with EGF-stimulated HEK 
293 cell extract. ................................................................................................................. 70 
Figure 3.4: Phosphomimetic Gld2 variants modulate catalytic activity and RNA binding.
........................................................................................................................................... 72 
Figure 3.5: Akt1 and PKA phosphorylate Gld2 at S116. ................................................. 77 
Figure 3.6: Model of Akt1-mediated regulation of Gld2. ................................................. 84 
Figure 4.1: Domain structure and amino acid composition of Cid1 and Dis3L2. ............ 93 
Figure 4.2: Cid1 displays a promiscuous substrate range in vitro. ................................... 98 
Figure 4.3: RNA uridylation of diverse RNA transcripts is found in wildtype and cid1 
deletion strains. ............................................................................................................... 100 
Figure 4.4: Changes in relative abundance of mRNAs in WT, Δcid1, and Δdis3L2 cells.
......................................................................................................................................... 102 
Figure 4.5: Genes differentially expressed in S. pombe deletion strains compared to 
wildtype........................................................................................................................... 102 
Figure 4.6: Northern blot and RT-qPCR showing differential expression of genes in 
wildtype versus Δcid1 or Δdis3L2 S. pombe. ................................................................. 103 
Figure 4.7: Search tool for the retrieval of interacting genes/proteins (STRING) diagram 
of RNAs with altered expression levels in a dis3L2 deletion strain compared to wildtype.
......................................................................................................................................... 105 
Figure 4.8: Growth assay of S. pombe WT, Δdis3L2, and Δcid1. .................................. 107 
Figure 4.9: Sedimentation assay of aggregated proteins in WT, Δcid1, and Δdis3L2 
deletion strains. ............................................................................................................... 108 
 
 
xviii 
 
List of Appendices 
Appendix A 
Table A1: Primers for cloning of Gld2 into pGEX-6P-2 and mutagenesis of Gld2. ...... 131 
Table A2: Kinases predicted to phosphorylate Gld2 at residues S62, S69, S95, S110 and 
S116. ............................................................................................................................... 131 
 
Figure A1: Purified Gld2 constructs. .............................................................................. 132 
Figure A2: Catalytic activity and RNA binding of Gld2 phosphomimetic variants....... 133 
Figure A3: PKA and Akt1 produce phosphorylated Gld2. ............................................. 134 
Figure A4: PKA-mediated phosphorylation down-regulates Gld2 catalytic activity. .... 134 
Figure A5: Gld2 S116A does not mimic wildtype activity and binding. ....................... 135 
 
Appendix B 
Table B1: Oligonucleotide primers. ................................................................................ 136 
Table B2: Genes up- or down-regulated in either S. pombe ∆cid1 deletion strain or S. 
pombe ∆dis3L2 deletion compared to wildtype S. pombe. ............................................. 136 
Table B3: Genes up-regulated at least 1.8-fold in the S. pombe ∆cid1 deletion strain 
compared to wildtype S. pombe. ..................................................................................... 148 
Table B4: Genes down-regulated at least 1.8-fold in the S. pombe ∆cid1 deletion strain 
compared to wildtype S. pombe. ..................................................................................... 148 
Table B5: Genes down-regulated at least 1.8-fold in the S. pombe ∆dis3L2 deletion strain 
compared to wildtype S. pombe. ..................................................................................... 149 
 
xix 
 
Table B6: Genes up-regulated at least 1.8-fold in the S. pombe ∆dis3L2 deletion strain 
compared to wildtype S. pombe. ..................................................................................... 151 
 
Figure B1: Colour map of gene expression changes between wildtype S. pombe and 
Δcid1 or Δdis3L2 strains. ................................................................................................ 155 
Figure B2: Search tool for the retrieval of interacting genes/proteins (STRING) diagram 
of RNAs with altered expression levels in cid1 and dis3L2 deletion strains compared to 
wildtype........................................................................................................................... 156 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xx 
 
List of Abbreviations 
32P   phosphorus-32  
6-FAM  6-carboxyfluorescein 
Abl   tyrosine-protein kinase Abl 
Ac-pre-miRNA Ago-cleaved pre-miRNAs 
Ade (A)  adenine 
AGC   protein kinase A, G, and C 
Ago   Argonaute 
Ago2   protein argonaute 2  
aha1   chaperone activator Aha1 
Akt1   RAC-alpha serine/threonine-protein kinase or protein kinase B 
ALDEx2  ANOVA-like Differential Expression version 2 
ANOVA   analysis of variance 
Ala (A)  alanine 
AMP   adenosine monophosphate 
Arg (R)  arginine 
Asn (N)  asparagine 
Asp (D)   aspartic acid 
ATP (A)  adenosine triphosphate 
BIK   Bcl2-interacting killer 
bip1   endoplasmic reticulum heat shock protein BiP1  
BSA   bovine serum albumin 
C. elegans  Caenorhabditis elegans 
Caf1   CCR4-associated factor 1 
CAT-1   cationic amino acid transporter 1 
Ccr4   glucose-repressible alcohol dehydrogenase transcriptional effector 
cdc1   DNA polymerase delta small subunit Cdc1 
cdc22    ribonucleoside reductase large subunit Cdc22 
cdc37   Hsp90 co-chaperone Cdc37 
cdc48 AAA family ATPase involved in ubiquitin-mediated protein 
degradation Cdc48 
 
xxi 
 
CDK5   cyclin dependent kinase 5 
cDNA   complementary DNA 
Cid1   caffeine-induced death suppressor protein 1 
Cid11   caffeine-induced death suppressor protein 11 
Cid12   caffeine-induced death suppressor protein 12 
Cid13   caffeine-induced death suppressor protein 13 
Cid14   caffeine-induced death suppressor protein 14 
Cid16   caffeine-induced death suppressor protein 16 
CK1α   casein kinase 1 isoform alpha 
CK2   casein kinase 2 
CK2α   casein kinase 2 subunit alpha 
clr   centered log-ratio 
CPEB   cytoplasmic polyadenylation element binding protein 
Cpsf   cleavage and polyadenylation stimulating factor 
cRACE  circular rapid amplification of cDNA ends 
CSD   cold shock domain 
CTP (C)  cytidine triphosphate 
dak2   dihydroxyacetone kinase Dak2 
Dcp1/2  mRNA-decapping enzyme subunits 1 and 2 
DGCR8  DiGeorge syndrome critical region in gene 8 
Dis3L2  Dis3-like 3′-5′ exoribonuclease 2 
DMEM  Dulbecco’s Modified Eagle’s Medium 
DNA   deoxyribonucleic acid 
DTT   dithiothreitol 
E. coli   Escherichia coli 
ecl1   extender of the chronological lifespan protein Ecl1 
EDTA   ethylenediaminetetraacetic acid 
EGF epidermal growth factor 
EGTA ethylene glycol-bis(β-aminoethyl esther)-N,N,N’,N’-tetraacetic 
acid 
eIF4   eukaryotic translation initiation factor 4 
 
xxii 
 
eIF4E   eukaryotic translation initiation factor 4E 
eIF4G   eukaryotic translation initiation factor 4G 
EMM   Edinburgh minimal media 
ERK   extracellular signal-regulated kinase 
Exp-5   exportin-5 
FBS   fetal bovine serum 
gal1   galactokinase Gal1 
gal7   galactose-1-phosphate uridylyltransferase Gal7 
gal10   UDP-glucose 4-epimerase/aldose 1-epimerase Gal10 
GFP   green fluorescent protein 
Gld2   germline-development 2 
Gld3   defective in germline-development protein 3 
Gld4   poly(A) RNA polymerase gld-4 
glo1   glyoxalase I 
Glu (E)  glutamic acid 
GMP   guanosine monophosphate 
GPCR   G-protein coupled receptor 
GST   glutathione S-transferase 
GTP (G)  guanosine triphosphate 
H. sapiens  Homo sapiens 
H2O2   hydrogen peroxide 
HBV   Hepatitis B virus 
HBx   Hepatitis B virus X-protein 
HCC   hepatocellular carcinoma 
HCV   Hepatitis C virus 
HEK 293   human embryonic kidney 293 cells 
HEK 293T  human embryonic kidney 293 cells with SV40 T-antigen 
HeLa   Henrietta Lacks cells 
HepB   Hepatitis B 
HepC   Hepatitis C 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
 
xxiii 
 
hExo   human exonuclease 1 
His (H)  histidine 
HO-1   heme oxygenase-1 
hsp78   mitochondrial heat shock protein Hsp78 
hsp90   Hsp90 chaperone 
hsp104   heat shock protein Hsp104 
HU   hydroxyurea 
IgG   immunoglobulin G 
IPTG   isopropyl β-D-1-thiogalactopyranoside 
kcat   turnover number 
Kd   dissociation constant 
KM   Michaelis constant 
kan   kanamycin 
KCl   potassium chloride 
KSRP   KH-type splicing regulatory protein 
LB   Luria Broth 
LC-MS  liquid chromatography-mass spectrometry 
let-7   lethal-7 
leu    leucine 
Lin28A  Lin-28 homolog A 
Lsm1-7  like Smith 1-7 
Lys (K)  lysine 
M. musculus  Mus musculus 
MDA-MB-231 M.D. Anderson metastatic breast adenocarcinoma 231 cells 
MgCl2   magnesium chloride 
MGV   mean gray value 
miR-122  microRNA 122 
miR-215  microRNA 215 
miR-564  microRNA 564 
miRISC  miRNA bound RISC 
miRNA  microRNA 
 
xxiv 
 
MOPS   3-(N-morpholino)propanesulfonic acid 
mRNA   messenger RNA 
mRNP   messenger ribonucleoprotein 
MS   mass spectrometry 
MS/dd-MS2  mass spectrometry/data dependent-mass spectrometry   
MT   mitochondrion 
N   any nucleotide 
n   sample size 
Na2VO4  sodium orthovanadate 
NaCl   sodium chloride 
NCBI   National Center for Biotechnology Information 
ncRNA  non-coding RNA 
nt   nucleotide   
NTR   nucleotidyltransferase 
NTP   nucleoside triphosphate 
OD600   optical density at 600 nm 
orf   open reading frame 
P bodies  processing bodies 
p value  probability value 
PAN poly(A) nuclease 
Pan2-Pan3 poly(A) specific ribonuclease subunits Pan2 and Pan3  
PABP   poly(A) binding protein 
PAP   poly(A) polymerase 
PAPD1  poly(A) polymerase associated domain containing 1 
PAPD4  poly(A) polymerase associated domain containing 4 
Parn   poly(A) specific ribonuclease 
PBS-T   1 x phosphate-buffered saline 1% Tween 
PCR   polymerase chain reaction 
PDK1   3-phosphoinositide-dependent protein kinase 1 
pGld2   phosphorylated Gld2 
pex22   peroxisomal membrane protein Pex22 (predicted) 
 
xxv 
 
pgi1   glucose-6-phosphate isomerase (predicted) 
PGK1   phosphoglycerate kinase 1 
PI3K   phosphoinositide 3-kinase 
PKA   protein kinase A  
plg7   phospholipase A2, PAF family homolog 
PMSF   phenylmethylsulfonyl fluoride 
Pneumo-G  pneumoviridae 
Pol II   RNA polymerase II 
Pol III   RNA polymerase III 
PP2A   protein phosphatase 2A 
ppAkt1  doubly phosphorylated Akt1 
pre-let-7a  precursor lethal-7a 
pre-miRNA  precursor microRNA 
pre-mRNA  precursor mRNA 
pri-miRNA  primary microRNA 
PRM   parallel-reaction monitoring  
PRR   proline-rich region 
pSer   phosphoserine 
psi1   DNAJ domain protein Psi1 
PTM   post-translational modification 
PVDF   polyvinylidene difluoride 
QKI-7   Quaking 
R   replicate 
RISC   RNA-induced silencing complex 
RNA   ribonucleic acid 
RNase   ribonuclease 
RNB   ribonuclease domain 
rpp0   60S acidic ribosomal protein Rpp0 (predicted) 
rpt1   19S proteasome regulatory subunit Rpt1 (predicted) 
rpt3   19S proteasome regulatory subunit Rpt3 (predicted) 
rpt6   19S proteasome regulatory subunit Rpt6 (predicted) 
 
xxvi 
 
RRM   RNA recognition motif 
RT   room temperature 
RT-qPCR  quantitative reverse transcription polymerase chain reaction 
rRNA   ribosomal RNA 
S1   nonspecific RNA binding domain 
S2 cells  Schneider 2 cells 
S. pombe  Schizosaccharomyces pombe 
S-M   Synthesis-Mitosis 
SDS   sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Ser (S)   serine 
snRNA  small nuclear RNA 
snRNP   small nuclear ribonucleoprotein   
ssa1   heat shock protein Ssa1 (predicted) 
ssa2   heat shock protein Ssa2 
ssc1   mitochondrial heat shock protein Hsp70 
sti1   chaperone activator Sti1 (predicted) 
STRING  Search Tool for the Retrieval of Interacting Genes/proteins 
suc22   ribonucleotide reductase small subunit Suc22 
Tap   nuclear RNA export factor 1  
tcg1   single-stranded telomeric binding protein Tgc1 
tdh1   glyceraldehyde-3-phosphate dehydrogenase Tdh1 
TENT   terminal RNA nucleotidyltransferase 
TENT2  terminal RNA nucleotidyltransferase 2 
TENT3A  terminal RNA nucleotidyltransferase 3A 
TENT3B  terminal RNA nucleotidyltransferase 3B 
TEV   tobacco etch virus 
thf1 C1-5,6,7,8-tetrahydrofolate (THF) synthase, trifunctional enzyme 
Thf1 
Thr (T)  threonine 
Tris-HCl  tris(hydroxymethyl)aminomethane hydrochloride 
 
xxvii 
 
tRNA   transfer RNA 
trx1   cytosolic thioredoxin Trx1 
TTP (T)  thymidine triphosphate 
TUT/Tutase  terminal uridylyltransferase           
TUT1   terminal uridylyltransferase 1 
TUT2   terminal uridylyltransferase 2 
TUT4   terminal uridylyltransferase 4     
TUT7   terminal uridylyltransferase 7 
tWT   treated wildtype 
U   uridine 
U6 snRNA  U6 small nuclear RNA 
ubp15   ubiquitin C-terminal hydrolase Ubp15 
ura    uracil 
UTP (U)  uridine triphosphate 
UTR   untranslated region 
vo   initial velocity 
Vmax   maximum velocity 
Val (V)  valine 
wos2   p23 homolog, predicted co-chaperone Wos2 
WT   wildtype 
X. laevis  Xenopus laevis 
Xrn1   5′-3′ exoribonuclease 1 
YES   yeast extract with supplements 
YPD   yeast extract peptone dextrose 
Zcchc6  zinc finger CCHC-type containing 6 
Zcchc11  zinc finger CCHC-type containing 11 
 
1 
 
Chapter 1 
1 Introduction 
1.1 Central Dogma of Molecular Biology  
In 1958 Francis Crick defined the Central Dogma of molecular biology as the flow of 
information from DNA to RNA to proteins1 (Figure 1.1). Deoxyribonucleic acid (DNA) 
contains the genetic information in the form of a double-stranded helix2, which serves as 
a blueprint for life. The genome contains all the genetic information for an organism, 
encoded in a four-letter DNA code represented by the nucleotide bases adenine, thymine, 
cytosine, and guanine. Genes are sequences of DNA that are transcribed to ribonucleic 
acid (RNA) polymers, including messenger RNAs (mRNAs) and non-coding RNAs 
(ncRNAs). RNA polymerase recognizes and binds to specific DNA sequences and uses 
the DNA as a template to synthesize complementary RNA strands3. Of the different RNA 
polymerases, RNA polymerase II (Pol II) transcribes mRNAs. The transcriptome 
includes the collection of all mRNAs in the cell. These RNA messages are read or 
translated by the ribosome to synthesize proteins of specific sequences as defined in the 
mRNA3,4.  
The mRNA carries the protein-encoding information in a four-letter code, similar to 
DNA. The thymine bases found in DNA are replaced by uracil in RNA transcripts, and 
the RNA bases are linked by a sugar phosphate backbone that contains ribose sugars 
instead of deoxyribose sugars found in DNA. The mRNA is recognized as a substrate by 
the ribosome in synthesizing all cellular proteins5. In protein synthesis, often referred to 
as mRNA translation, the mRNA is read in nucleotide (nt) triplets known as codons. 
RNAs encode up to 64 different codons, which either correspond to an amino acid or 
serve as a stop signal (stop codon) that terminate translation.  
The genetic code is redundant and there can be more than one codon per amino acid; 
a total of 20 canonical amino acids are encoded by 61 codons. Three codons (UAG, 
UAA, UGA) serve as stop codons6. In some organisms, including Escherichia coli and 
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humans, UGA is recoded to the 21st amino acid selenocysteine in a small set of genes7–9. 
In a certain species of archaea and bacteria, UAG is reassigned to pyrrolysine, the 22nd 
genetically encoded amino acid7,10.  
Small RNA molecules, transfer RNA (tRNA), serve as adaptors or decoders of the 
three-letter nucleic acid code into amino acids. tRNAs contains an anti-codon that is 
complementary to a codon or set of codons. Each tRNA species is charged with the 
cognate amino acid by the aminoacyl-tRNA synthetases11. tRNAs encode identity 
elements that allow aminoacyl-tRNA synthetases to specifically recognize tRNAs and 
ligate them with the correct amino acid6. Following elongation factor binding, the 
aminoacyl tRNA anti-codon base-pairs with the corresponding mRNA codon in the 
ribosome. The decoding process allows the correct amino acid, as specified in the 
mRNA, to be added to the growing protein chain. The ribosome, comprised of ribosomal 
RNAs (rRNAs) and protein subunits, catalyzes the peptidyl transfer reaction that adds the 
next amino acids to a growing peptide. The protein product is completed once a stop 
codon is reached and, following recognition by release factors, the ribosome dissociates 
and is prepared for the next round of translation12.  
The primary structure of a protein is determined by its amino acid sequence. As the 
peptide grows, it forms a secondary structure. The secondary structure is influenced by 
the amino acid sequence and intramolecular interactions are formed between the amino 
acid residues and backbone atoms. At the secondary structure level, protein 
conformations include α-helices, β-sheets, and random coils. Most proteins then fold into 
a ground state or low energy tertiary structure referred to as the native state. Quaternary 
structures may form when different proteins or subunit monomers that have already 
formed tertiary structures interact with each other to form higher order complexes13.  
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Figure 1.1: Central Dogma of Molecular Biology. 
The schematic diagram depicts transcription and translation. For protein coding genes, 
their DNA sequences are transcribed to mRNAs. The translation machinery then decodes 
the mRNA into a specific protein sequence (N, N-terminal; C, C-terminal). The 
nucleotide bases are colour-coded: green, adenine; red, thymine; dark blue, guanine; 
orange, cytosine; pink, uracil.  
 
1.2 Regulation of mRNA 
1.2.1 mRNA transcription in eukaryotes 
Transcription of mRNA starts with Pol II and transcription factors binding to a DNA 
promoter and opening the double-stranded helix to form a transcription bubble3,4 (Figure 
1.2). During transcription elongation, Pol II moves along the DNA template and adds 
complementary RNA nucleotides to synthesize the growing mRNA transcript. 
Transcription ends when the complex reaches the transcription terminator and the 
resulting RNA is known as a precursor mRNA (pre-mRNA)14. 
The pre-mRNA undergoes a series of modifications before becoming a mature 
mRNA. The processing starts as the pre-mRNA is formed with the addition of a 7-
methylguanosine cap on the 5′-end15,16. RNA triphosphatase first hydrolyzes the 5′-
triphosphate to a diphosphate; RNA guanylyltransferase then adds a guanosine 
monophosphate (GMP). Finally, RNA guanine-7 methyltransferase will the methylate the 
guanosine base at position N716.  
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The mRNA 5′-cap is important for many events including mRNA stability, 
processing, nuclear export, and translation16. The pre-mRNA also require splicing to 
remove the non-protein coding introns15,17. The spliceosome is a complex of five small 
nuclear ribonucleoproteins (snRNPs) that catalyzes the splicing event and requires 
specific sequences within the intron for efficient splicing17,18. Once the polyadenylation 
signal sequence and the downstream GU-rich motif are transcribed, the mRNA is cleaved 
between those two regions at the cleavage site and transcription is terminated19–21. The 3′-
end of the transcript is polyadenylated by poly(A) polymerase (PAP) and the resulting 
poly(A) tail is bound by poly(A) binding proteins (PABPs)19–21. 
For the mRNA to leave the nucleus, various mRNA-binding proteins come together 
to form a messenger ribonucleoprotein (mRNP) export complex. The complex is 
exported out of the nucleus by nuclear pore complexes and will undergo changes in the 
cytoplasm to release the mRNA and prevent the mRNA from returning to the nucleus22.  
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Figure 1.2: Transcription of mRNA. 
The double-stranded DNA (blue and dark red strands) is bound by RNA polymerase II 
(orange oval, Pol II) and transcription factors such as transcription factor IIB (green oval) 
and transcription factor IID (purple oval) to form a transcription bubble. The pre-mRNA 
(purple and black line) is transcribed as Pol II moves along the DNA strand. The introns 
(black lines) are spliced out and a 7-methylguanosine cap (red circle) is added to the 5′-
end as transcription occurs. Once transcription is terminated, a poly(A) tail is added by a 
poly(A) polymerase (dark red oval) to the 3′-end of the mRNA and bound by poly(A) 
binding proteins (light blue ovals). Various mRNA binding proteins such as the 
transcription-export complex (pink oval) and nuclear RNA export factor 1 and p15 
heterodimer (Tap-p15, yellow oval) will bind the mRNA to form a messenger 
ribonucleoprotein (mRNP) export complex to export the mRNA out of the nucleus. Once 
in the cytoplasm, the mRNA binding proteins will undergo conformational changes to 
release the mRNA and this prevents the mRNA from returning to the nucleus.  
 
1.2.2 Role of the poly(A) tail 
The poly(A) tail plays an important role in the life cycle of mRNA. The poly(A) is 
added to the 3′-end of the mRNA during RNA processing after cleavage by nuclear PAPs 
and is important for events such as mRNA nuclear export, stability, and translation19–21. 
Transcripts lacking a poly(A) tail are confined in the nucleus23. More recent studies show 
that the poly(A) tail induces mRNA export by contributing to the length of the mRNA 
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transcript and the export can actually be inhibited if the poly(A) tail is too long24. The 
poly(A) tail is required to bind PABP and it is the PABPs that confer stability to the 
mRNA25,26. Indeed, a mRNA transcript without a poly(A) tail can be stabilized if PABP 
is tethered to the transcript25. The poly(A) tail is also involved in translation through 
PABP26–29. PABP binds eukaryotic translation initiation factor 4G (eIF4G), a component 
of the eukaryotic translation initiation factor 4 (eIF4) translation initiation complex, that 
then binds to the 5′-end cap-binding eukaryotic translation initiation factor 4E (eIF4E)27–
30. This allows the mRNA to take on a circular form to promote translation and, possibly, 
the stability of the mRNA by preventing decapping at the 5’-end and deadenylation at the 
3′-end26,28,29. 
While initial polyadenylation occurs in the nucleus by canonical PAPs, the poly(A) 
tails of mRNAs can be further extended by non-canonical PAPs in the cytoplasm to 
facilitate translation31–34. Polyadenylation of mRNAs by mammalian homologs of the 
non-canonical PAP germline-development 2 (Gld2) has been shown to enhance mRNA 
translation in Xenopus oocytes31. Another study showed that dormant mRNAs in the 
cytoplasm have shortened poly(A) tails and require polyadenylation to be active for 
translation32,34. The extended poly(A) tail recruits additional PABP and the associated 
proteins required for translation26–29,34. The activation of dormant mRNAs is commonly 
observed during development with mRNAs involved in meiosis and mitosis34. In 
Caenorhabditis elegans, the absence of Gld2 led to abnormal germline cell growth35,36. 
The poly(A) tails of maternal mRNAs during oocyte maturation are extended to promote 
translation33, and the absence of the extended tails can be observed in mature oocytes and 
early-stage embryos when the non-canonical PAP is deleted37.  
 
1.2.3 5′-3′ and 3′-5′ degradation of mRNAs  
Degradation of mRNA can occur in both the 3′-5′ and 5′-3′ directions (Figure 1.3A). 
In eukaryotes, deadenylation-dependent degradation of the poly(A) tail is initially carried 
out by the poly(A) specific ribonuclease subunits Pan2 and Pan3 (Pan2-Pan3) of the 
poly(A) nuclease (PAN) deadenylase complex in the nucleus. The complex has been 
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observed to slightly trim the poly(A) tail to approximately 70-80 nts in Saccharomyces 
cerevisiae and 110 nts in mammalian cells before the mRNA transcript is exported out of 
the nucleus26,38–42. Most of the deadenylation is carried out in the cytoplasm by the 
glucose-repressible alcohol dehydrogenase transcriptional effector and CCR4-associated 
factor 1 (Ccr4-Caf1) complex43,44. This triggers the dissociation of PABP, leaving the 3′-
end exposed for degradation by the exosome. Deadenylation, however, initially triggers 
the 5′-3′ decay pathway. The loss of PABP will de-circularize the mRNA, exposing the 
5′-end cap. This leads to decapping by the mRNA-decapping enzyme subunits 1 and 2 
(Dcp1/2) and like Smith 1-7 (Lsm1–7) decapping complexes. Following decapping, the 
RNA is degraded by the 5′-3′ exoribonuclease 1 (Xrn1)45.  
An alternate deadenylation-independent RNA degradation pathway characterized by 
the addition of uridine residues to polyadenylated mRNAs was identified in 
Schizosaccharomyces pombe46. A similar, uridylation-dependent RNA degradation 
process has also been found in human cells46–50 (Figure 1.3B). mRNAs with poly(A) tails 
less than 25 nts lose the protection of PABPs and are polyuridylated by human terminal 
uridylyltransferase 4 (TUT4, Zcchc11) and terminal uridylyltransferase 7 (TUT7, 
Zcchc6), leading to degradation by Dis3-like 3′-5′ exonuclease 2 (Dis3L2)47. Dis3L2 is a 
3′-5′ cytoplasmic exonuclease, that specifically degrades 3′-uridylated RNA species, but 
is not part of the exosome51. Dis3L2 recognizes polyuridylated mRNAs51 and miRNAs52 
and catalyzes their 3′-5′ degradation. Mutations in Dis3L2 have been linked to Perlman 
syndrome and formation of Wilms’ tumor in children53. Due to its ability to recognize 
and degrade any RNAs that are polyuridylated, Dis3L2 is believed to play a key role in 
maintaining cellular RNA homeostatsis53. The poly(U) tails of mRNAs are also 
recognized by the Dcp1/2 and Lsm1–7 decapping complexes54, leading to 5′-3′ 
degradation by Xrn145. Interestingly, depletion of Lsm1 from the Lsm1-7 complex leads 
to an increase in mRNAs with oligo(U) tails, suggesting that mRNAs with 3′-uridine 
residues are first recognized by the decapping complexes and subjected to 5′-3′ decay 
before 3′-5′ degradation47.  
This uridylation-dependent decay pathway is the major decay pathway for histone 
mRNAs (Figure 1.3C). These mRNAs encode a unique 3′-stem-loop structure, which is 
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uridylated at the end of S-phase to initiate degradation49. The terminal uridylyltransferase 
TUT4 is the key player in histone mRNA uridylation; knockdown of TUT4 reduces 
histone mRNA uridylation and increases overall histone mRNA abundance50. In addition, 
TUT7 was shown to uridylate mature histone mRNA. TUT7 interacts with the 
exonuclease 3′-hExo to maintain a length of 3 nts after the stem-loop structure and both 
enzymes take part in the initial degradation of the histone mRNA55. When the histone 
mRNA 3′-end stem-loop structure is polyuridylated, the RNA is subsequently degraded 
by both the 5′-3′56 and Dis3L2 3′-5′ degradation pathways49. 
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Figure 1.3: mRNA degradation pathways. 
Three major RNA degradation pathways in eukaryotes. A) Deadenylation-dependent 
degradation of mRNAs begins with the Pan2-Pan3 deadenylase complex slightly 
trimming the poly(A) tail and continues in the cytoplasm with extensive deadenylation by 
Ccr4-Caf1. This causes PABPs (light blue ovals) to dissociate from the tail and will 
trigger 3′-5′ degradation by the exosome as well as 5′-end decapping (5′-cap, red circle) 
by Dcp1/2 and Lasm1-7 and 5′-3′ degradation by Xrn1. B) Uridylation-dependent 
degradation of mRNAs is initiated when poly(A) tails less than 25 nts lose the protection 
of PABPs and are polyuridylated by TUT4 or TUT7. The poly(U) tail is recognized by 
the U-specific exonuclease Dis3L2 for 3′-5′ degradation. The poly(U) tail also triggers 
decapping by Dcp1/2 and Lsm1-7 and 5′-3′ degradation by Xrn1. C) Replication-
dependent histone mRNAs encode a 3′-end stem-loop structure instead of a poly(A) tail. 
The stem-loop acts as a cis element for mRNA degradation and is bound by stem-loop 
binding protein (SLBP) and other proteins (not shown in figure)49. The mRNAs are 
degraded through the uridylation-dependent degradation pathway. 
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1.3 miRNAs: Functions in Gene Expression 
MicroRNAs (miRNAs) are small, single-stranded, regulatory RNAs that were 
discovered in the 1990s57,58. They are approximately 19-24 nts in length and take part in 
degrading mRNAs to suppress protein synthesis. miRNAs regulate gene expression by 
binding to complementary sequences in the target mRNA58. In animals, miRNAs regulate 
mRNAs through the RNA-induced silencing complex (RISC). As miRNAs in animals are 
typically not perfect complements to their mRNA targets, the mRNA is not degraded by 
endonucleolytic cleavage. The mRNA will be degraded and/or translationally suppressed 
through other methods (section 1.3.1)59,60. miRNAs play important roles in critical 
cellular pathways such as proliferation and apoptosis, ultimately affecting the well-being 
of the entire organism58,61. Correspondingly, de-regulation of miRNAs in humans has 
been shown to result in cardiovascular diseases62,63 and other diseases such as 
cancer58,61,64,65 and diabetes66.  
 
1.3.1 Role of miRNAs in regulating gene expression  
Many models have been put forth to explain translation repression5,67,68. Some models 
suggest that miRNA bound RISC (miRISC) inhibits translation initiation by competing 
with the 5′-cap binding protein eIF4E to bind the mRNA 5′-cap, preventing assembly of 
the 40S and 60S ribosomal subunits on the mRNA, or inhibiting formation of the 
translation initiation complex5,67,69–71. miRNAs also inhibit translation during elongation 
where miRISC causes early release of the ribosomes from the mRNA72. The miRISC has 
been suggested to prevent circularization of the mRNA, preventing translation from 
starting67,68. The miRISC can also sequester the mRNAs in processing bodies (P bodies), 
preventing translation of the mRNA67,73.  The partial complementarity of the miRNA to 
its target mRNA directs the mRNA towards decay pathways instead of mRNA cleavage 
by RISC by recruiting the Ccr4-Caf1 complex for deadenylation60,67,74. Deadenylation 
will lead to deadenylation-dependent 3′-5′ decay and 5′-3′ decay through mRNA 
decapping as described in section 1.2.3.  
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1.3.2 miRNA maturation pathway  
In animals, miRNA maturation takes place in the nucleus and the cytoplasm67,75 
(Figure 1.4). Most miRNAs are transcribed by Pol II as they are encoded within the 
sequences of coding and noncoding RNA transcripts67,75,76. miRNAs are mostly encoded 
within the introns but can be found in the exons67,75.  
In addition, some miRNAs such as miR-23a/27a/24-2 have their own promoters that 
are recognized by Pol II76. A small subset of miRNAs with their own promoters, such as 
C19MC miRNAs and miR-886, are transcribed by RNA polymerase III (Pol III)77,78. The 
resulting RNA is known as a primary miRNA (pri-miRNA) and takes the form of a long 
RNA strand with a hairpin-loop structure. Each hairpin-loop structure corresponds to one 
miRNA and clusters of miRNA sequences will have multiple hairpin-loop structures on 
the RNA strand. Drosha, a class II RNase III enzyme, with the help of a cofactor 
(DiGeorge syndrome critical region in gene 8 (DGCR8) in humans) processes the pri-
miRNA to the hairpin loop structure of about 60-70 nts79,80. Drosha recognizes a large 
loop (≥10 nts) at the end of the hairpin structure as well as structural features of the 
hairpin stem81.  
This processed form is known as the precursor miRNA (pre-miRNA). The pre-
miRNA is transported out of the nucleus by exportin-5 (Exp-5), a nuclear transport 
receptor82,83. Once in the cytoplasm, the pre-miRNA is cleaved by the RNase III enzyme 
Dicer to form a double-stranded mature miRNA that is approximately 22 nts 
long67,75,84,85.  
The double-stranded miRNA is then loaded onto the Argonaute (Ago) proteins to 
form the RISC. The miRNA will undergo strand selection where the passenger strand is 
degraded and the guide miRNA strand is left in the RISC86,87. Thermodynamic stability is 
an important factor in strand selection. The double-stranded miRNA is unwound and the 
miRNA strand with the weakest 5′-end binding is chosen as the guide strand. Thus, there 
is a bias to have an uracil residue on the 5′-end of the guide strand as this contributes to 
weaker binding. However, many other factors are involved in selecting the guide strand. 
Some examples are the orientation of the double-stranded duplex when it is loaded onto 
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RISC, the cell type, and proteins such as Ago, whose functions in the process remain 
unknown86. The RISC scans the mRNA pool to find the target mRNA through base-
pairing interactions between the guide miRNA and mRNA 3′-untranslated region (UTR) 
to suppress translation of the mRNA target60,67. 
 
 
Figure 1.4: Maturation pathway of miRNAs. 
Schematic diagram depicting the miRNA maturation process. The primary miRNA (pri-
miRNA) is transcribed from the DNA and processed by Drosha and DGCR8 to a single 
hairpin loop structure with a 2 nucleotide (nt) 3′-overhang, known as the precursor 
miRNA (pre-miRNA). The pre-miRNA is exported out of the nucleus by the nuclear 
transport receptor protein exportin-5 (blue) and undergoes processing by Dicer to form a 
double-stranded mature miRNA. The miRNA then undergoes strand selection by 
Argonaute (maroon) and incorporation into the RNA-induced silencing complex (RISC) 
where it will then bind its target mRNA to form the mRNA RISC (mRISC).  
 
1.3.3 Regulation of miRNA through untemplated nucleotide addition 
Recent high-throughput sequencing studies revealed the presence of untemplated 
nucleotide additions to the 3′-termini of nearly 40% of miRNAs88,89. As part of miRNA 
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maturation and degradation, untemplated uridine90,91 and adenine92 residues are added to 
pre-miRNAs and mature miRNAs. These additional nucleotides present an efficient 
means to control the level of active miRNA in a cell. Nucleotide additions to the 3 ′-end 
of miRNAs are widespread in eukaryotes and catalyzed by several terminal RNA 
nucleotidyltransferases (TENTs)48,90,93–102.  
While single nucleotide additions play a crucial role in miRNA maturation, recent 
reports suggest that monoadenylation of miRNAs also leads to increased miRNA 
stability92,103. Monoadenylation of miRNAs are carried out by the same enzymes that 
polyadenylate mRNAs. The minimal TENT Gld2 is able to polyadenylate mRNAs in the 
cytoplasm as well as monoadenylate miRNAs54,92. Gld2, thus, promotes miRNA 
stabilization: Gld2-mediated monoadenylation stabilizes miRNA miR-122 transcripts in 
the liver104 and human fibroblasts92 and plays a role in the translational regulation of 
p53105,106(Figure 1.5B). In addition, Gld2 knockout mice show decreased miRNA 
monoadenylation107. 
Uridylation of miRNAs can occur on pre-miRNAs and mature miRNAs. In the 
miRNA maturation pathway, a small group of pre-miRNAs known as Group II pre-
miRNAs are processed to a single nucleotide overhang on the 3′-end and require the 
addition of a second nucleotide to generate the required 2 nt 3′-overhang108. In vitro 
uridylation assays and in vivo knockdowns showed that the humans TENTs TUT4, 
TUT7, and Gld2 act redundantly in monouridylating the Group II pre-let-7 pre-miRNA90 
(Figure 1.5A). This single nucleotide addition leads to the generation of a 2 nt 3′-
overhang that would allow recognition and processing by Dicer, followed by the 
formation of the multiprotein RISC (Figure 1.5A), which leads to RNA silencing and 
cleavage by argonaut75,90,110,111. 
Polyuridylation, as opposed to monouridylation, of Group II pre-miRNAs leads to 
degradation by Dis3L2 (Figure 1.5C). In general, polyuridylation requires the presence of 
an accessory protein to enhance RNA binding. Lin-28 homolog A (Lin28A) is a RNA 
binding protein that recruits TUT4, and to a lesser extent TUT7, via its zinc knuckle 
domain to polyuridylate pre-let-791,112,113. The full-length Lin28A protein recognizes the 
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let-7 stem-loop and a conserved GGAG motif near the 3′-end114. Lin28A suppresses the 
biogenesis of the tumor suppressor let-7 to prevent stem cell differentiation and protein 
levels slowly decrease during development to promote differentiation115. Lin28A is an 
oncogene as high levels correlate with a poor prognosis due to the suppression of mature 
let-7, leading differentiated cells to become pluripotent stem cells115,116. Lin28A 
expression is, however, tissue-specific after development and can be detected in tissues 
such as the placenta116.  
A recent structure of Ago-cleaved pre-miRNAs (ac-pre-miRNAs) contains a 5′-
overhang due to trimming of the 3′-end by Ago2 or an unknown nuclease117 (Figure 
1.5D). The overhang structures are thought to stem from imperfect pre-miRNA 
processing. The presence of the overhangs allows TUT4 and TUT7 binding in a Lin28A-
independent manner, leading to polyuridylation and rapid RNA degradation117. In 
addition to pre-miRNA polyuridylation, which prevents miRNA maturation, the TENT 
terminal uridylyltransferase 1 (TUT1, Star-PAP) was shown to polyuridylate mature 
miRNAs, marking them for degradation118.     
TENTs play an essential role in pre-miRNA maturation and are further involved in 
miRNA degradation. These mechanisms control the amount of miRNA transcripts in the 
cell, but do not directly influence their specific activity. However, a recent report 
suggests that TUT4 directly controls miR-26a activity93,94. The addition of a single 3′-
uridine to mature miR-26a, a miRNA involved in cytokine expression, silences miR-26a 
activity without altering miRNA abundance94 (Figure 1.5B). Deep sequencing of TUT4-
depleted mouse livers revealed a decrease in the number of uridylated miRNAs but not a 
decrease in miRNA abundance93. TUT4 and TUT7 were shown to be redundant in 
monouridylating the 3’-end of mature miRNAs95. Depletion of one or both enzymes did 
not affect mature miRNA levels, suggesting that monouridylation leads to silencing and 
not degradation95. These uridylation events were observed for several distinct miRNA 
species such as let-7a, let-7g, and miR-10a, likely representing a general and direct 
mechanism to regulate miRNA activity93,95. 
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Figure 1.5: miRNA modifications. 
The miRNA is regulated at various points during its maturation through untemplated 
nucleotide additions. A) Group II pre-miRNAs have a 1 nt 3′-overhang and can be 
monouridylated or monoadenylated to produce the 2 nt 3′-overhang recognized by Dicer. 
B) Mature miRNAs are regulated by Gld2 mediated 3′ monoadenylation, enhancing their 
stability, or by TUT4 catalyzed 3′ monouridylation, leading to silencing. C) Group II pre-
miRNAs are polyuridylated by TUT4 or TUT7 in collaboration with Lin28A, leading to 
3′-5′ degradation by Dis3L2. D) Ago-cleaved pre-miRNAs (ac-pre-miRNAs) with a 5′-
overhang are polyuridylated by TUT4, TUT7, or Gld2, possibly leading to rapid 
degradation.  
 
1.4 Terminal RNA Nucleotidyltransferases 
Many terminal RNA nucleotidyltransferase (TENT) homologs have a biochemically 
characterized biological function and are categorized as PAPs or terminal 
uridylyltransferases (Tutases), yet some homologs remain uncharacterized. Tutases have 
been identified as novel key players in mRNA turnover47,48,119–121, with additional roles in 
pre-mRNA122, non-adenylated histone mRNA49,50,55,56, and miRNA metabolism93–
95,112,123. Humans encode three Tutases (TUT1124,125, TUT447,50,90,93–95,126, 
TUT747,55,90,95,117) and two non-canonical PAPs (Gld292,104–106,127, PAPD1128,129). In 
fission yeast, several PAPs (Cid11130, Cid12131, Cid13132, Cid14133,134) and Tutases 
(Cid1135,136, Cid16137) have been identified. A variety of TENTs have been characterized, 
and we highlighted these discoveries in a recent review138. In the following sections, I 
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will focus on the TENTs relevant to this thesis: S. pombe TENT caffeine induced death 
protein 1 (Cid1) and the human TENTs TUT1, TUT4, TUT7, and Gld2. 
 
 
Figure 1.6: Domain organization of selected TENTs. 
TENTs share the major catalytic domains but differ in their RNA binding domains. Ntr, 
Nucleotidyltransferase domain; PAP, Poly(A) polymerase associated domain; Zn, Zinc 
finger; PnG, PneumoG domain; Atr, Atrophin-like domain; RRM, RNA recognition 
motif; PRR, proline-rich region.   
 
1.4.1 Adenylation vs. uridylation  
Enzymes with uridylyl- and adenylyltransferase activity are closely related in amino 
acid sequence and similar in their protein domain architecture and structure. Significant 
sequence similarity between PAPs and Tutases has obscured identification of sequence or 
structural features that differentiate a true adenylyltransferase from a true 
uridylyltransferase.  
The biochemical characterization of the non-canonical PAP Cid1 from S. pombe 
revealed an unexpected in vitro and in vivo Tutase activity, introducing Cid1 as the first 
identified uridylyltransferase121. The catalytic core of Cid1 consists of a 
nucleotidyltransferase domain and PAP-associated domain, much like its 
adenylyltransferase counterpart Gld2109,136. This homologous catalytic core is also found 
in TUT4 and TUT7. All of these enzymes are members of the DNA polymerase β-like 
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superfamily (Figure 1.6). While Cid1, TUT4, and TUT7 have been shown to act as 
uridylyltransferases in vivo46,50,93–95,112,123,136,139, Gld2 has been shown to act as both an 
adenylyltransferase and uridylyltransferase31,92,104,105,109,140. 
The crystal structure of U-specific Cid1 revealed the molecular basis of nucleotide 
discrimination: a single histidine residue in Tutases sterically hinders ATP from entering 
the active site (Figure 1.6)141. Some uridylyltransferases such as Naegleria gruberi Cid1 
encode a phenylalanine instead of a histidine at this site, however both aromatic amino 
acids may serve to block ATP from the active site through steric hindrance109. Mutation 
of this histidine to an asparagine in Cid1 and to a leucine in Xenopus laevis TUT7 yielded 
an enzyme that lost its specificity for UTP, indicating that the histidine is crucial for UTP 
selectivity141,142.  
It is important to note that adenylation and uridylation can have opposing effects on 
mRNA and miRNA stability (Figures 1.5 and 1.7). Generally, the addition of an adenine 
residue to mature miRNAs leads to stability104 while an uridine residue leads to 
silencing93. Group II pre-miRNAs, however, require the addition of an uridine residue90 
on the 3′-end for proper maturation, while an oligo(U) tail, with the help of Lin28A, will 
lead to degradation by Dis3L291,112. The addition of an oligo(U) tail to a shortened 
poly(A) tail (less than 25 nts) of mRNAs can lead to degradation by the 3′-5′ exonuclease 
Dis3L250 and decapping of the 5′-end45. On the other hand, an oligo(A) tail will lengthen 
the poly(A) tail and extend the half-life of the mRNA31,96,143–145. In addition, histone 
mRNAs are subjected to 5′-3′ and 3′-5′ degradation when polyuridylated49. These 
opposing biological roles by very similar enzymes emphasize the need to define the 
biochemical activity of every TENT in order to correctly assign their biological function. 
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Figure 1.7: Overview of mRNA modifications by adenylation and uridylation in 
humans. 
Polyadenylation of A) mRNAs by Gld2 and B) pre-mRNA by TUT1 extends their half-
life. C) TUT4 or TUT7 uridylation of histone mRNAs leads to 5′-3′ and 3′-5′ 
degradation. D) TUT4 or TUT7 uridylation of mRNAs with short poly(A) tails leads to 
5′-3′ and 3′-5′ degradation.    
 
1.4.2 Human uridylyltransferases  
Like the yeast homolog Cid1, human TUT4 and TUT7 both encode a 
nucleotidyltransferase (NTR) domain and an adjacent PAP-associated domain141,146–150 
(Figure 1.6). While Cid1 lacks obvious RNA binding motifs, TUT4 and TUT7 encode 
several zinc finger domains thought to be responsible for substrate binding and substrate 
specificity. Both enzymes share a similar domain structure with three CCHC zinc fingers, 
an N-terminal C2H2 zinc finger, and a C-terminal catalytic core consisting of the NTR 
domain and the PAP-associated domain (Figure 1.6). An additional copy of the catalytic 
core exists in the N-terminal region and is believed to be inactive as it lacks the aspartate 
triad in the NTR domain required for catalytic activity126. Due to the similarity in domain 
structure between TUT4 and TUT7, studies have shown that they may play redundant 
cellular roles47,90,112. TUT4 and TUT7 localize to the cytoplasm and can add single 
nucleotides to miRNAs (Figure 1.5A, B) or many uridine residues to histone mRNAs, 
miRNAs, and mRNAs (Figures 1.5C, D and 1.7C, D)50,93,94,112,123. The three CCHC-zinc 
finger domains flanking the active site are thought to assist in RNA binding112 and the 
C2H2 domain plays a specific role in the miRNA decay pathway, mediating the 
association of TUT4 to the RNA binding protein Lin28A117 (Figure 1.6). Lin28A recruits 
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Tutases to certain substrate RNAs and is most likely required for processive 
uridylation112. Mutational analysis of the conserved cysteine residues in the C2H2 zinc 
finger domain showed a decrease in Lin28A-enhanced uridylation activity112. Additional 
domains unique in TUT4 (Atrophin-like and Pneumo-G like domain, Figure 1.6) are not 
required for Tutase activity, but may be involved in substrate specificity and regulation of 
TUT495. Taken together, these studies suggest polyuridylation in humans is coordinated 
by multiple Tutases that control mRNA degradation pathways.  
Terminal uridylyltransferase 1 (TUT1, Star-PAP) is localized to the nuclear speckle 
and plays a role in cellular stress response, global regulation of miRNA abundance, and 
intron splicing88,118,124,125,151–153. TUT1 encodes an NTR domain and a PAP-associated 
domain but differs from the other TENTs with a proline-rich region (PRR) that is inserted 
in the NTR domain. TUT1 also encodes a N-terminal C2H2 zinc finger and RNA 
recognition motif (RRM)154 (Figure 1.6). TUT1 activity is associated with both 
adenylation-dependent pre-mRNA stabilization (Figure 1.7B) and uridylation-dependent 
RNA turnover. TUT1 restores the 3′-end uridyl residues of the U6 small nuclear RNA 
(snRNA) in the nucleus124,125,152.  
TUT1 utilizes an unusual mechanism of 3′-cleavage and polyadenylation when 
modifying pre-mRNAs155. TUT1 is activated by phosphorylation which directs substrate 
specificity and enhances activity. The activated enzyme binds to a GC-rich region in the 
3′-UTR of its pre-mRNA substrates via its RRM and C2H2 zinc finger
122,151,156. Upon 
binding, TUT1 directly interacts with the cleavage and polyadenylation stimulating factor 
(Cpsf) 160 and Cpsf 73 which subsequently recruit Cpsf 100 and Cpsf 30122. Cpsf 73 acts 
as an endonuclease and cleaves the pre-mRNA strand, followed by TUT1-catalyzed 
polyadenylation and subsequent stabilization of the mRNA122. Among the best-
characterized pre-mRNA targets of TUT1 are coding sequences for heme oxygenase-1 
(HO-1) and Bcl2-interacting killer (BIK). HO-1 and BIK are involved in oxidative stress 
and apoptotic responses, respectively122,151,155,157. Under oxidative stress, TUT1 is 
phosphorylated at serine and threonine residues in the PRR and targets HO-1120,122,155,158–
161. Cellular stress such as viral infections and DNA damage will activate a different 
signaling pathway that results in phosphorylation of the PRR in TUT1, resulting in TUT1 
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targeting BIK151,162–164. TUT1 can also be phosphorylated at serine 6 in the N-terminal 
zinc finger domain by casein kinase 1 isoform α (CK1α) independently of oxidative 
stress162.  
 
1.4.3 Gld2, the minimal human nucleotidyltransferase  
While single nucleotide additions play a crucial role in miRNA maturation, recent 
reports suggest that monoadenylation of miRNAs leads to increased miRNA 
stability92,103. The TENT homolog Gld2 was first described as a non-canonical PAP 
involved in C. elegans germline development, stabilizing mRNAs through 
polyadenylation36 (Figure 1.7A). Gld2 may associate with RNA-binding proteins to target 
specific RNAs as the enzyme lacks identifiable RNA binding domains165. In C. elegans, 
efficient and processive mRNA polyadenylation requires the association of Gld2 with 
Gld3, a developmental regulator36. In humans, Gld2 has been shown to associate with the 
RNA binding proteins QKI-7 to polyadenylate mRNA targets166. Additionally, Gld2 
promotes miRNA stabilization. Gld2-mediated monoadenylation stabilizes miRNA miR-
122 transcripts in the liver104 and human fibroblasts92, while it also plays a role in the 
translational regulation of p53105,106 (Figure 1.5B). Gld2 knockout mice show decreased 
miRNA monoadenylation, suggesting a primary role of Gld2 in miRNA 
monoadenylation107. In liver cells, miR-122 abundance is likely controlled as a balance 
between the stabilizing effect of Gld2-catalyzed adenylation and the antagonistic, 
destabilizing effect of 3′-deadenylation by poly(A) specific ribonuclease (Parn)127.  
Biochemical assays with recombinant human Gld2 discovered a previously unknown 
Gld2-mediated uridylation activity. Different reports documented Gld2 catalyzed 
adenylation and uridylation of miR-12292 and monouridylation of pre-let-790 in vitro. As 
such, the biological role of Gld2 was unclear, as both uridylation and adenylation activity 
were shown, which have opposing effects on RNA stability.  
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1.4.4 The founder uridylyltransferase Cid1 
S. pombe Cid1 was initially identified as a protein required for S-M  phase cell cycle 
checkpoint control135 and was thought to exhibit PAP activity promoting mRNA 
stability165. Deletion of Cid1 prevents yeast cells from growing when exposed to the cell 
cycle check point inhibitors caffeine and hydroxyurea135. Overexpression of Cid1, 
however, allowed the cells to suppress the effects of hydroxyurea135.  
When a deadenylation-independent pathway initiated by the addition of uridine 
residues to polyadenylated mRNAs was identified in S. pombe, it raised the possibility of 
Cid1 acting as a Tutase46. From a detailed biochemical and structural 
characterization121,141,146,147,165, it has now become clear that Cid1 is in fact a Tutase, 
catalyzing the polyuridylation of mRNAs in vitro, with predominantly monouridylated 
RNAs produced by Cid1 in vivo46,51. Upon uridylation, the Lsm1-7 decapping complex is 
recruited for mRNA 5′-3′ degradation46 and 3′-5′ degradation is carried out by the 
exonuclease Dis3L251,168–172. It is unknown how (U)-tail length is controlled in the cell, 
and whether these RNA species are exclusively uridylated by Cid1, as several additional 
TENT homologs are present in S. pombe109.   
Cid1 is known as the minimal TENT, containing only the two domains necessary for 
catalytic activity, the NTR domain and PAP-associated domain. These are also the only 
two domains present in Cid1’s adenylyltransferase counterpart Gld2. As both enzymes 
lack defined RNA binding domains, both enzymes display substrate promiscuity in 
vitro109,173. Substrate selectivity in vivo is thought to be achieved by interactions with 
RNA binding interacting proteins31,36,145,166,174.  
The major difference between Cid1 and Gld2 lies in their nucleotide preference, Cid1 
prefers UTP while Gld2 prefers ATP109,136. This is due to the presence of a critical 
histidine residue in the PAP-associated domain of Cid1 that sterically hinders ATP from 
entering the catalytic site141. Gld2 lacks this histidine residue and is thus able to accept 
ATP109. Interestingly, Cid1 is capable of adding a biotinylated ATP derivative, in the 
absence of UTP, to in vitro RNA transcripts under optimized conditions and is currently 
used for 3′-biotinylation of RNAs175. 
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1.5 Scope of Thesis  
The regulation of RNAs through the addition of untemplated nucleotides to their 3 ′-
ends has become an increasingly recognized regulatory modification. Adenylation and 
uridylation are associated with opposite biochemical outcomes with regard to RNA fate. 
Generally, adenylation stabilizes RNAs while uridylation silences miRNAs or marks 
RNAs for degradation. These additions play important roles in the regulation of mRNAs, 
either directly through nucleotide additions to the 3′-end of mRNAs or indirectly through 
miRNA regulation19,20,101,138,175. The enzymes that perform these tasks, TENTs, are thus 
of great interest. Therefore, I hypothesize that TENTs are required to maintain RNA 
homeostasis. In this thesis, the abilities of the TENTs Gld2 and Cid1 to catalyze 
nucleotide addition and regulate RNA stability were examined using precise biochemical 
assays. 
Gld2 is a member of the non-canonical poly(A) polymerases, which include enzymes 
with varying nucleotide specificity, ranging from strictly ATP-adding to ambiguous to 
exclusively UTP-adding enzymes. Human Gld2 has been associated with transcript 
stabilizing miRNA monoadenylation and cytoplasmic mRNA polyadenylation92,104,166. 
More recent data revealed an unexpected miRNA uridylation activity, which promotes 
miRNA maturation90. These conflicting data raise the question of Gld2 nucleotide 
specificity. Chapter 2 biochemically characterizes human Gld2 and demonstrates that it is 
a bona fide adenylyltransferase in vitro with only weak activity toward other nucleotides. 
Despite its sequence similarity with uridylyltransferases (TUT4, TUT7), I show that Gld2 
displays an 83-fold preference for ATP over UTP. I further show that Gld2 is 
promiscuous for its RNA substrate, with activity toward miRNA, pre-miRNA, and 
polyadenylated RNA substrates. In vitro Gld2 activity is restricted to adding single 
nucleotides109 while processivity observed in vivo likely relies on additional RNA-
binding proteins166. In a phylogenetic analysis of the PAP/Tutase superfamily, I further 
show that uridylyltransferase activity, which is derived from distinct adenylyltransferase 
ancestors, arose multiple times during evolution via insertion of an active site histidine 
residue. A corresponding histidine insertion into the Gld2 active site switches substrate 
specificity from ATP to UTP109.  
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Chapter 3 elucidates the first link between oncogenic kinase activity and the 
regulation of miRNA stability. The de-regulation of miRNAs is associated with multiple 
human diseases, yet cellular mechanisms governing miRNA abundance remain largely 
unknown58. While Gld2 activity was shown to stabilize miRNAs92,104, the regulation of 
Gld2 itself remained unclear. Human miR-122 is required for Hepatitis C proliferation 
and low miR-122 abundance is associated with hepatic cancer176. Gld2 catalyzes the post-
transcriptional addition of a single adenine residue (A+1) to the 3′-end of miR-122, 
enhancing its stability92. I found that Gld2 activity is regulated by site-specific 
phosphorylation in its predicted disordered N-terminal domain. I identified two 
phosphorylation sites (S62, S110) where phosphomimetic substitutions increased Gld2 
activity and one site (S116) that markedly reduced activity. Using mass spectrometry, I 
confirmed that HEK 293 cell extracts readily phosphorylate the N-terminus of Gld2 at 
S62. I also identified protein kinase A (PKA) and protein kinase B (Akt1) as kinases that 
site-specifically phosphorylate Gld2 at S116, abolishing Gld2-mediated nucleotide 
addition. The data demonstrate a novel phosphorylation-dependent mechanism to 
regulate Gld2 activity, revealing tumor suppressor miRNAs as a previously unknown 
target of Akt1-dependent signaling. 
Uridylation-dependent RNA decay is a widespread eukaryotic pathway modulating 
RNA homeostasis99,168. Tutases add untemplated uridine residues to RNA 3′-ends, 
marking them for degradation by the U-specific exonuclease Dis3L2168. In S. pombe, 
Cid1 uridylates a variety of RNAs121,136. Chapter 4 investigates the prevalence and impact 
of uridylation-dependent RNA decay in S. pombe by transcriptionally profiling cid1 and 
dis3L2 deletion strains. I found that the exonuclease Dis3L2 represents a bottleneck in 
uridylation-dependent mRNA decay, whereas Cid1 plays a redundant role that can be 
complemented by other Tutases. Deletion of dis3L2 elicits a cellular stress response, up-
regulating transcription of genes involved in protein folding and protein degradation. 
Misfolded proteins accumulate in both deletion strains, yet only trigger a strong stress 
response in dis3L2 deficient cells. While deletion of cid1 increases sensitivity to protein 
misfolding stress, a dis3L2 deletion showed no increased sensitivity or was even 
protective. Furthermore, uridylyl- and adenylyltransferases were shown to cooperate to 
generate a novel 5′-NxAUUAAAA-3′ RNA motif on dak2 mRNA. These studies 
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elucidate the role of uridylation-dependent RNA decay as part of a global mRNA 
surveillance, and perturbation of this pathway leads to the accumulation of misfolded 
proteins and elicits cellular stress responses. 
This thesis presents work characterizing the adenylyltransferase Gld2 and identifies 
site-specific serine phosphorylation as a means of TENT regulation. In addition, the 
cellular impact of the founder uridylyltransferase Cid1 on global RNA uridylation was 
explored. Altogether, the work takes a closer look at the regulation and impact of the 
minimal TENTs Gld2 and Cid1 that can be used as a starting point in the study of other 
TENTs. 
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Chapter 2 
2 Nucleotide specificity of the human terminal 
nucleotidyltransferase Gld2 (TUT2) 
2.1 Introduction 
Since microRNA (miRNA) discovery in the early 1990s1,2, it has become evident that 
post-transcriptional gene regulation by miRNAs is involved in most biological 
processes3–7. The latest miRBase release contains 24,521 experimentally validated 
miRNA genes from 206 species8. Dysfunctional miRNA expression, processing, and 
degradation have been found in breast cancer9, acute myeloid leukemia10, ovarian 
cancer11, and hepatocellular carcinoma12. Deregulated miRNA processing also 
contributes to other major diseases such as Hepatitis C13 and cardiovascular diseases14. 
Because miRNAs regulate genes that change cellular fate, miRNAs and proteins involved 
in miRNA regulation are promising next-generation cancer therapeutic targets. In 
addition, specific components of the RNA processing machinery are currently used as 
biomarkers for cancer detection15–19.   
The generation of miRNAs is a multistage process and translational inhibition by 
miRNAs is achieved through base pairing with the 3’-UTR of the respective target 
mRNA, leading to mRNA decay or silencing20. Recent high-throughput sequencing 
studies revealed the presence of untemplated nucleotide additions to the 3 ′ termini of 
nearly 40% of miRNAs21,22. Of these, depending on the miRNA species, ~50% displayed 
an extra adenine, 25% contained a single additional uridine, and the remaining 25% 
contained multiple nucleotides appended to the 3′-termini22. During miRNA maturation 
and degradation, untemplated uridine23,24 and adenine25 residues are added to pre-
miRNAs and mature miRNAs. These untemplated nucleotide additions are an efficient 
means to control the levels of active miRNAs in the cell. The seemingly innocuous 
addition of a single nucleotide can initiate miRNA maturation, stabilization, or convert an 
active miRNA to an inactive form26. While multiple adenine residues are added to mRNA 
for stabilization, extending the transcript life-span27, multiple uridine residues mark both 
miRNA and mRNA for degradation28–30. The presence of untemplated nucleotides on a 
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variety of miRNAs is now well known; however, the corresponding enzymes have only 
recently become the focus of biochemical characterization. 
Nucleotidyltransferases such as the human terminal uridylyltransferases (TUTs) 
TUT4 (Zcchc11, TENT3A), TUT7 (Zcchc6, TENT3B) and the minimal homolog Gld2 
(TUT2, PAPD4, TENT2) have been shown to play fundamental roles in the regulation 
and maturation of miRNAs let-7 and mir-122. Tutase homologs are part of the 
nucleotidyltransferase superfamily of enzymes and were initially identified as 
adenylyltransferases associated with miRNA and mRNA adenylation. Gld2 was first 
described as a cytoplasmic non-canonical poly(A) polymerase involved in 
Caenorhabditis elegans germline development. C. elegans Gld2 displayed very little 
activity on its own however, and relies on an additional protein, Gld3, to promote 
adenylation31,32. In Drosophila, specific depletion of the Gld2 homolog WISPY 
connected its function with mRNA polyadenylation required for oocyte to egg 
activation33, as well as long term memory34 (Figure 2.1A). Recent data showed that in 
addition to mRNA adenylation, WISPY adenylates miRNAs in S2 cells leading to a 
reduction of miRNA levels35. This observation that adenylation reduces miRNA levels35 
contradicts reports that monoadenylation stabilizes naturally unstable miRNAs25 and 
demonstrates the complexity of untemplated nucleotide additions.  
In humans, Gld2 has been equally associated with miRNA and mRNA adenylation as 
well as miRNA uridylation. The first reports associated human Gld2 with mRNA 
polyadenylation36 by monitoring translation of a reporter mRNA tethered to human Gld2 
and injected into Xenopus oocytes. In vivo, RNA polyadenylation requires either artificial 
RNA tethering36 or accessory RNA binding proteins such as the cytoplasmic 
polyadenylation element binding protein (CPEB) in Xenopus37,38 and Gld3 in C. 
elegans31. Further studies showed that Gld2 mediated monoadenylation stabilizes miR-
122 transcripts in human fibroblasts25 and plays a role in translational regulation of 
p5339,40. Monoadenylation is, in contrast to polyadenylation not entirely dependent on 
RNA binding proteins, as purified Gld2 from human cells displayed catalytic activity in 
vitro. With the discovery of the poly(U) polymerase activity of enzymes previously 
thought to be poly(A) polymerases, specifically the human Gld2 homologs TUT4 and 
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TUT741, most recent research has uncovered a previously unknown Gld2 mediated 
uridylation activity. D’Ambrogio and colleagues demonstrated for the first time that 
human Gld2 is the enzyme responsible for monoadenylation and subsequent stabilization 
of miRNA-122, but they also reported a weaker uridylation activity25. Gld2 has further 
been shown to catalyze the monouridylation of pre-microRNA let-7a, which is crucial for 
its maturation24. Flag-tagged human Gld2 purified from HEK 293T cells adds a single 
uridine to pre-let-7a but also displayed catalytic activity adding GTP and ATP, but not 
CTP in vitro24. Interestingly, Gld2-mediated polyuridylation has been observed on pre-
let-7a overhang variants42 in the absence of accessory proteins. Further evidence linking 
Gld2 to pre-microRNA uridylation stems from knockdown assays, showing that TUT4, 
TUT7 and Gld2 redundantly control pre-let-7 maturation and are required for let-7 
biogenesis24. Gld2 can thus function as either a Poly(A)-Polymerase (PAP) or a TUT in 
vitro.   
Gld2 is composed of two major domains, a PAP associated domain and a 
nucleotidyltransferase (NTR) domain (Figure 2.1B). Its closest human homologs, TUT4 
and TUT7 are comprised of the same domains but feature additional RNA-binding 
motifs, such as Zinc-finger domains. TUT4 and TUT7 have been characterized in vivo 
and in vitro as true uridylyltransferases and are involved in multiple processes including 
miRNA and mRNA uridylation. For example, uridylation of the let-7a precursor by 
TUT4 can drive processing by Dicer or mark the precursor miRNA for degradation, thus 
directly controlling let-7a levels in the cell23,26,30,43. Gld2 has been proposed to carry out a 
similar function during miRNA maturation24,42. While the role of TUT4 and TUT7 in 
these processes is becoming increasingly clear, the catalytic activity and biological role 
of the minimal nucleotidyltransferase Gld2 is uncertain. Evidence for both uridylation 
and adenylation activity of the human enzyme has been shown in in vivo and in vitro 
experiments, but a conclusive investigation of Gld2 nucleotide preference is lacking.  
We here present a biochemical characterization of Gld2, identifying it as a bona fide 
adenylyltransferase in vitro with only weak activity towards UTP and GTP. Conversely, 
Gld2 displays a wide target RNA substrate range, adenylating multiple RNAs in vitro. 
The data suggest that Gld2 RNA substrate selectivity may require association with other 
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protein factors in the cell. A detailed phylogenetic analysis shows that uridylyl- and 
adenylyltransferases are closely related, and that uridylyltransferase activity arose 
independently multiple times during evolution.  
 
 
Figure 2.1: Proposed catalytic activities and domain organization of Gld2. 
A) Gld2 has been implicated in nucleotide addition to multiple RNA substrates in 
different pathways. B) Domain organization of Gld2 and its homologs TUT4 and TUT7. 
Dark purple: Pneumo-G domain; Red: C2H2 Zinc finger domain; Blue: 
Nucleotidyltransferase domain; Orange: Poly(A) polymerase associated domain; Green: 
CCHC type Zinc finger domain; Light purple: Atrophin-like domain.           
 
2.2 Materials and Methods 
2.2.1 Gld2 cloning and site-directed mutagenesis 
Total RNA was extracted from HeLa cells using the GeneJET RNA purification Kit 
(Thermo Scientific) and reverse transcription was performed with SuperScript II Reverse 
Transcriptase (Invitrogen) using an oligo(dT)16 primer. PCR was carried out on the 
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cDNA with gene specific primers (Gld2EcoR1for 5′-GAATTCGATGTTCCCAAACTC 
AATTTTGGG-3′ and Gld2Xho1rev 5′-CTCGAGTCTTTTCAGGA-CAGCAGCTC-3′). 
The cDNA was digested with EcoRI/XhoI and ligated into pET20b. Quickchange Site 
directed mutagenesis (Agilent) was employed according to manufacturer’s instructions to 
generate a Gld2-His insertion variant, using primers Tut2Hisfor 5′-
GAACCTTTTGATGGAACA CATAATACAGCCAGAGCAGTGC-3′ and Tut2Hisrev 
5′-GCACTGCTCTGGCTGTA TTATGTGTTCCATCAAAAGGTTC-3′. The construct 
and mutation were verified by DNA sequencing (Genewiz). 
2.2.2 Gld2 expression and purification 
Escherichia coli BL21 (DE3) RIL cells (Agilent) were transformed with pET20b-
Gld2 and grown in LB medium containing ampicillin (100 µg/mL) and chloramphenicol 
(34 µg/mL) at 37°C until OD600 = 0.6. The temperature was lowered to 20°C and 
isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a final concentration of 250 
µM to induce protein expression. Cells were harvested after 19 hours by centrifugation 
and suspended in Buffer A (10 mM Tris-HCl, pH 8.0, 200 mM KCl, 5 mM MgCl2). Cells 
were broken by the addition of lysozyme followed by sonication on ice. The cell lysate 
was centrifuged for 45 minutes at 15,000g and 4°C. Cell free extract was loaded onto 
HisPur Ni-NTA resin (Thermo Scientific) equilibrated with Buffer A. The resin was 
washed with Buffer B (10 mM Tris-HCl, pH 8.0, 200 mM KCl, 5 mM MgCl2, 10 mM 
imidazole) and proteins were eluted with Buffer C (10 mM Tris-HCl [pH 8.0], 200 mM 
KCl, 5 mM MgCl2, 250 mM imidazole). The elution fractions containing Gld2 were 
dialyzed against Buffer D (10 mM Tris-HCl, pH 8.0, 200 mM KCl, 5 mM MgCl2, 10% 
glycerol) overnight at 4°C with gentle mixing and stored at -80°C. Gld2 protein 
concentration was determined by a Bradford test. 
2.2.3 Size exclusion chromatography 
A 200 µL sample containing Gld2 in Buffer A was passed through an ENrich SEC 
650 high-resolution size exclusion column (Bio-Rad) equilibrated with Buffer A. The 
flow rate was 0.75 mL/min and 1 mL fractions were collected upon injection of the 
sample. The fractions that corresponded to the peaks on the absorbance graph were 
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subjected to ammonium sulfate protein precipitation and analyzed by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on a 15% polyacrylamide gel. 
For the purposes of calibration, vitamin B12 (Mr ≈ 1.3 kDa), bovine insulin (Mr ≈ 6 
kDa), cytochrome c (Mr ≈ 13.6 kDa) bovine carbonic anhydrase (Mr ≈ 30 kDa), 
ovalbumin (Mr ≈ 43 kDa), BSA (Mr ≈ 67 kDa), ferritin (Mr ≈ 440 kDa) and 
thyroglobulin (Mr ≈ 669 kDa) were used as marker components and chromatographed 
under identical conditions. 
2.2.4 RNA substrate preparation 
The following RNA substrates were purchased from Sigma Aldrich: 
monophosphorylated  human let-7a-5p (5′ (p)-UGAGGUAGUAGGUUGUAUAGUU-
3′), unphosphorylated human let-7a-0p (5′-UGAGGUAGUAGGUUGUAUAGUU-3′), 
diphosphorylated human let-7a-5p-2p (5′ (pp)-UGAGGUAGUAGGUUGUAUAGUU-
3′), triphosphorylated human let-7a-5p-3p (5′ (ppp)-UGAGGUAGUAGGUUGUAUAGU 
U-3′), the poly(A) tail mimic 15A RNA (5′ (p)-AAAAAAAAAAAAAAA-3′), human 
microRNA miR-122-5p (5′ (p)-UGGAGUGUGACAAUGGUGUUUG-3′), and total E. 
coli tRNA. The coding sequence for a ribozyme-pre-let-7a with a T7 Promoter sequence 
was cloned into pUC19 for in vitro transcription with T7 RNA polymerase using the 
following primers (pre-let7 5′-CTAGATAATACGACTCACTATAGGGAGACTACTA 
CCTCACTGATGAGTCCGTGAGGACGAAACGGTACCCGGTATAGGTTGTATAG
TTTTAGGGTCACACCCAACTGGGAGATAACTATACAATCTACTGTCTTTCGAA 
-3′ and pre-let-7rev 5′-ATCCTTCGAAAGACAGTAGATTGTATAGTTATCTCCCA G 
TGGTGGGTGTGACCCTAAAACTATACAACCTACTACGGGTACCGTTTCGTCCT 
CACGGACTCATCAGTGAGGTAGTAGTCTCCCTATAGTGAGTCGTATTA-3′). 
Primers were phosphorylated, annealed and cloned into pUC19 using XbaI/BamHI. For 
in vitro transcription, the DNA template was amplified using primers Theforward (5′-
GTTGGGAAGGGCGATCGGTG-3′) and let-7PCRrev (5′-GAAAGACAGTAGATTGT 
ATAG-3′). The PCR product was purified by phenol chloroform extraction, and RNA 
was transcribed with T7 RNA polymerase as described previously44. Upon transcription, 
the ribozyme constructs auto-cleaves into ribozyme and pre-let-7a. The transcripts were 
separated by electrophoresis on a 12% denaturing polyacrylamide gel, the band 
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corresponding to self-cleaved pre-let-7a was excised from the gel and eluted as described 
previously45. 
2.2.5 Determination of enzymatic activity and substrate range 
10 µL reactions were carried out containing 100 nM Gld2 in Buffer D and 1 µM of 
the respective RNA substrates. Dithiothreitol (DTT) and MgCl2 were added for a final 
concentration of 1 mM and 3.2 mM, respectively. [α-32P]-UTP or [α-32P]-ATP (Perkin 
Elmer) were used as indicated at a final concentration of 0.33 µM. All reactions were 
incubated at 37°C for 20 minutes and stopped by the addition of 2 x RNA loading dye 
(95% v/v formamide, 0.1% w/v xylene xyanol, 0.1% w/w bromophenol blue, 10 mM 
ethylenediaminetetraacetic acid (EDTA)). Reactions were analyzed via gel 
electrophoresis on a 12% denaturing polyacrylamide gel and visualized with a 
phosphorimager (Storm 860 Molecular Imager). The radiolabelled RNA Decade marker 
(Ambion) was used as reference. 
2.2.6 Determination of enzyme kinetics 
20 µL reactions were carried out containing 100 nM Gld2 in Buffer D and 2 µM of 
let-7a. DTT and MgCl2 were added to a final concentration of 1 mM and 3.2 mM, 
respectively. Separate reactions contained one of the four NTPs at various concentrations. 
Three technical replicates were performed for each nucleotide concentration. Higher 
nucleotide concentrations were achieved by using a mixture of [α-32P]-labelled and 
unlabelled nucleotides. Nucleotide concentrations were adjusted so that in an 8-minute 
time course the reaction progressed linearly and < 10% of the total substrate RNA was 
converted to product. The following nucleotide concentrations were used:  ATP 0 - 15 
µM (0 µM, 0.01 µM, 0.1 µM, 1 µM, 10 µM, 15 µM); UTP 0 - 1000 µM (0 µM, 0.01 µM, 
0.1 µM, 1 µM, 10 µM, 50 µM, 100 µM, 300 µM, 1000 µM); GTP 0 - 1300 µM (0 µM, 1 
µM, 10 µM, 50 µM, 100 µM, 300 µM, 1000 µM, 1300 µM); CTP 0 - 1500 µM (0 µM, 1 
µM, 10 µM, 100 µM, 600 µM, 1000 µM, 1200 µM, 1500 µM). All reactions were 
incubated at 37°C for 30 seconds before Gld2 was added (at t = 0) and 5 µL samples 
were then taken out at 2, 4, 6, and 8 minutes. The reactions were stopped with the 
addition of 2 x RNA loading dye. Reactions were analyzed via gel electrophoresis on a 
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12% denaturing polyacrylamide gel and visualized by phosphorimaging overnight. To 
quantify product formation, a strip of Whatman filter paper was spotted with different 
known concentrations for each [α-32P]-labelled nucleotide and imaged on the same 
phosphorimaging screen. Spot intensity was quantified using ImageJ. Kinetic constants 
were derived from plotting initial velocity (vo) against nucleotide concentration. Kinetics 
were fitted to the standard Michaelis–Menten curve using Kaleida Graph 3.1 (Synergy 
Software) and SigmaPlot (Systat Software). Error bars represent 1 Standard Deviation 
from 3 replicates. 
2.2.7 Phylogenetic analysis 
Sequences were downloaded from the National Center for Biotechnology Information 
(NCBI). Sequence alignment and alignment editing was carried out using Muscle46 and 
the Multiseq alignment editor from VMD 1.8.747. A maximum likelihood phylogeny for 
Gld2 sequences was determined using PhyML48. The starting tree was generated with 
BioNJ, and the tree space was searched with the SPR followed by the NNI algorithm to 
find the best tree. The JTT+Γ model with 4 rate categories was applied. Likelihood 
parameters were initially estimated from the alignment, Shimodaira–Hasegawa bootstrap 
values were computed as implemented in PhyML. 
 
2.3 Results 
2.3.1 Gld2 displays RNA substrate promiscuity 
Gld2 has been implicated in multiple pathways of mRNA and miRNA regulation. To 
test whether Gld2 displays enzymatic activity in vitro, we recombinantly expressed and 
purified full length human Gld2 from E. coli. Gld2 eluted from a gel filtration column as 
a monomer. To evaluate Gld2 activity, we first assessed its substrate range. Previously 
suggested roles for Gld2 activity are in miRNA regulation, including miR-122 
adenylation25 and the uridylation of pre-let-7a and let-7a24,38. Another study linked Gld2 
to mRNA adenylation49. We therefore included miR-122, pre-let-7a, let-7a, total human 
mRNA and a poly(A) tail mimic comprised of 15 adenines (15A) in our initial assays and 
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total E. coli tRNA as a control.  
Surprisingly, Gld2 displayed adenylation activity on all substrates in vitro (Figure 
2.2). For miRNAs and the 15A RNA a single band was observed, corresponding to 
monoadenylation of the substrate RNAs. For the premature miRNA substrate, pre-let-7a, 
a band around 70 bases was observed, indicating single nucleotide addition. While the in 
vitro transcribed pre-let-7a was purified as a single transcript (Figure 2.3), additional 
bands of lower molecular weight were observed. These bands are likely due to the 
adenylation of partially degraded substrate RNA or degradation during the enzymatic 
reaction. For both total tRNA and total mRNA multiple bands were observed, but due to 
heterogeneity of the substrates we are unable to confirm that these are single nucleotide 
additions. Nevertheless, no clusters of ladder-like nucleotide additions were observed in 
these cases, indicating that the heterogenic substrates were likely monoadenylated.  
 
Figure 2.2: RNA substrates of Gld2. 
Gld2 was incubated with different RNA substrates and [α-P32]-ATP as indicated. 
Formation of [α-32P]-labelled RNA products was monitored by electrophoretic separation 
and subsequent phosphorimaging. Gld2 catalyzed [α-32P]-ATP addition to RNA 
substrates pre-let-7a (72 nts), mature human miRNAs let-7a-5p (22 nts), miR122 (22 nts), 
an oligo (A) tail mimic 15A (15 nts), and total E. coli tRNA and total human mRNA. A 
representative gel is shown. C is no enzyme control. 
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Figure 2.3: In vitro transcription of pre-let-7 RNA. 
Pre-let-7a was transcribed as a ribozyme-fusion RNA, which self-cleaves after 
transcription. The band corresponding to pre-let-7a (72 nts) was excised from the gel, 
purified and a single band was observed in a denaturing polyacrylamide gel 
electrophoresis after purification.  
 
2.3.2 Nucleotide preference of recombinant Gld2 
We determined the specificity of Gld2 for all of the four nucleotides ATP, CTP, GTP 
and UTP. In enzyme assays containing a single nucleotide species, pre-let-7a, and Gld2, 
the enzyme was active with all NTPs (Figure 2.4A). Gld2 can accommodate each NTP in 
the active site and catalyze their 3′ addition to pre-let-7a. In a competition assay, which 
included all four nucleotides in equimolar concentrations with only one [α-32P]-labelled 
nucleotide, only ATP was added to pre-le-7a (Figure 2.4B). Thus, while Gld2 displays 
relaxed specificity towards RNA substrates in vitro, it exhibits a clear preference for ATP 
in the presence of all four NTPs.  We further investigated whether the 5′-end of the RNA 
substrates influenced substrate recognition. No difference in enzyme activity was seen 
when differentially 5′-phosphorylated RNA substrates were assayed with [α-32P]-ATP 
(Figure 2.4C).  
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Figure 2.4: Nucleotide substrates of Gld2. 
Gld2 was incubated with varying nucleotides and the precursor miRNA let-7a or mature 
miRNA let-7a-5p. A) Addition of single [α-32P]-labelled nucleotides to pre-let-7a and 
Gld2 as indicated. B) Competitive nucleotide addition: In a competition assay, Gld2 was 
incubated with pre-let-7a in the presence of all four unlabelled nucleotides in equimolar 
amounts with a portion of the indicated nucleotide in an [α-32P]-labelled form. C) 5' end 
phosphorylation: Gld2 activity on let-7a-5p substrates with differentially phosphorylated 
5' ends were assayed with [α-32P]-ATP. Representative gels are shown. 5'-no p = 
unphosphorylated, 5'-p = monophosphate, 5'-pp = diphosphate, 5'-ppp = triphosphate. 
 
2.3.3 Gld2 is an adenylyltransferase 
Our initial experiments showed that Gld2 catalyzes the addition of all four 
nucleotides to pre-let-7a (Figure 2.4A). In the subsequent competition assay, a clear 
preference for ATP was observed (Figure 2.4B). This led us to further investigate the 
nucleotide specificity of Gld2, and we performed a detailed kinetic characterization of 
Gld2 with all four nucleotides with let-7a (Figure 2.5, Table 2.1). Our kinetic analysis 
confirmed that Gld2 displays the most affinity for ATP (KM ~ 0.2 µM) and is most 
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efficient with ATP. Significantly increased KM values for the other nucleotides, suggests 
far weaker binding affinity. Gld2 showed increases in KM of > 700-fold for UTP, 240-
fold for CTP, and > 1000-fold for GTP. The relative catalytic efficiency for the reactions 
indicates an 83-fold preference of ATP over UTP and 71-fold over GTP. Overall catalytic 
efficiency is greatest for ATP (kcat/KM = 12.8 x 10
-5 µM-1s-1) with 12.9% relative 
efficiency for CTP (kcat/KM = 1.66 x 10
-5 µM-1s-1), and 1.2% for UTP (kcat/KM = 0.15 x 10
-
5 µM-1s-1) and 1.4% for GTP (kcat/KM = 0.18 x 10
-5 µM-1s-1). Taken together, these data 
indicate that Gld2 NTP specificity is determined by productive binding of Gld2 to the 
respective nucleotide. While ATP is preferred and outcompetes all other NTPs, no 
nucleotide is specifically excluded from the active site. 
 
 
Figure 2.5: Dependence of the reaction rate on nucleotide concentration. 
The plot shows the initial velocity of the enzyme reaction plotted against concentration of 
A) ATP, B) CTP, C) GTP and D) UTP. Three technical replicates were performed for 
each nucleotide concentration. Error bars show one standard deviation. 
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Table 2.1: Nucleotide addition kinetics of Gld2. 
Relative catalytic efficiency is the relative percentage in kcat/KM that is calculated as the 
ratio of kcat/KM for the nucleotide listed in the far-left column over the kcat/KM for ATP. 
Physiological nucleotide conditions are derived from Traut et al., 1994. Standard 
deviations are reported. Reaction conditions are given in Materials and Methods. 
 Vmax (µM/s) KM (µM) kcat (s-1) kcat/KM (µM-1s-1) 
ATP (2.93 ± 0.16) x 10-6 0.229 ± 0.077 (2.93± 0.16) x 10-5 12.8 x 10-5 
UTP (24.8 ± 1.17) x 10-6 169 ± 23.3 (24.8 ± 1.17) x 10-5 0.15 x 10-5 
CTP (91.4 ± 5.16) x 10-6 55.0 ± 21.9 (91.4 ± 5.16) x 10-5 1.66 x 10-5 
GTP (40.3 ± 5.97) x 10-6 230 ± 112 (40.3 ± 5.97) x 10-5 0.18 x 10-5 
 
 Relative efficiency kcat/KM Physiological concentrations 
ATP 100% 2102 µM 
UTP 1.2% 253 µM 
CTP 12.9% 91 µM 
GTP 1.4% 305 µM 
   
2.3.4 Nucleotidyltransferase specificity arose multiple times during 
evolution 
Gld2 is a member of the non-canonical poly(A) polymerases, a diverse group of 
enzymes with varying RNA and nucleotide preferences. It includes enzymes with 
nucleotide specificity ranging from strictly ATP to ambiguous ATP or UTP, to exclusive 
UTP-adding enzymes. While some enzymes have a distinct substrate preference, such as 
the U6 snRNA uridylating enzyme TUT628,50, which is both UTP and U6 snRNA 
specific, other enzymes are more promiscuous in their substrate specificity. TUT4 and 
TUT7, for example, have been shown to uridylate miRNAs24,36, as well as histone 
mRNA51 and cytoplasmic mRNA30. The Schizosaccharomyces pombe homolog Cid1 
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protein was initially thought to act as an mRNA adenylating enzyme but was later 
characterized as a uridylyltransferase with 1% residual adenylation activity52.  
Gld2 was initially annotated as an adenylyltransferase, but recent in vivo24 and in 
vitro24,25,38 evidence and its sequence similarity to confirmed TUTs (30% and 32% amino 
acid sequence identity with TUT4 and TUT7, respectively) suggests a possible 
uridylyltransferase activity. The similar domain structure of uridylyl- and 
adenylyltransferases, as well as a high sequence similarity, suggests that these enzymes 
evolved from a common ancestor. To elucidate the phylogenetic background evolution of 
these enzymes, we performed a detailed phylogenetic analysis of the enzyme superfamily 
to trace the evolutionary origins of NTP specificity. The phylogeny of the 
nucleotidyltransferase family includes over 400 sequences (Figure 2.6).  
Our analysis shows that nucleotidyltransferases display a classical star phylogeny, 
with several distinct subgroups. Interestingly, uridylyl- and adenylyltransferases do not 
form two separate clades, but rather Tutases emerge from distinct groups dominated by 
PAPs. Uridylyltransferases are derived from distinct subfamilies of adenylyltransferases, 
and Tutase activity, thus, evolved multiple times independently. One group shows the U6 
snRNA uridylating enzyme TUT650 evolved from a parent clade composed of known and 
putative adenylyltransferases. The nucleotide specificity of TUT6 is, however, not 
restricted to snRNA uridylation, as it was additionally found to adenylate selected 
mRNAs53,54. TUT6 is most closely related to the non-canonical mitochondrial poly(A) 
polymerase PAPD1, which mediates RNA decay by polyadenylation55. A second distinct 
subgroup includes the uridylyltransferase Cid1, which initiates RNA decay by 
uridylation29, and Cid14, a poly(A) polymerase that acts on rRNAs56 and telomeres57. 
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Figure 2.6: Phylogeny of the Tutase/PAP superfamily. 
Gld2 is most closely related to the genuine uridylyltransferases TUT4/TUT7. Known 
enzymatic activities are colour-coded: purple, UTP preference; green, ATP preference; 
black, unknown. Bootstrap values over 90% are denoted with a star. Sequence data were 
downloaded from the Integrated Microbial Genomes database. The tree was calculated 
with PHYML using a BioNJ starting tree and SPR tree search followed by NNI branch 
swapping to optimize the tree. Bootstrap values were computed according to the 
Shimodaira–Hasegawa re-estimation of log-likelihood test implemented in PHYML. 
 
2.3.5 Insertion of a histidine residue confers UTP specificity 
Gld2 displays clear nucleotide specificity for ATP, as demonstrated by kinetic 
analysis of Gld2 activity on all four nucleotides and in competition experiments. Our 
phylogenetic analysis of the nucleotidyltransferase family suggests that 
uridylyltransferase activity evolved from adenylyltransferases multiple times during 
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evolution (Figure 2.6). Previous reports showed that the mutation of the S. pombe Cid1 
uridylyltransferase active site histidine (H336, Figure 2.7) to asparagine broadens its 
substrate specificity to include ATP58. In Gld2, the corresponding amino acid is lacking 
(Figure 2.7A). Consequently, we tested whether an insertion of a histidine residue at the 
position homologous to Cid1 position H336 (between Gld2 amino acids T439 and N440 
(Figure 2.7B)) confers UTP specificity over ATP. Purified recombinant Gld2 and Gld2-
His (Figure 2.8A) were tested with RNA substrates let-7a (Figure 2.8B) and 15A (Figure 
2.8C) and radiolabelled ATP or UTP. As expected, Gld2 displayed activity with ATP and 
UTP for both substrates in a non-competitive assay (Figures 2.8B panel 1, and 2.8C panel 
1 and Figure 2.4A). The Gld2-His insertion variant, however, displayed significantly 
decreased activity with ATP. For let-7a, no activity was observed with ATP, while a band 
is visible when incubated with UTP. Similarly, we observed no band for the poly(A) tail 
mimic 15A when incubated with ATP, while incubation with UTP lead to a ladder-like 
addition of nucleotides. In all cases, unlike UTP, ATP was excluded as a substrate. Thus, 
the insertion of a histidine residue homologous to Cid1 H336 conferred UTP selectivity 
in Gld2. 
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Figure 2.7: Nucleotide preference is defined by a histidine residue. 
A) Excerpt from a multiple sequence alignment of 440 nucleotidyltransferase sequences. 
After the alignment sequences were grouped into phylogenetic subgroups and two 
representative sequences are depicted. Sequence similarities within each group were 
colour-coded. Confirmed nucleotidyltransferases Cid1, TUT4, TUT6 and TUT7 and their 
homologs contain a histidine (#), which confers uridyl selectivity. Adenylyltransferases 
either substitute histidine with a smaller amino acid (leucine in PAPD1) or entirely lack 
this residue (Gld2). B) Excerpt of a structural alignment between Cid1 (pdb 4FHP) and 
PAPD1 (pdb 3PQ1). The depicted ribbon diagram shows a structural superposition of 
human mitochondrial PAPD1 (grey) and Cid1 (cyan). Asn367 of Cid1 aligns with the 
homologous Asn273 of PAPD1. Cid1 His336 points into the active site and makes 
contact with UTP.  
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Figure 2.8: Insertion of an active site histidine into Gld2 alters nucleotide specificity. 
A) Gld2 and Gld2-His purification. Recombinant His-tagged Gld2 and the Gld2-His 
mutant were purified via Ni-NTA chromatography to apparent homogeneity as judged by 
SDS-PAGE. B) and C): Nucleotide preference of Gld2 and Gld2-His. Recombinant 
enzymes were incubated with and without RNA substrates and radiolabelled ATP or 
UTP. Formation of [α-32P]-labelled RNA products was monitored by electrophoretic 
separation and subsequent phosphorimaging. RNA substrates were B) let-7a and C) 15A. 
Representative gels are shown. 
 
2.4 Discussion 
2.4.1 Gld2 is an adenylyltransferase 
Previous studies presented evidence associating Gld2 with monoadenylation25 or 
monouridylation24,25,38 of miRNAs in humans. While monoadenylation confers increased 
miRNA stability, monouridylation is a required step in biogenesis of Group II miRNAs. 
During maturation, Group II miRNAs are processed into pre-miRNAs with a single 
nucleotide 3′-overhang. TUT4, TUT7, and potentially Gld2 add an essential uridyl 
residue to 1 nt 3′-overhang pre-miRNA to yield a 2 nucleotide 3′-overhang, which is a 
prerequisite for processing by Dicer24,42. In Xenopus laevis and Caenorhabditis elegans, 
Gld2 is required for polyadenylation of specific mRNAs, aided by RNA binding proteins 
such as CPEB and Gld3, respectively31,38.  
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To elucidate the nucleotide preference of human Gld2, we carried out a detailed 
enzyme kinetic analysis. Using purified enzyme, we demonstrated that Gld2 is an 
adenylyltransferase preferentially adding single nucleotides to small RNAs. The catalytic 
efficiency of Gld2 is reduced 83-fold for UTP in comparison to ATP. Conversely, the 
uridylyltransferase Cid1 displays a 100-fold higher specificity for UTP over ATP58,59. 
Our data shows a clear preference of ATP over all other nucleotides. The rate-limiting 
step is most likely the NTP binding event. The KM for ATP is 0.23 µM, which is about 
10,000-fold lower than the cellular ATP concentration of 2.1 mM60. Thus, Gld2 
encounters a vast excess of ATP in the cell and will attain maximal substrate turnover. 
Cellular UTP, GTP, and CTP concentrations are overall lower than ATP concentrations60. 
In addition, we measured KM values in the 100 μM range for the other NTPs. 
Physiological concentrations for UTP and GTP are between 250-300 μM60, which is 
between 1 and 6-fold higher than the respective KM. The overall higher KM of Gld2 for 
UTP, CTP, and GTP combined with a much higher cellular ATP concentration further 
shifts enzymatic activity towards adenylation. Interestingly, at a CTP concentration 1000-
fold in excess of the physiological concentration the catalytic turnover for CTP is 30-fold 
higher than for ATP. Once NTP binding occurs, the other NTPs are ligated to the 
substrate RNA more rapidly than ATP (Table 2.1). Nevertheless, the low affinities of 
Gld2 for nucleotides other than ATP and the fact the other NTPs fail to outcompete ATP 
(Figure 2.4B) indicate Gld2 activity is shifted to adenylation under physiological 
conditions.  
 Our data indicate that Gld2 may not have evolved to function exclusively with 
ATP, as we could show that Gld2 is active with UTP as well as GTP and CTP, albeit with 
low efficiency. While we cannot exclude that post-translational modifications or 
interactions with other proteins may influence nucleotide specificity, our data suggests 
that the observed NTP specificity is only in part determined by binding constants. Gld2 
nucleotide specificity alone provides an 83-fold preference for ATP over UTP, which is 
combined with a cellular environment that has 10-fold excess of ATP compared to the 
other NTPs. Gld2 substrate preference and the cellular nucleotide concentrations together 
increase Gld2 selectivity towards ATP to >800-fold, enhancing the enzyme’s specificity 
without evolving a precisely selective adenylyltransferase. 
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2.4.2 Gld2 monoadenylates small RNA substrates 
In in vitro activity assays, Gld2 monoadenylates a variety of small RNAs, and does 
not specifically discriminate between different substrate RNAs. Our data shows that Gld2 
displays activity on tRNAs, miRNAs, pre-miRNAs and mRNA alike, with a slight 
preference for miRNAs (Figure 2.2). This agrees with earlier studies of X. laevis and C. 
elegans Gld2 homologs, which showed a role for Gld2 in miRNA metabolism32. The 
RNA substrate promiscuity that we observed with human Gld2 may be related to the fact 
that this minimal adenylyltransferase lacks RNA binding domains, which are thought to 
confer substrate specificity in Gld2’s closest human homologs, TUT4 and TUT7 (Figure 
2.1). Interestingly, we found no evidence of polyadenylation activity on any of the 
employed substrates. For processive polyadenylation, human Gld2 most likely requires 
the assistance of RNA proteins in vivo, which may confer specificity or activate 
elongation. Intriguingly, an extended incubation of Gld2 or Gld2-His with 15A RNA and 
UTP lead to a ladder-like addition of nucleotides (Figure 2.8C). While UTP is not the 
natural Gld2 substrate, it is possible that polyuridylation, in contrast to polyadenylation, 
does not require accessory proteins. 
Several studies from non-human Gld2 homologs show that in the presence of RNA 
binding proteins such as CPEB38 and Gld331 in X. laevis and C. elegans, respectively, 
Gld2 can processively add multiple adenine residues. To date, no such interaction has 
been shown for human Gld2, but the fact that Gld2 alone hardly discriminates between 
several RNA substrates suggests the regulation of substrate specificity by additional RNA 
binding proteins. While humans lack a Gld3 homolog, several CPEB homologs are 
encoded in the genome. In X. laevis, an additional poly(A) polymerase Gld4 enzyme 
polyadenylates p53 mRNA in a CPEB dependent manner. In this case, Gld2 is not 
associated with CPEB directly, but regulates its expression via miR-122 adenylation39. In 
C. elegans the RNA binding protein Gld3 stimulates Gld2 catalyzed polyadenylation by 
increasing its affinity to the substrate RNA32. Similarly, TUT7 can be triggered to 
polyuridylate RNA substrates in association with the RNA binding protein Lin28A23,61. 
Potential Gld2 associated proteins, however, remain to be identified. 
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2.4.3 Convergent evolution of Tutase activity by histidine insertion in 
the PAP active site 
Recent biochemical and structural data on fission yeast Cid158,59 and X. laevis TUT762 
suggested that the nucleotide preference of nucleotidyltransferases is determined by a 
single histidine near the active site (Figure 2.7A and B). In Cid1, histidine 336, which is 
located on a flexible loop near the catalytic site, sterically excludes ATP from the active 
site. Prior experiments have shown that mutation of this histidine to a smaller amino acid 
broadens nucleotide specificity in uridylyltransferases to include ATP, concluding that an 
asparagine to histidine mutation confers ATP specificity58,59,62. Our multiple sequence 
alignment (Figures 2.7B) and structural superposition of Cid1 and human mitochondrial 
PAPD1 (Figure 2.7B) show that the Asn337 in Cid1 is homologous to Asn273 residue of 
PAPD1. This Asn is strictly conserved in all members of the nucleotidyltransferase 
superfamily. The multiple sequence alignment clearly shows that Cid1 His336 is an 
inserted residue relative to the PAPD1 homolog (Figure 2.7A). His336 points directly 
into the active site in the structural superposition, making contact with the UTP substrate, 
while the Asn337/Asn273 residue is oriented away from the active site (Figure 2.7B). 
The Asn conformation is structurally conserved between Tutases and PAPs. 
Consequently, UTP selectivity of Gld2, which is phylogenetically derived from TUT4/7 
(Figure 2.6), is conferred by a histidine insertion, rather than an Asn to His mutation as 
previously suggested58,59,62. 
The here presented phylogenetic analysis shows that the presence/absence of the 
TUT-specific histidine is consistent within all nucleotidyltransferase groups and 
coincides with the divergence of uridylyltransferases from adenylyltransferases. While 
previous studies alluded to a point mutation from histidine (denoted with # in Figure 
2.7B) to asparagine58, conferring ATP over UTP selectivity, our sequence alignment 
clearly shows that the respective asparagine (denoted with a * in Figure 2.7B) is part of a 
highly conserved motif found in all nucleotidyltransferases. Thus, a histidine insertion 
rather than a mutation confers uridine specificity. In agreement with our biochemical 
data, the respective residue is absent from the Gld2 amino acid sequence, which vacates 
the active site for the larger ATP. Similarly, Cid14 is also lacking the respective histidine 
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residue, conferring a preference of ATP over UTP. Consequently, a histidine insertion 
into Gld2 switched the nucleotide preference from ATP to UTP, excluding the larger 
ATP from the active site. Gld2-His shows no activity towards ATP but is active on 
multiple substrates with UTP (Figure 2.8B and C). These data clearly show that a single 
amino acid insertion can change nucleotide specificity in nucleotidyltransferases. 
The human uridylyltransferases TUT4 and TUT7 are closely grouped within the 
phylogeny and are likely the result of recent gene duplication in the chordata linage. 
Consistent with their amino acid sequence similarity, Gld2 is most closely related to the 
TUT4/7 phylogenetic group, although Gld2 has the conserved Tutase histidine deleted. In 
adenylyltransferases, such as human PAPD1 and its homologs, leucine replaces histidine. 
How a leucine insertion impacts enzyme activity and substrate specificity remains to be 
elucidated. Considering that uridylyltransferase activity has evolved multiple times, the 
flexible loop which harbors histidine 336 in Cid1 can be denoted as a preferred spot for 
mutations and insertions, allowing for facile alterations in substrate specificity. Once 
RNA specificity has been determined, the ability to change nucleotide specificity through 
this preferred spot would allow the cell to easily obtain different enzymes that 
differentially modify the same RNAs.  
The phylogeny, supported by our mutational analysis of Gld2, shows that 
uridylyltransferase activity diverged from adenylyltransferase activity multiple times 
during evolution and prior to the split of slime molds and bilateria. Interestingly, non-
canonical nucleotidyltransferases are very prevalent in Fungi, which include several 
nucleotidyltransferase clades (e.g., Cid16, Cid11/13) not found in other organisms. These 
homologs appear to result from initial gene duplication, giving rise to Cid16 and Cid 
11/13 groups, with a more recent duplication leading to the divergence of Cid11 and 
Cid13. The nuclear poly(A) polymerase Cid1163 and the Cid13 homolog encode an Arg, 
while Cid16 homologs a Lys in position His336 of Cid1. The biological function of these 
enzymes is not entirely clear, but the small positively charged side chain suggests a role 
in RNA adenylation, as ATP could still be spatially accommodated in the active site. One 
nucleotidyltransferase clade of entirely unknown function contains PAPD1-like proteins 
with homologs in Drosophilidae and plants. No data are available on nucleotide 
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specificity or biological function of these proteins. This group is diverse in its active site 
constituents. Interestingly, members of the Drosophilidae encode two PAPD1-like 
homologs. One homolog encodes an arginine, and one a histidine, suggesting a recent 
gene duplication to allow for both uridylyltransferase and adenylyltransferase activity. 
These homologs could potentially share a specific RNA substrate range or interacting 
protein partners, while differing in nucleotide preference, thus fulfilling distinct 
biological functions. 
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Chapter 3 
3 Gld2 activity is regulated by phosphorylation in the N-
terminal domain 
3.1 Introduction 
MicroRNAs (miRNAs) are critical regulators of gene expression that are essential to 
human life, normal cellular function, and development. De-regulation of miRNAs is, 
perhaps not surprisingly, associated with a number of human diseases1. MiRNAs regulate 
the expression of many genes, including oncogenes, by complementary base pairing with 
the 3′-untranslated regions (UTRs) of mRNAs, which normally inhibits protein 
synthesis1.  
MiRNAs themselves are post-transcriptionally regulated by the addition of single or 
multiple adenine (A) or uridine (U) residues to their 3′-ends. This untemplated RNA 
editing is now recognized as an important mechanism regulating cellular miRNA 
homeostasis2,3. The addition of a single A to the 3′-end on certain miRNAs leads to 
increased stability4. Conversely, the activity of mature miRNAs is reduced by the 
addition of a single 3′-U residue5,6. The addition of multiple U residues to precursor 
miRNAs (pre-miRNAs) triggers subsequent degradation by the U-specific exonuclease 
Dis3L2 (Dis3-like 3′-5′ exonuclease 2)3. Although uridylation is commonly associated 
with silencing and degradation of RNAs, monouridylation of Group II pre-miRNAs 
lacking a critical 3′-end overhang nucleotide is required for miRNA maturation and 
processing by Dicer7. Cellular mechanisms that regulate miRNAs through 3′-terminal 
nucleotide additions are of fundamental relevance to the molecular basis of diseases 
characterized by de-regulated miRNA metabolism3,8. 
A diverse family of terminal RNA nucleotidyltransferases (TENTs) catalyzes 3′-A 
and U additions to RNAs in human cells. The nucleotidyltransferase Gld2 (germline-
development 2, TENT2) was first identified as a regulator of meiosis in Caenorhabditis 
elegans9 and was later shown to extend the poly(A) tails of mRNAs (Figure 3.1A), 
leading to enhanced mRNA stability and increased abundance of the encoded protein10. 
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In humans, Gld2 stabilizes miR-122 in the liver and fibroblasts through 
monoadenylation4,11 and mRNAs via polyadenylation12 (Figure 3.1A).  
Gld2 is thought to be part of a larger protein complex involved in RNA modification 
and germ cell formation13. Although some reports7 suggested that Gld2 may function as a 
uridylyltransferase, we recently characterized human Gld2 as a bona fide 
adenylyltransferase in vitro14. Our data confirmed a basal activity of Gld2 with UTP, but 
the 80-fold higher catalytic efficiency for ATP makes the enzyme strongly selective for A 
additions14. Gld2 encodes a nucleotidyltransferase domain and a poly(A) polymerase-
associated domain that are required for catalytic activity as well as a predicted disordered 
N-terminal domain of unknown function10 (Figure 3.1B), yet lacks identifiable RNA 
binding motifs. The crystal structure of a truncated C. elegans Gld2 in complex with the 
interacting protein Gld3 shows that the two essential Gld2 catalytic domains share the 
same fold as other nucleotidyltransferases15. 
Cellular mechanisms that regulate miRNAs through 3′-end nucleotide additions are of 
fundamental relevance to the molecular basis of diseases characterized by de-regulated 
miRNA metabolism3,8. Gld2 and its substrate miR-122 play a role in Hepatitis C virus 
(HCV) infection and in hepatic cancer16. MiR-122 is one of the most abundant miRNAs 
in the liver, with an essential role in maintaining liver homeostasis and differentiation16. 
During HCV infection, miR-122 binds to two sites in the viral 5′-UTR of the Hepatitis C 
viral RNA and is required for HCV infection16,17. The miR-122 interaction with the 5′-
UTR enhances viral replication by increasing the formation of ribosome complexes to 
increase viral protein production. The binding of miR-122 to protein argonaute-2 (Ago2) 
in the RNA-induced silencing complex (RISC) also protects viral RNA from 
exonucleases16. Interestingly, the HCV core protein was shown to bind to Gld2 in the 
cytoplasm and inhibit its nucleotide addition activity. The subsequent reduction in miR-
122 abundance allows HCV to maintain low levels of viral protein production to facilitate 
continuous viral replication and infection of host cells18. Consequently, inhibition of Gld2 
by the HCV core protein decreases miR-122 stability and abundance. Low miR-122 
levels, in turn, are associated with hepatic cancer, linking HCV infection to the 
development of hepatocellular carcinoma (HCC)18,19. Hepatitis B virus X-protein (HBx) 
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was also shown to reduce Gld2 protein levels and cause an increase in cationic amino 
acid transporter 1 (CAT-1), a target of miR-12220–22. CAT-1 is involved in the 
tumorgenesis of the Hepatitis B virus (HBV)20. Miravirsen, an anti-miR-122 
oligonucleotide, is in Phase II trials to treat Hepatitis C and has been shown to decrease 
levels of miR-122 for a prolonged period of time, resulting in decreased HCV RNA 
levels in patients23–25. As high levels of miR-122 have been observed in colorectal liver 
metastasis, Miravirsen has been suggested as a potential anti-cancer drug as well26. 
While it is clear that Gld2 plays a role in promoting miRNA stability3,14,16, cellular 
mechanisms that regulate Gld2 activity were previously unknown. In HCC cells, miR-
122 is destabilized despite no observed changes in Gld2 protein levels18,19. These data 
suggest the existence of a clinically relevant mechanism that regulates Gld2 activity via 
post-translational modification. We demonstrate that Gld2 activity is indeed regulated by 
phosphorylation. We found that Gld2 is phosphorylated at specific serine residues in the 
predicted disordered N-terminal domain in vivo, which dramatically impact catalytic 
activity and substrate specificity. We found protein kinases A (PKA) and B (Akt1) site-
specifically phosphorylate Gld2 at S116, which abolishes 3′-nucleotide addition activity. 
The data reveal tumor suppressor miRNAs as a previously unrecognized target of 
oncogenic protein kinases. 
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Figure 3.1: Pathways regulated by Gld2 and Gld2 domain architecture. 
A) Known functions of Gld2. Gld2 stabilizes mature miRNA and mRNA through 
monoadenylation or polyadenylation of the 3’-end. Mononucleotide addition of Group II 
pre-miRNAs on the 3′-end by Gld2 allows recognition by Dicer to be processed to mature 
miRNAs. This is followed by strand selection by Argonaute (AGO) and incorporation 
into the RNA-induced silencing complex (RISC). The different pathways are represented 
by solid or dashed lines. B) Schematic of Gld2 showing the nucleotidyltransferase 
domain (NTR) and poly(A) polymerase-like domain (PAP).  
 
3.2 Materials and Methods 
3.2.1 Multiple sequence alignment 
Alignments was performed as previously described in Chapter 214. Briefly, 250 
mammalian Gld2 sequences were downloaded from NCBI. Sequence alignment and 
alignment editing were performed with Muscle27, MultiSeq from VMD 1.8.728, and 
Wasabi29. 
 
64 
 
3.2.2 Plasmids 
Homo sapiens Gld2 was codon-optimized (Genewiz, South Plainfield, NJ, USA) for 
expression in Escherichia coli. The gene was cloned into pGEX-6P-2 with an N-terminal 
TEV cleavage site using BamHI and XhoI restriction sites. Mutants were generated 
through site-directed mutagenesis30. All primers are listed in Appendix A Table A1. 
Successful cloning was verified by DNA sequencing at the London Regional Genomics 
Centre, London, ON, Canada. Cloning of Akt1 and PDK1 and Akt1 production and 
purification were previously described31. 
3.2.3 Gld2 protein production and purification 
Wildtype Gld2, glutamic acid mutants, and alanine mutants were transformed into E. 
coli BL21 (DE3) cells (Invitrogen, Carlsbad, CA, USA) and grown to an OD600 of 0.6 at 
37°C. Protein production was induced by 500 µM isopropyl β-D-1-thiogalactopyranoside 
(IPTG) and grown at 16°C for 18 hrs. Cells were harvested in GST wash buffer (50 mM 
Tris-HCl [pH 8.0], 300 mM NaCl, 5 mM MgCl2) and ethylenediaminetetraacetic acid 
(EDTA)-free mini protease inhibitor cocktail (Roche, Basel, Switzerland) before cell 
lysis with a French pressure cell press. The cell lysate was centrifuged at 64,000 x g for 1 
hr at 4°C and the supernatant was loaded onto a GSTrap Fast Flow 5mL (GE Healthcare). 
Protein purification was automated on the ÄKTA Pure (GE Healthcare). Protein was 
eluted with an increasing gradient of GST elution buffer (50 mM Tris-HCl [pH 8.0], 300 
mM NaCl, 5 mM MgCl2, 10 mM reduced glutathione). Eluted fractions were pooled, 
concentrated, and dialyzed against storage buffer (50 mM Tris-HCl [pH 8.0], 200 mM 
NaCl, 5 mM MgCl2, 10% glycerol) at 4°C overnight. The proteins were aliquoted and 
stored at -80°C until further use. 
3.2.4 Western blotting 
Purified enzyme samples were combined with 3 x sodium dodecyl sulfate (SDS) 
loading dye (188 mM Tris-HCl [pH 6.8], 3% SDS (w/v), 30% glycerol, 0.01% 
bromophenol blue, 300 mM Dithiothreitol (DTT)) and electrophoresed on two identical 
10% polyacrylamide SDS gels. One gel was stained with Coomassie Brilliant Blue G-250 
and imaged on the ChemiDoc MP Imaging System (BioRad). The other gel was 
 
65 
 
transferred to a polyvinylidene difluoride (PVDF) membrane using the Trans-Blot Turbo 
Transfer System (BioRad). The membrane was blocked in 3% bovine serum albumin 
(BSA), 1 x phosphate-buffered saline 1% Tween (PBS-T) for 2 hrs at room temperature 
(RT) and incubated with anti-Gld2 (PA5-25015, ThermoFisher Scientific) in 3% BSA, 1 
x PBS-T (1:1000) overnight at 4°C. The membrane was washed 3 x 10 min in 1% BSA, 1 
x PBS-T at RT, incubated with IRDye 800CW goat anti-rabbit IgG (926-32211, LI-COR) 
in 1% BSA, 1 x PBS-T (1:5000) for 2 hrs at RT, washed 3 x 10 min in 1 x PBS-T, and 10 
min in 1 x PBS. The membrane was imaged on the Odyssey Classic (LI-COR). 
3.2.5 Nucleotide addition assay 
Gld2-catalyzed reactions and product quantification were carried out as described 
previously in Chapter 2. Briefly, reactions contained 1 µM ATP (0.835 µM unlabelled 
ATP and 0.165 µM [α-32P]-ATP (Perkin Elmer)), 2 µM 5p-miR-122 (22 nt) or 15A RNA 
(15 nt) (SigmaAldrich), and 100 nM Gld2. Each Gld2 enzyme was incubated with 1 µM 
unlabelled and [α-32P]-labelled ATP and 2 µM RNA substrate. Reactions were incubated 
at 37°C and samples were taken every 2 minutes and stopped with the addition of 2 x 
RNA loading dye. Reactions were analyzed via electrophoretic separation and subsequent 
phosphorimaging on a Storm 860 Molecular Imager. Product formation was quantified by 
spotting a range of known concentrations of [α-32P]-ATP onto a strip of Whatman filter 
paper that was imaged on the same phosphorimaging screen as the gel. Specific activity 
was calculated from the linear slope of the curve using Microsoft Excel and the standard 
errors and deviations were obtained from triplicate reactions. SigmaPlot (Systat 
Software) was used to determine statistical significance (p values) for changes in Gld2 
activity. 
3.2.6 Fluorescence anisotropy 
Dissociation constants (Kd) of Gld2 substrates miR-122 and 15A were determined in 
100 µL reactions in black plates containing 3.2 mM MgCl2, 1 mM DTT, 20 nM 5′-end 
labelled miR-122 (22 nt) or 15A RNA (15 nt), and 0-100 nM Gld2 enzyme incubated for 
20 minutes at room temperature in the dark. The RNAs were labelled on the 5′-end with 
6-carboxyfluorescein (6-FAM) (SigmaAldrich) and the following enzyme concentrations 
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were used (nM): 0, 0.5, 1, 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 30, 40, 50, 60, 80, 100. 
Fluorescence polarization was measured on a Victor3V (PerkinElmer) with an excitation 
of 492 nm and emission of 535/20 nm. Readings were subtracted from the no enzyme 
control and three technical replicates were performed for each RNA and enzyme. 
SigmaPlot (Systat Software) was used to generate the plots, determine the Kd, and 
calculate the standard errors and p values. 
3.2.7 Identification of potential kinases 
Two online tools were used to generate a list of potential Gld2 kinases. PhosphoMotif 
Finder identifies putative kinase binding sequences in a query sequence based on the 
binding motifs of kinases as well as their substrate sequences identified in the literature32. 
GPS 3.0 predicts kinase phosphorylation sites in the query sequence using a 
computational prediction program33. 
3.2.8 Dot plot kinase activity assays 
Kinase assays were performed as previously described31. Briefly, reactions containing a 
kinase, wildtype Gld2, and [γ-32P]-ATP (Perkin Elmer) were carried out at 37°C. 
Samples were taken at various timepoints and stopped by spotting on P81 paper. The P81 
paper was washed, air-dried, exposed to a phosphor screen, and visualized with a 
phosphorimager (Storm 860 Molecular Imager).  
3.2.9 Kinase activity assays using SDS gels 
In the following assays, Gld2 was tested as a protein substrate for several human 
kinases. Kinase assays were performed in 60 µL reactions containing 900 nM Gld2, 
kinase buffer (20 mM MOPS [pH 7.0], 25 mM β-glyceraldehydephosphate, 25 mM 
MgCl2, 5 mM EGTA [pH 8.0], 1 mM Na2VO4, 0.1 mM ATP, 13.2 nM [γ-
32P]-ATP 
(Perkin Elmer)). Reactions were initiated with the addition of the specified kinase. Since 
kinases varied in activity, final concentrations were adjusted according to published 
values using 25 nM CK2α, 1.43 nM CK2 holoenzyme, 33 nM fully activated 
ppAkt1T308,S473, 30 nM Abl, 0.45 nM PKA, or 12 nM CDK5 in a kinase dilution buffer 
(0.1 mg/mL BSA, 5 mM MOPS [pH 7.2], 25 mM β-glyceraldehydephosphate, 5 mM 
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MgCl2, 1 mM EGTA [pH 8.0], 1 mM Na2VO4, 100 mM NaCl). Reactions were incubated 
at 37 °C for 15 minutes on a microcentrifuge shaker. Samples (20 µL) were taken every 5 
minutes and the reaction was stopped with the addition of 2 x SDS loading dye. Purified 
recombinant kinases CK2α, CK2 holoenzyme, Abl, PKA, and CDK5 were a generous 
gift from Dr. David W. Litchfield (The University of Western Ontario, Canada). Reaction 
products at each time point were separated on a 10% polyacrylamide SDS gel. The gel 
was exposed to a storage phosphor screen overnight at -80°C and visualized with a 
phosphorimager (Storm 860 Molecular Imager). Kinase assays and quantification were 
previously described31,34.  
3.2.10 Isolation of phosphorylated Gld2 for downstream assays 
For mass spectrometry and downstream Gld2 activity assays, large-scale kinase 
reactions were performed as above with 0.1 mM unlabelled ATP and 80 nM PKA for 15 
minutes. To isolate the resulting phosphorylated Gld2 (pGld2), the reactions were loaded 
onto GST SpinTrap columns (GE Healthcare) and pGld2 was eluted with GST elution 
buffer. The isolated pGld2 was used immediately for downstream assays. The large-scale 
kinase reaction was repeated with a control lacking the kinase. 
3.2.11 Phosphorylation of Gld2 using HEK 293 cell extract 
HEK 293 cells in 100 mm plates were grown to approximately 90% confluency in 
Dulbecco’s Modified Eagle’s Medium (DMEM) (319-005-3L, Wisent) with 10% fetal 
bovine serum (FBS) (098150, Lot #185700, Wisent) and 1% penicillin-streptomycin 
(450-201-EL, Wisent). Epidermal growth factor (EGF) was added to each plate to a final 
concentration of 50 ng/mL and incubated at 37°C for 1 hr. Cells were harvested and 
resuspended in 5 x kinase buffer with 5 mM phenylmethylsulfonyl fluoride (PMSF). 
Cells were broken with a Q125 Sonicator (Qsonica) six times at 20% amplitude and 1 sec 
on, 1 sec off. Using the cell extract as a source of active kinases, we performed a kinase 
reaction. This was repeated with unstimulated HEK 293 cell extract. Gld2 was isolated 
using a GST Spintrap column and possible Gld2 phosphorylation sites were analyzed by 
mass spectrometry. 
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3.2.12 Mass spectrometry 
Mass spectrometry (MS) analysis of tryptic digested peptides was carried out on the 
EasyLC1000-QExactive tandem LC-MS system (ThermoFisher Scientific). A full 
scanning (full MS/dd-MS2 TopN, data dependent acquisition mode in a Q-Exactive) was 
performed to obtain an overview of all possible protein modifications within Gld2. 
Parallel-reaction monitoring (PRM) was then carried out to further verify the 
phosphorylation at S62 or S116 in Gld2. We analyzed Gld2 and Gld2 phosphorylated by 
purified recombinant kinases and by HEK 293 cell extract. Gld2 or pGld2 was 
precipitated in ice-cold acetone/ethanol/acetic acid (50/50/0.1 v/v/v). The protein 
precipitate was re-suspended in 8 M urea then reduced in 5 mM DTT at 37°C for 1 hr and 
alkylated in 14 mM iodoacetamide in darkness at RT for 1 hr. Unreacted iodoacetamide  
was neutralized by adding 5 mM DTT and final protein concentration was determined by 
Bradford assay. Trypsin digestion was performed at 37°C overnight with a 
protein:trypsin ratio of 20:1 w/w. The digest was desalted in a C18 column (Phenomenex, 
Torrance, CA, USA) according to the manufacturer’s protocol and re-suspended in MS-
grade water for MS injection. Data were analyzed using Skyline software 35. 
 
3.3 Results 
Gld2 plays an important role in miRNA stability, but the regulation of Gld2 activity 
or substrate specificity is unknown. Studies in other nucleotide polymerases36,37 found 
that phosphorylation of serine and threonine residues can increase activity or 
processivity. For example, serine phosphorylation in the disordered C-terminal domain of 
RNA polymerase II is required for transcription initiation and elongation36. 
Phosphorylation of the terminal uridylyltransferase TUT1 at S6 is required for TUT1 
nuclear retention and regulation of specific mRNAs37. Multiple independent proteome-
level mass spectrometry studies of human cells revealed phosphorylated residues in 
Gld238–40, including five conserved serine residues (S62, S69, S95, S110, S116) in the 
predicted disordered N-terminal domain (Figure 3.2). Despite these observations, the 
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putative Gld2 kinase(s) and the impact of phosphorylation on Gld2 activity was 
unknown. 
 
Figure 3.2: Multiple sequence alignment of mammalian Gld2 sequences. 
Sequences were downloaded from NCBI and the alignment and editing were performed 
with Muscle27, MultiSeq from VMD 1.8.728, and Wasabi29. Numbers above the alignment 
indicate the position in H. sapiens Gld2.  
 
3.3.1 Phosphorylation of the Gld2 N-terminal domain by HEK 293 cells 
Although the above studies suggest the existence of a Gld2 kinase in human cells, we 
analyzed Gld2 following incubation with HEK 293 cell lysates to confirm 
phosphorylation activity towards Gld2. The HEK 293 cells were stimulated with 
epidermal growth factor (EGF) to activate cellular kinases. Purified Gld2 (Appendix A 
Figure A1) was incubated with cell extracts from HEK 293 cells after EGF stimulation of 
signaling pathways. The phosphorylation status of Gld2 was subsequently analyzed by 
mass spectrometry and we unambiguously identified phosphorylation at S62 in the 
sample incubated with EGF-stimulated cell lysate (Figure 3.3B). We did not identify 
pS62 in unstimulated cells or in recombinantly produced Gld2. As Gld2 has been 
previously shown to be involved in miRNA metabolism4,7, this indicates the existence of 
physiologically relevant signaling pathways connecting EGF-stimulated protein kinases 
to miRNA metabolism via phosphorylation-dependent regulation of Gld2. EGF activates 
many cellular pathways involved in regulating growth, proliferation, differentiation, and 
survival. EGF binds to receptor tyrosine kinases, leading to their activation. This in turn 
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activates cascades of cellular kinases. Within 10 minutes of EGF stimulation, mammalian 
cells display 100s of new phosphorylation events41. Data from this study also indicate 
that following EGF stimulation 30 tyrosine and more than 100 serine/threonine kinases 
are activated by phosphorylation, which may be responsible for S62 phosphorylation. 
Any of these serine/threonine kinases are potential candidates for catalyzing S62 
phosphorylation. 
 
 
Figure 3.3: Gld2 is phosphorylated at S62 when incubated with EGF-stimulated 
HEK 293 cell extract. 
Mass spectra of Gld2 after incubation with cell extracts from EGF stimulated HEK 293 
cells showing A) unphosphorylated S62 and B) phosphorylation at S62 (bolded and 
underlined). The intensity for y and b-ions resulting from fragmentation of the peptide 
containing S62 is shown; these intensities are overlaid on the retention time position of 
the full peptide mass. M/z values for each y and b ion are shown. Gld2 was isolated using 
a GST Spintrap column before mass spectrometry. Trypsin was used to generate the Gld2 
peptides and the ions from the peptides are shown in the mass spectra. A full scanning 
was performed to obtain all possible modifications and was followed by parallel reaction 
monitoring (PRM) to verify the modification at S62. 
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3.3.2 Gld2 N-terminal domain phosphomimetic variants regulate 
catalytic activity                     
To rapidly assess the effects of phosphorylation at positions in the Gld2 N-terminal 
domain, human Gld2 variants were produced in Escherichia coli with respective serine 
phosphorylation sites mutated to the phosphomimetic glutamic acid30. Wild type and 
phosphomimetic Gld2 variants were produced and purified to homogeneity (Appendix A 
Figure A1). Kinetic parameters for specific activity and binding affinity were determined 
for wildtype Gld2 and phosphomimetic variants with glutamate substitutions at the 
phosphorylation sites S62, S69, S95, S110, and S116 
Nucleotide addition activity was measured by incubating each enzyme variant with an 
RNA substrate and [α-32P]-ATP (Figures 3.4, and A2A, A2B). Enzymatic and binding 
assays were conducted with RNA substrates miR-122 and a mRNA poly(A) tail mimic of 
15 adenine residues (15A). MiR-122 and 15A RNA were used based on previous studies 
demonstrating their competence as Gld2 substrates4,14. 
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Figure 3.4: Phosphomimetic Gld2 variants modulate catalytic activity and RNA 
binding. 
A) Activity assay gels of wildtype and mutant Gld2. Wildtype (WT) Gld2 and glutamic 
acid mutants were incubated with [α-32P]-ATP and miR-122 (22 nts) or 15A RNA (15 
nts) at 37°C with samples taken every 2 minutes for 8 minutes. Reactions were repeated 
in triplicate (R1-3) and analyzed via gel electrophoresis and phosphorimaging. A no 
enzyme control was performed for each RNA substrate in triplicate and the average of the 
no enzyme triplicates for each RNA was calculated for the 0-minute timepoint. Reaction 
products were quantified by exposing a Whatman filter strip dotted with different known 
concentrations of [α-32P]-ATP to the same phosphorscreen as the gel. R, replicate. B) and 
C) Bar graphs showing the fold change in specific activity at 1 μM ATP calculated from 
the activity assays and binding affinity (Kd) between wildtype Gld2 and Gld2 glutamic 
acid mutants with B) miR-122 (22 nts) or C) oligo(A) tail mimic 15A RNA (15 nts). 
Specific activity is the activity of an enzyme per milligram of purified enzyme and was 
calculated from the linear slope of the curve. Fluorescence anisotropy was used to 
determine the Kd. Each Gld2 enzyme was incubated with a RNA substrate fluorescently 
labelled on the 5’-end with 6-FAM and incubated at room temperature for 20 minutes. 
Fluorescence polarization was measured at Ex. 492nm and Em. 535/20 nm and the Kd 
was calculated using SigmaPlot. Error bars represent one standard error calculated from 
triplicate reactions. Significant changes calculated using a two-tailed t-test are indicted by 
asterisks. p ≤ 0.05 (*); p ≤ 0.01 (**); p ≤ 0.001 (***). Fold changes were calculated using 
data from Table 3.1 and Appendix A Figure A2.      
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Depending on the residue location, phosphomimetic substitutions had distinct effects 
on enzyme activity (Table 3.1, Figure 3.4). S62E markedly increased activity with both 
RNAs compared to wildtype Gld2, indicating an overall activating effect. In contrast, a 
S116E mutation severely decreased Gld2 activity with miR-122 and 15A RNA. 
Interestingly, S110E increased activity for miR-122 but decreased activity for 15A RNA. 
Gld2 S69E showed no significant changes in activity for either RNA while S95E was 
1.6-fold more active with 15A RNA. 
Based on a comparison of the specific activities (Figure 3.4, Table 3.1), only S62E 
and S116E displayed statistically significant changes in activity with both RNA 
substrates. S62E enhanced the nucleotide addition activity by ~5-fold. S116E exhibited 
the opposite effect, decreasing Gld2 activity by 111-fold with miR-122 and 16-fold with 
15A RNA. As the S62E and S116E mutants displayed opposite effects on Gld2 activity, a 
double mutant (S62E/S116E) was generated to investigate cumulative effects. 
Interestingly, the inhibitory effect of the S116E mutation overpowered the activating 
effect of the S62E mutation and decreased the activity of Gld2 74-fold with miR-122 and 
5-fold with 15A RNA compared to the wildtype enzyme. The double mutant 
counteracted the silencing effect of S116E alone by 3.1-fold with 15A RNA and 1.5-fold 
with miR-122. 
The ability of the mutants to alter the nucleotide addition activity varied between 
RNA substrates. The molecular basis for the higher specific activity of Gld2 with miR-
122 compared to 15A RNA remains to be elucidated to discern whether Gld2 recognizes 
a specific RNA sequence and/or discriminates substrates based on the RNA length. 
 
3.3.3 Gld2 phosphomimetic substitutions impact RNA substrate affinity        
As changes in catalytic activity were RNA-dependent, the RNA binding affinities of 
all Gld2 phosphomimetic variants were quantified using fluorescence anisotropy (Figures 
A2C, A2D). The binding affinities (Kd) for all enzyme variants were in the nanomolar 
range (Figure 3.4, Table 3.1). Changes in RNA binding affinity were substrate dependent. 
 
74 
 
The binding affinity to miR-122 was unchanged for most mutants, except for S62E, 
which showed a 5.5-fold increase in RNA binding compared to wildtype Gld2 with miR-
122. The same mutant showed no change in binding to a 15A substrate. For the 15A 
RNA, two mutants (S69E and S95E) showed a decrease in affinity, while all other 
mutants showed no change. With a 6.6-fold reduced Kd compared to wildtype, Gld2 S95E 
showed the most dramatic impact on 15A RNA binding; S69E was 3.3-fold decreased in 
binding affinity to 15A. 
Overall, our phosphomimetic analysis suggests that each phosphorylation site has a 
distinct role in regulating Gld2 activity or substrate selectivity. We found that S62E 
increases activity with either no change (15A) or with increased binding affinity (miR-
122), which may favor miRNA stabilization over mRNA. S69E and S95E caused no 
significant change in activity, but decreased affinity towards 15A RNA, indicating a 
reduced preference for mRNA adenylation. S110E appears to have an insignificant 
impact on activity and binding on the tested substrates. Finally, S116E and the 
S62E/S116E double mutant markedly reduced activity without significantly impacting 
RNA binding. The data indicate that Gld2 S116E and the double mutant are able to bind 
to the RNA target, but perhaps not in a catalytically competent conformation. 
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Table 3.1: Activity and RNA-binding of wildtype (WT) and phosphomimetic Gld2 
variants. 
 
miR-122 15A RNA 
 
Specific activity 
(µmol/min/mg) 
Kd (nM) 
Specific activity 
(µmol/min/mg) 
Kd (nM) 
WT 3452 ± 182 15 ± 3 448 ± 10 1.7 ± 0.3 
S62E 14186 ± 774 2.7 ± 0.8 2919 ± 239 2.3 ± 0.3 
S69E 4670 ± 272 30 ± 9 555 ± 22 5.8 ± 1.1 
S95E 2191 ± 78 22 ± 6 698 ± 30 11 ± 2 
S110E 7340 ± 433 18 ± 5 171 ± 7 2.9 ± 0.6 
S116E 31 ± 5 19 ± 5 28 ± 0.05 3.8 ± 0.8 
S62E/S116E 47 ± 2 12 ± 3 89 ± 6 3.4 ± 0.6 
S116A 150 ± 0.05 35 ± 7 38 ± 16 7.4 ± 1.8 
Standard error is reported; specific activities at 1 µM ATP. 
 
3.3.4 PKA and Akt1 site-specifically phosphorylate Gld2 at S116            
As the phosphomimetic mutants displayed significant changes in activity and RNA 
substrate binding compared to wildtype Gld2, we next identified kinases that 
phosphorylate the Gld2 N-terminus. PhosphoMotif Finder42 and GPS 3.033 were used to 
generate a list of potential kinases (Table A2). Using the kinase assay detailed in 
Materials and Methods, wildtype Gld2 was incubated with recombinant and active human 
kinases (CK2α, CK2 holoenzyme, CDK5, PKA, and Akt1) predicted to have a 
recognition motif in Gld2 (Figure 3.5A). The kinase Abl, which was not identified as a 
potential Gld2 kinase, was used as a negative control. We used our recently developed 
approach31 combining genetic code expansion with in vivo enzymatic phosphorylation to 
prepare fully activated and purified recombinant Akt1 with programmed phosphorylation 
at both activating sites (ppAkt1T308,S473). This method involves protein production in an E. 
coli strain that co-expresses the kinase PDK1 to phosphorylate Akt1 at T308. The strain 
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also genetically encodes phosphoserine (pSer) at UAG codons. The serine codon at 
position 473 was replaced with a UAG codon to direct pSer incorporation in Akt1. 
Following incubation of Gld2 and [γ-32P]-ATP with each kinase in separate reactions, 
the radio-labelled phosphorylated Gld2 (pGld2) product was only observed when Gld2 
was incubated with PKA or ppAkt1T308,S473 (Figure A3, Figure 3.5A). Quantification of 
the Akt1-dependent reaction showed a rapid increase in phosphorylated Gld2 over a 15 
min time course (Figure 3.5B). Independent pGld2 preparations resulting from incubation 
with PKA or ppAkt1T308,S473 were analyzed by mass spectrometry to determine the site(s) 
of phosphorylation. Both unphosphorylated Gld2 and Gld2 incubated with CK2α, which 
was inactive in phosphorylating Gld2, were also analyzed by mass spectrometry as 
controls (Figure 3.5C). S116 was unambiguously identified as the site of specific 
phosphorylation by Akt1 and PKA. Phosphorylation at S116 was not observed in 
unphosphorylated Gld2 or in the preparation incubated with CK2α. Next, S116 was 
mutated to an alanine residue (Figure A1) to determine if S116 represents the sole Akt1 
and PKA phosphorylation site on Gld2. The kinase assay was repeated with Gld2 S116A 
incubated with PKA or ppAkt1T308,S473 (Figure 3.5A). For both kinases, no 
phosphorylated Gld2 S116A product was observed, confirming that PKA and Akt1 
phosphorylate Gld2 specifically and exclusively at S116. 
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Figure 3.5: Akt1 and PKA phosphorylate Gld2 at S116. 
A) Gld2 or Gld2 S116A were incubated with [γ-32P]-ATP and the indicated kinases. 
Formation of phosphorylated Gld2 (75 kDa) was monitored by electrophoretic separation 
and subsequent phosphorimaging. R, replicate. B) Quantification of phosphorylated 
product formation from a kinase reaction over 15 minutes. C) Mass spectra of 
unphosphorylated Gld2 or Gld2 phosphorylated by CK2α, ppAkt1T308,S473 (ppAkt1), or 
PKA. Unphosphorylated peptide is indicated by the light pink peak and the 
phosphorylated peptide by the dark pink peak. Position 116 is bolded and underlined. D) 
Bar graphs showing the fold change in specific activity at 1 µM ATP between treated WT 
(tWT) and Gld2 phosphorylated by PKA with miR-122 (22nt) or oligo(A) tail mimic 15A 
RNA (15nt). The inset shows the fold change in activity of Gld2 phosphorylated by PKA 
compared to tWT. Error bars show one standard error calculated from triplicate reactions. 
Significant changes calculated using a two-tailed t-test are indicted by asterisks. p ≤ 
0.001 (***).  
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3.3.5 Phosphorylation of Gld2 at S116 abolishes nucleotide addition 
activity                      
The phosphomimetic mutant (S116E) was not competent in nucleotide addition, yet 
the variant retained RNA binding affinity (Figure 3.4, Table 3.1). As Akt1 and PKA both 
phosphorylate S116, we produced pGld2S116 following incubation with PKA as noted 
above to investigate the nucleotide addition activity of Gld2 with phosphate on S116. We 
performed nucleotide addition activity assays with pGld2S116 and with an 
unphosphorylated Gld2 control without PKA addition (treated wildtype, tWT). 
PKA-dependent phosphorylation of Gld2 decreased nucleotide addition activity by 
two orders of magnitude (Figures 3.5D, A4). Significant reductions in activity were 
observed for both 15A RNA (~45-fold) and miR-122 (~400-fold) substrates. Although 
both pGld2S116 and the S116E phosphomimetic variant reduced nucleotide addition 
activity, as we anticipated, the phosphate at S116 had a significantly stronger inhibitory 
effect compared to acidic amino acid substitutions (~3-fold). This observation is even 
more striking in light of the fact that our pGld2S116 preparations are only partially 
phosphorylated (Figure 3.5C), suggesting phosphorylation of the Gld2 N-terminal 
domain is a potent mechanism for the cell to control nucleotide addition activity. 
Nucleotide addition activity assays and binding assays were also performed for the 
S116A mutant (Table 3.1, Figure A5). Alanine substitutions are often used as phospho-
ablated enzyme models. Although the mutant was expected to act similarly to the 
wildtype enzyme, the alanine substitution in fact reduced the activity by 23-fold with 
miR-122. As described above, the S116E mutation reduced activity by 111-fold with 
miR-122, indicating that a serine residue is crucial at this position and cannot be replace 
by alanine. Thus, S116A is not an appropriate model for an unphosphorylated Gld2 and 
indicates that a serine in position S116 is required for activity. We previously showed 
that alanine is not necessarily a good model for a non-phosphorylatable residue31. 
Overall, these data indicate that ppAkt1T308,S473 dependent phosphorylation of Gld2 
inactivates Gld2. Our data reveals a novel molecular pathway linking Akt1 activity to 
miR-122 stability and activity in vivo. 
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3.4 Discussion 
3.4.1 Gld2 activity is regulated by phosphorylation 
Gld2 is a key regulator in the stabilization and maturation of tumor suppressors miR-
122 and let-74,7,11. Cellular mechanisms that regulate Gld2 mediated nucleotide addition 
were previously unknown. Data from HCC cells18 and proteomic analysis38,40 implicated 
post-translational modification as a potential mechanism regulating Gld2 activity. Here, 
we presented the first evidence that serine phosphorylation of Gld2 has a profound 
impact on catalytic activity and RNA binding. 
We identified phosphorylation sites in the N-terminal domain of Gld2 that positively 
or negatively regulate nucleotide addition activity. Our findings are reminiscent of 
regulation identified in other polymerases. Phosphorylation of specific serine residues in 
the C-terminal domain of RNA polymerase II and in the terminal uridylyltransferase 
TUT1 regulate their activity and substrate recognition36,37. For RNA polymerase II, serine 
phosphorylation in the disordered C-terminal domain is required for promoter 
clearance36. Phosphorylation of the uridylyltransferase TUT1 at position S6 plays a role 
in its regulation of specific mRNAs and in its nuclear retention, possibly by facilitating 
interactions between TUT1 and nuclear proteins37. Similarly, we found that both 
phosphomimetic mutations to acidic residues or true phosphorylation of Gld2 at different 
sites in the N-terminal domain substantially altered substrate specificity, enhanced, or 
abolished enzyme activity. Although these phosphorylation sites are conserved among 
mammalian Gld2 proteins, they are not conserved in the human terminal 
uridylyltransferases TUT4 and TUT7, as these enzymes lack the large disordered N-
terminal region. 
Undoubtedly, human cells possess a robust Gld2 phosphorylation activity (Figure 
3.3). We found that lysates from EGF-stimulated HEK 293 cells were active in 
phosphorylating Gld2 at S62. In this particular experiment, we were not able to identify 
additional phosphorylation sites in Gld2, suggesting that additional Gld2 kinases may not 
be activated or sufficiently active in our experimental conditions. While Akt1 and PKA 
are expressed in HEK 293 cells, Akt1 activity in these cells even upon EGF stimulation is 
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low43 and likely not sufficient to yield quantitative phosphorylation of Gld2 S116 
required for mass spectrometry. Alternatively, Gld2 phosphatases may be active at sites 
other than Ser62. The data, nevertheless, show that human cells are competent in 
phosphorylation of Gld2 in its N-terminal domain. 
Our experiments with phosphomimetic mutants indicate that phosphorylation at S62 
significantly increases Gld2 activity with miR-122 and the 15A RNA. Although Gld2 
S62E showed a significant increase in activity with both RNAs, increased binding 
affinity was only observed with miR-122. It is interesting to note that wildtype Gld2 is 9-
fold more active with miR-122 than with the poly(A) tail mimic. Even the increase in 
activity with the poly(A) tail mimic by S62E does not reach the level of wildtype activity 
with miR-122. In contrast, experiments with Gld2 S116E and pGld2S116 show that 
phosphorylation at this site abolishes nucleotide addition activity. Although enzyme 
activity is more than 100-fold reduced with miR-122, Gld2 S116E and pGld2S116 still 
retained very low levels of enzymatic activity. In comparison, a mutation in the active 
site, D215A, completely abolished enzyme activity on miRNA substrates4,18. D215A is 
part of the conserved catalytic triad responsible for activity3,44,45, while S116 is found in 
the predicted disordered N-terminal domain, which was previously shown to be 
dispensable for catalytic activity in the related uridylyltransferase Cid146–48, but we here 
show that its function lies in the regulation of enzyme activity. Using enzymatic assays 
and mass spectrometry, we identified and validated Akt1 and PKA as kinases with site-
specific phosphorylation activity at S116 in Gld2. Although acidic amino acids are not 
always able to mimic the functional impact of phosphate31, the glutamate variant showed 
reduced activity similarly to the pGld2S116 enzyme.  Phosphorylation at S116, however, 
led to a significantly greater reduction in Gld2 activity, which was two orders of 
magnitude below the activity of the unphosphorylated enzyme. Thus, phosphorylation at 
S116 effectively controls Gld2 activity. 
During HCV infection, the Hepatitis C core protein binds to Gld2 to inhibit its 
adenylation activity. Core protein binding is somewhat inefficient, with 13% binding at a 
1:1 ratio. Nonetheless, this inhibition leads to a reduction of cellular miR-122 levels by 
30%18. Even partial phosphorylation of cellular Gld2 at S116 is expected to have a 
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similar or greater effect on miR-122 levels, making post-translational modification of 
Gld2 an efficient means to control cellular miRNA levels. 
Although phosphorylation of S116 inhibits Gld2 catalytic activity, RNA binding 
affinity was unperturbed, suggesting Gld2 phosphorylated at S116 binds the RNA 
substrate in a non-productive conformation. The crystal structures of related 
nucleotidyltransferases from yeast49 and C. elegans15,50 as well as the human terminal 
uridylyltransferases TUT1 and TUT751,52 revealed a conserved positively charged surface 
that may facilitate RNA binding. Despite these efforts, no structural information is 
available on the N-terminal domain of Gld2. Our data suggest that Gld2 can assume 
different RNA binding modes. The wildtype Gld2 enzyme binds RNA with high affinity 
in a catalytically competent mode, which is perhaps stabilized yet further in the activating 
mutants S62E and S110E. Conversely, Gld2 variants with phosphomimetic substitution 
or phosphorylation at S116 appear to bind the RNA substrate in a non-catalytic mode that 
interferes with nucleotide addition. This is not unique to Gld2, as other cases of 
catalytically incompetent enzymes have been described in the literature. A small deletion 
in RNA polymerase (RNAP) leads to a catalytically incompetent RNAP, that remains 
bound to the promoter complex53. It is also well known that phosphorylation of the C-
terminal domain of RNAP II is required for promoter clearance but not its activity36,54. 
While the structural basis for phosphorylation-dependent modulation of Gld2 activity is 
not yet defined, our experiments suggest an allosteric mechanism. We identified Gld2 
variants that impact activity independently of RNA binding, indicating that allosteric or 
conformational changes in the Gld2 RNA complex may play an important role in Gld2 
catalyzed nucleotide addition. 
Furthermore, in the cell, phosphorylation of Gld2 may affect interactions with 
proteins that are implicated in RNA substrate selectivity12,55–58. In humans, Gld2 was 
recently shown to interact with the RNA-binding protein Quaking (QKI-7) to facilitate 
polyadenylation of target mRNAs. QKI-7 was shown to bind between residues 1-141 on 
Gld258, which correspond to the predicted disordered N-terminal domain, including all of 
the phosphorylation sites investigated here. Future efforts will determine the effect of 
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phosphorylation on the ability of RNA binding proteins to interact with and regulate Gld2 
activity and substrate specificity. 
 
3.4.2 Oncogenic protein kinases signal to miRNA regulation 
We identified Gld2 as a previously unknown substrate of two oncogenic kinases. 
PKA and Akt1 belong to the evolutionarily conserved AGC family of protein kinases that 
are activated upon stimulation with growth factors such as EGF59. PKA is the key kinase 
in the cyclic AMP signaling pathway that is activated upon hormone binding to G-protein 
coupled receptors (GPCR). PKA activation has been shown to modulate the expression of 
miR-122 through the extracellular signal-regulated kinase (ERK)60 and miRNA let-7b 
levels through protein phosphatase 2A (PP2A) activation but the underlying pathway 
remained unclear61. 
Akt1 is a central hub of the PI3K/Akt signaling pathway, which is the most 
commonly activated signal transduction pathway in human cancers62. Active Akt1 signals 
for cell survival and proliferation while also inhibiting apoptosis59. Akt1 activity is 
dependent on phosphorylation at two key regulatory sites (T308, S473). Over-active and 
hyper-phosphorylated Akt1 is a hallmark of diverse human malignancies62,63, while the 
unmodified Akt1 protein is inactive and rapidly degraded in cells64. Several reports show 
that Akt1 expression is regulated by miRNAs. The miRNAs miR-564 and miR-215 
directly negatively regulate Akt1 mRNA stability65,66, while miRNA let-7 inhibits cyclin 
D1 expression, leading to reduced Akt1 phosphorylation at S47367. Conversely, miRNA-
122 overexpression is associated with increased Akt1 phosphorylation in T-cell 
lymphoma and renal cell carcinoma cells68, enhancing cancer progression. These reports 
correlate PKA or Akt1 activity with miRNA levels yet fail to identify the factor linking 
PKA or Akt1 activity to miRNA levels, exposing gaps in our understanding of the signal 
transduction network. In addition, neither PKA nor Akt1 were previously shown to 
directly phosphorylate any regulator of RNA. 
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Although miRNAs are known to regulate Akt1, the ability of Akt1 activity to regulate 
an enzyme involved in the regulation of miRNA metabolism has not been documented 
previously. The Akt isozyme Akt2 is known to phosphorylate the single-stranded RNA 
binding protein KH-type splicing regulatory protein (KSRP), allowing it to switch its 
RNA preference from mRNA to primary miRNA (pri-miRNA) and facilitate Drosha 
processing to pre-miRNA69. Although KSRP binds RNA, no enzyme that directly 
regulates RNA stability has been previously identified as a substrate of Akt1. Using 
precise biochemical experiments, we found that both Akt1 and PKA site-specifically 
phosphorylate Gld2 at S116, abolishing Gld2 activity with miRNA and mRNA 
substrates. 
 
3.4.3 Relevance of Akt1-dependent regulation of miRNAs to disease 
Hyperactivity of Akt1 and PKA is common in many cancers70,71. Our data suggest 
that phosphorylation of Gld2 by these kinases would further promote carcinogenesis by 
destabilizing tumor suppressor miRNAs, thus, further inducing tumorigenesis. 
Abolishing Gld2 activity leads to a decrease in levels of tumor suppressor miRNAs 
including miR-122 and let-77,16 (Figure 3.6). Decreased miR-122 and let-7 levels and 
activity enable over- or un-regulated expression of their target genes, including 
oncogenes with roles in cell growth, metastasis, and apoptosis16,72. 
In a related disease context, Gld2 is down-regulated in Hepatitis B and inhibited in 
Hepatitis C infections16,18. Both HBV and HCV are contributing factors in the 
development of HCC and other liver diseases due to the dysregulation in miR-122 levels 
and the resulting expression of miR-122 regulated oncogenes16,19. The extent of Gld2 
catalyzed mRNA adenylation, and the effect of specific phosphorylations on the 
transcriptome and miRnome remain to be investigated and may reveal additional 
contributions of Gld2 regulation to pathogenesis. 
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Figure 3.6: Model of Akt1-mediated regulation of Gld2. 
Gld2 monoadenylates miRNAs to increase stability and adds a single nucleotide to pre-
miRNAs to enable recognition by Dicer and miRNA maturation. Decreased miRNA 
levels (e.g. let-7b61) are associated with increased Akt1 phosphorylation status and 
activity. Thus, fully activated Akt1 (ppAkt1T308,S473) phosphorylates Gld2 at S116 and 
silences the stabilizing/maturing effect of Gld2 on miRNA. Through phosphorylation of 
Gld2, Akt1 activity is expected to reduce miRNA levels. Phosphorylation is indicated by 
the orange circles.          
 
3.4.4 Conclusion 
While hundreds of Akt1 substrates have been validated and/or predicted in human 
cells73, miRNA editing enzymes were not previously known to be part of the Akt1 
signaling network. Similarly, it was unclear how Gld2 activity may be regulated to 
respond to external stimuli and signaling pathways, in turn controlling miRNAs and an 
even larger number of downstream mRNA substrates. We here revealed the first link 
between the activity of oncogenic kinases Akt1 and PKA and the regulation of Gld2. We 
found that HEK 293 cells contain N-terminal Gld2 kinase activity and that 
phosphorylation sites in the N-terminal domain of Gld2 can either positively or 
negatively regulate nucleotide addition activity. We identified Gld2 as a bona fide 
substrate of PKA and Akt1 and the site-specific phosphorylation catalyzed by either 
kinase at Gld2 S116 abolishes nucleotide addition activity. While the overall impact of 
Akt1/PKA signaling on miRNA metabolism remains to investigated in a cellular context, 
these data significantly enhance our knowledge on miRNA regulation and reveal a 
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previously unrecognized link between oncogenic signal transduction and the regulation of 
tumor suppressor miRNAs. 
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Chapter 4 
4 RNA surveillance by uridylation-dependent RNA decay in 
Schizosaccharomyces pombe 
4.1 Introduction 
RNA synthesis and degradation are regulated through a variety of mechanisms that 
amend the transcriptome to match cellular needs throughout the cell cycle and adaptation 
to environmental changes1. Messenger RNA (mRNA) degradation can proceed by two 
general pathways, in either a 5′-3′ or 3′-5′ direction, catalyzed by exonucleases or the 
exosome complex, respectively. These canonical RNA degradation processes usually 
commence with an initial deadenylation step, followed by decapping by Dcp1/2 and the 
Lsm1–7 complex. Decapped mRNA is subsequently accessible to 5′-3′ decay catalyzed 
by the exonuclease Xrn1, while exosome-catalyzed 3′-5′ degradation does not require 
decapping2. Recently, a second deadenylation-independent pathway of mRNA decay was 
discovered and appears to be conserved in many eukaryotes. Here, uridylation of 
polyadenylated mRNAs recruits the Lsm1–7 complex and subsequently leads to mRNA 
degradation by designated exonucleases2. This template-independent addition of 
nucleotides is catalyzed by terminal RNA nucleotidyltransferases (TENTs), a subfamily 
of the polymerase β superfamily of nucleotidyltransferases3. TENTs add ribonucleoside 
monophosphates to an RNA substrate through a catalytic process involving two metal ion 
cofactors3. Of note, non-templated 3′-end uridylation of a variety of RNA species plays 
key roles in eukaryotic RNA processing pathways including mRNA and pre-miRNA 
degradation, pre-miRNA maturation, and miRNA silencing4–6. RNA uridylation is 
catalyzed by terminal uridylyltransferases (Tutases), and polyuridylated RNAs are 
subsequently degraded by the U-specific exonuclease Dis3L26–8. While uridylation and 
deadenylation-dependent RNA decay show some redundancy, uridylation is conserved in 
many different species indicating that it is important for RNA turnover9–11. 
Fission yeast Cid1 (caffeine-induced death suppressor protein 1) was first discovered 
in a genetic screen identifying components of the S-M cell cycle checkpoint 
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in Schizosaccharomyces pombe12. Although S. pombe Δcid1 strains are viable, they are 
sensitive to a combination of hydroxyurea, a ribonucleotide reductase inhibitor, and 
caffeine, which overrides the S-M checkpoint and induces mitosis. Overexpression of 
Cid1 confers resistance to this combination of stressors12. Cid1 was originally thought to 
be a poly(A) polymerase due to its significant in vitro poly(A) polymerase activity13, but 
recent evidence characterized it as an efficient Tutase in vitro and in vivo14–16. Cid1 
encodes a catalytic nucleotidyltransferase motif and a poly(A) polymerase-associated 
motif17, but lacks an identifiable RNA recognition motif. Interestingly, nucleotide 
specificity appears to have evolved after RNA specificity, with adenylyltransferases and 
uridylyltransferases playing opposing roles in promoting RNA stability or degradation in 
eukaryotes, respectively18. Nucleotide specificity depends on a critical histidine residue 
(H336), which is responsible for UTP over ATP preference19,20 (Figure 4.1A). A H336N 
mutation in Cid1 converts the enzyme to an adenylyltransferase16,20, whereas a histidine 
insertion in its human adenylyltransferase counterpart Gld2 confers UTP specificity18. 
One of the first Cid1 RNA substrates to be identified was actin1 mRNA, which was 
shown to be uridylated upon S-phase arrest in a Cid1-dependent manner15. In S. pombe, 
RNA uridylation mediates mRNA turnover: Cid1 uridylates polyadenylated mRNAs to 
trigger Lsm1–7-mediated decapping of the RNA 5′-end and subsequent degradation by 
the U-specific exonuclease Dis3L27,10. Biochemical and structural investigations revealed 
that despite the absence of a specific RNA recognition motif (Figure 4.1B), Cid1 is 
capable of binding and uridylating RNAs in a sequence-independent manner14. Due to its 
substrate promiscuity, Cid1 is thought to participate in a widespread mechanism of 
mRNA decay in S. pombe11,17,19,21,22, and substrate specificity and selectivity may require 
accessory proteins, in analogy to the human homologs, Tutases TUT4 and TUT7 and the 
adenylyltransferase Gld218,23–26. 
Following uridylation, RNAs are quickly degraded by the U-specific 3′-5′ 
exonuclease Dis3L26–8,27–29. Recent studies revealed that Dis3L2-catalyzed 
exonucleolytic RNA degradation constitutes an alternative pathway for RNA decay, 
independent of exosome and Xrn1-catalyzed decay pathways7. In S. pombe, Dis3L2 
localizes to the cytoplasm and does not associate with the exosome but interacts with 
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components of the cytoplasmic mRNA degradation pathway. While a recent study 
reported no significant changes in mRNA accumulation in a dis3L2 deletion strain, 
uridylated mRNAs were found elevated in a dis3L2 and lsm1 double mutant strain, and 
recombinant Dis3L2 degraded uridylated RNA transcripts in vitro7. In humans, Dis3L2 is 
involved in the degradation of uridylated mRNA and miRNA transcripts6,7,30–32. 
Mutations in Dis3L2 in humans are associated with the Perlman syndrome of fetal 
overgrowth, likely due to its role in the degradation of miRNAs and pre-miRNAs of the 
let-7 family33. Dis3L2 displays a typical RNase II-like protein domain organization, and 
encodes two cold shock domains (CSDs), an exonucleolytic ribonuclease domain (RNB), 
and a nonspecific RNA binding domain (S1) (Figure 4.1B). Structural analysis of Dis3L2 
showed that in the absence of RNA, the enzyme displays an open conformation28 and 
RNA binding induces a closed conformation, where three RNA binding domains form a 
funnel to position the RNA substrate for exonucleolytic degradation32. 
In S. pombe, the Cid1/Dis3L2 RNA degradation pathway constitutes one of three 
mRNA surveillance pathways. While the individual proteins, Cid1 and Dis3L2, are now 
recognized and biochemically and structurally characterized, it is unclear whether the 
three RNA decay pathways (Xrn1, exosome, and Cid1/Dis3L2) are dedicated to specific 
substrate RNAs or act as three global albeit independent decay mechanisms. In this study, 
we capture the extent of the Cid1/Dis3L2 mediated RNA degradation and find that 
depletion of uridylation-dependent RNA decay causes the accumulation of misfolded 
proteins and an increase in abundance of mRNAs involved in the stress response. Using 
deep sequencing, we find that while Cid1 depletion has little impact on mRNA 
homeostasis, Dis3L2 represents a bottleneck in uridylation-dependent RNA decay and its 
depletion leads to an increase in mRNAs involved in protein folding and degradation 
pathways. We conclude that perturbation of uridylation-dependent RNA decay elicits a 
stress response, likely due to the accumulation of misfolded proteins. 
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Figure 4.1: Domain structure and amino acid composition of Cid1 and Dis3L2. 
A) Amino acid sequence alignment adapted from18. Enzymes known to exercise Tutase 
activity encode a histidine residue (His336 in Cid1, highlighted in yellow), that sterically 
hinders the larger ATP from entering the active site. Adenylyltransferases (PAPs) do not 
encode the respective histidine residue. Nucleotide preference for S. pombe Cid11 and 
Cid16 is undetermined, though Cid16 likely prefers UTP. B) Dis3L2 displays a typical 
RNase II domain organization, encoding two cold shock domains (CSD), an 
exonucleolytic ribonuclease domain (RNB), and a nonspecific RNA binding domain 
(S1). Cid1 is composed of a nucleotidyltransferase domain (NTR) and a 
poly(A)polymerase domain (PAP).  
 
4.2 Materials and Methods 
4.2.1 Yeast strains and growth conditions 
S. pombe strains were obtained from Bioneer (Alameda, CA, USA): Wildtype 
(BG_0000H6, ade6-M210 ura4-D18 leu1-32); Δdis3L2 (BG_H0669; orfΔ 
SPAC2C4.07c: kanMX4/ORF ade6-M210 ura4-D18 leu1-32) and Δcid1 (BG_H0513; 
orfΔ SPAC19D5.03: kanMX4/ORF ade6-M210 ura4-D18 leu1-32). Liquid cultures were 
grown at 30°C in YPD supplemented with adenine to an optical density of OD600 = 0.5. 
For spotting assays, yeast were grown on Edinburgh minimal media (EMM) (3 g/l 
potassium hydrogen phthalate, 2.2 g/l sodium phosphate dibasic, 5 g/l ammonium 
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chloride, 20 g/l dextrose, 2.1 g/l mineral salts, 0.02 g/l vitamins, 3 mg/l trace elements) 
supplemented with 12 g/l L-leucine (leu), 2 g/l uracil (ura), 2 g/l adenine (ade). 
4.2.2 Spotting assays 
S. pombe cells were inoculated in 4 mL EMM-URA-LEU-ADE liquid media 
overnight in a 30°C incubator shaker. 100 μl of cells were diluted 1:10 in ddH2O to 
measure the OD600 to determine cell density. Cells were standardized to OD600 = 1 in the 
first row of wells on a 96-well plate. A 1:5 serial dilution of cells was performed in the 
subsequent five rows of wells. Cells were spotted on YES, and EMM-uracil-leucine-
adenine media agar plates with or without 100 μM H2O2, 5 mM caffeine, 2 mM caffeine, 
5 mM hydroxyurea, 2 mM hydroxyurea, and 2.5 mM caffeine + 10 mM hydroxyurea. 
Plates were incubated in a 30°C incubator. Photographs of plates were taken on different 
days to document growth. Spotting assays were photographed, and the image was 
modified to black and white with the background blackened out and the yeast colonies 
being white. The circular selection tool on ImageJ was used to select an equal area of 
colonies and the mean gray value (MGV) was measured for density of cell growth. The 
blackened plate background gave a MGV of 0 and complete colony growth gave a value 
of 255. Wildtype values were normalized to 1 and the growth of deletion strains were 
normalized against wildtype to give a fraction of 1. Unpaired t-test was employed to infer 
statistical significance between wildtype and each deletion strain at 95% confidence 
interval. 
4.2.3 Cid1 cloning, purification, and activity assays 
Total RNA was extracted from S. pombe cells using MasterPure Complete DNA and 
RNA Purification kit (Epicentre) and reverse transcribed with SuperScript II Reverse 
Transcriptase (Invitrogen) and random hexamer primers. The resulting cDNA was 
amplified by PCR using gene specific primers (Cid1F 5′-AAGCTTATGAACATTTCTT 
CTGCACAATTTATTCCTGGTGT-3′ and Cid1R 5′-CTCGAGCTCAGAATTGTCACC 
ATCGGTTTCATTC-3′) and inserted into a pET-20b(+) expression vector with HindIII 
and XhoI restriction sites. The construct was confirmed by DNA sequencing (London 
Regional Genomics Centre). Escherichia coli BL21 Codon Plus cells were transformed 
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with pET-20b(+) encoding His-tagged cid1and grown in LB media with ampicillin (100 
μg/ml) and chloramphenicol (34 μg/ml) at 37°C to an OD600 of 0.6. Protein expression 
was induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final 
concentration of 1 mM and the culture was grown overnight at 18°C. Cells were 
harvested and resuspended in Buffer A (50 mM HEPES, pH 6.8, 100 mM NaCl, 2 mM 2-
mercaptoethanol) supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF) and 
0.25 mg/ml lysozyme and lysed with a French Pressure Cell. Following 1 hour of 
centrifugation (41 000 rpm at 4°C), cell free extract was loaded onto a gravity column 
containing HisPur Ni-NTA resin (Thermo Scientific) pre-equilibrated in Buffer A. The 
resin was washed with Buffer B (50 mM HEPES, pH 6.8, 100 mM NaCl, 2 mM 2-
mercaptoethanol, 50 mM imidazole) and Cid1 was eluted with Buffer C (50 mM HEPES, 
pH 6.8, 100 mM NaCl, 100 mM imidazole). After concentrating the eluted protein, 
remaining contaminants were removed by size exclusion chromatography using a 
Superdex™ 200 Increase 5/150 GL column and Buffer A. Protein concentration was 
determined using a Bradford assay and purified proteins were stored at −80°C with 10% 
glycerol. Enzyme activity assays were carried out as described previously18. 
4.2.4 Circular rapid amplification of cDNA ends (cRACE) and Northern 
blotting 
RNA was isolated using the Masterpure RNA purification kit (Epicentre), 
dephosphorylated with shrimp alkaline phosphatase (NEB), and phenol chloroform 
extracted. For decapping, RNA was incubated with tobacco acid pyrophosphatase (NEB) 
and circularized with T4 RNA ligase (NEB). Reverse transcription was carried out using 
Superscript Reverse Transcriptase (ThermoFisher) and random hexamer primers. Gene 
specific amplification was carried out using primers listed in Appendix B Table B1 and 
PCR products cloned into pCR3.1- TopoTA vector (ThermoFisher) and sequenced at the 
London Regional Genomics Centre. Northern blots were performed as previously 
described34 using 5 or 10 μg of total RNA and 5′-32P-labelled gene specific probes 
amplified from genomic DNA using primers listed in Appendix B Table B1. 
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4.2.5 RT-qPCR 
Reverse transcription and quantitative PCR (RT-qPCR) were performed as 
described35. Briefly, total RNA was extracted using the Masterpure RNA purification kit 
(Epicentre) and reverse transcribed using the High-Capacity cDNA Reverse 
Transcription kit (Applied Biosystems). PowerUp SYBR Green Master Mix (Applied 
Biosystems) was used for the qPCR and amplification was performed on the ViiA 7 Real-
Time PCR System. Six biological replicates of each S. pombe strain (wildtype, Δdis3L2, 
and Δcid1) were analyzed in technical triplicates. All primers are listed in Table B1. 
4.2.6 Yeast sedimentation assay and Western blot 
Wildtype, Δdis3L2, and Δcid1 S. pombe strains were streaked onto YPD agar plates 
supplemented with adenine, uracil, and leucine and incubated at 30°C. Three biological 
replicates for each strain were grown in 5 mL YPD media supplemented with adenine, 
uracil, and leucine overnight at 30°C. The OD600 of all cultures was measured the next 
morning before the cells were centrifuged at 4000 × g for 5 min at 4°C. The 
sedimentation assay was adapted from36. Briefly, cell pellets were lysed in 200 μl lysis 
buffer (100 mM Tris–HCl pH 7.5, 200 mM NaCl, 1 mM ethylenediaminetetraacetic acid 
(EDTA), 1 mM dithiothreitol (DTT), 5% glycerol, 0.5% Triton-X, 2 mM 
phenylmethylsulfonyl fluoride (PMSF)) supplemented with protease inhibitors (Roche, 
04 693 159 001) using glass beads on a Disruptor Genie. Cells were disrupted with six 30 
s bursts followed by 30 s on ice between each burst. The lysates were separated from the 
glass beads and 50 μl was added to 50 μl SUMEB (1% sodium dodecyl sulfate (SDS), 8 
M urea, 10 mM 3-(N-morpholino)propanesulforic acid (MOPS), 10 mM EDTA, 0.01% 
bromophenol blue). The remaining lysates were centrifuged at 500 × g for 15 mins at 4°C 
and 100 μl of the supernatant was added to 100 μl of SUMEB. The pellets were 
resuspended in 100 μl lysis buffer with no PMSF and 100 μl SUMEB. Samples were 
analyzed on a 10% SDS gel and total protein in each lane was quantified using the Bio-
Rad ChemiDoc MP and Image Lab software. Total lysates were blotted for PGK1 
(ThermoFisher Scientific, 459250) as loading control. 
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4.2.7 RNA sequencing and data analysis 
Three biological and three technical replicates for each S. pombe strain (WT, 
Δdis3L2 and Δcid1) were grown in YPD media to an OD600 of 0.6–0.65. RNA was 
isolated using the Masterpure RNA purification kit (Epicentre). Ribosomal RNAs were 
depleted using the Ribo zero RNA kit and the RNA library was generated with the 
NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina. Samples were 
analyzed on the MiSeq sequencing v2. Sequencing reads were mapped to the S. 
pombe mitochondrion (MT) genome (NC_001326.1) using the CLC Genomics 
Workbench and changes in gene expression were analyzed with the ANOVA-like 
Differential Expression (ALDEx2) tool37 and an effect size cut-off of 1.5. The relative 
expression (abundance) of each gene within a sample was calculated as the median 
centered log-ratio (clr) from 1000 Monte Carlo Dirichlet instances. Genes were 
considered to be differentially expressed if the ALDEx2 effect size was greater than 1.5 
(i.e. the difference in abundance between two strains was at least 1.5-fold greater than the 
difference between biological replicates). Genes differentially up- or down-regulated by 
at least 1.5-fold were analyzed for enrichments in specific pathways using the Search 
Tool for the Retrieval of Interacting Genes/proteins (STRING)38. 
 
4.3 Results 
4.3.1 Recombinant Cid1 displays ambiguous substrate specificity in 
vitro 
Previous studies have shown that S. pombe Cid1 uridylates a variety of RNA 
substrates in vivo15, which may subsequently be degraded by the exonuclease Dis3L27. 
To assess whether Cid1 uridylation is ambiguous or dedicated to specific substrates, we 
produced and purified full length Cid1 and assessed its substrate specificity on several 
RNA substrates in vitro. We found that Cid1 uridylates a poly(A) tail mimic (15A), 
tRNA, total mRNA, pre-miRNA and miRNAs equally (Figure 4.2). It appears that Cid1 
uridylates RNA substrates regardless of their secondary structure (pre-miRNA hairpin 
structure, tRNA structure), or sequence (miRNAs and poly(A) RNA). Total yeast tRNA 
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and total human RNA preparations from cell lines HEK 293T and MDA-MB-231 are 
heterogeneous mixtures by nature and the frequency of poly- versus monouridylation 
cannot be assessed. In these cases, the observed products are presented in a smear, 
consistent with either the uridylation of RNA substrates of varying length or also a 
mixture of poly- and monouridylation events. Substrates 15A RNA, miRNAs and pre-
miRNA were either purchased oligoribonucleotides or products of in vitro transcription 
(pre-let-7a)18. For these homogenous RNA substrates, the predominant product is 
consistent in length with a monouridylated RNA product. In the case of the 15A 
nucleotide poly(A) tail mimic 15A RNA, a second band at ∼35 nucleotides is detectable, 
indicating the addition of roughly 20 uridines in vitro. For the microRNA substrates miR-
122 and let-7a, polyuridylation can be observed in the form of a ladder-like pattern, as a 
result of multiple nucleotide additions with variable product lengths. Thus, Cid1 displays 
no substrate preference in vitro and can act as both a distributive or processive Tutase. 
 
Figure 4.2: Cid1 displays a promiscuous substrate range in vitro. 
Cid1 was incubated with different RNA substrates and [α-32P]-UTP as indicated. 
Formation of [α-32P]-labelled RNA products was monitored by electrophoretic separation 
and subsequent phosphorimaging. Cid1 catalyzed [α-32P]-UTP addition to RNA 
substrates pre-let-7a (72 nts), mature human miRNAs let-7a-5p (22 nts) and miR122 (22 
nts), an oligo(A) tail mimic 15A (15 nts), total yeast tRNA, and total RNA isolated from 
HEK 293T or MDA-MB-321 cells. Radiolabelled RNA Decade marker is used for 
reference. 
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4.3.2 RNA uridylation is prominent in wildtype S. pombe and a cid1 
deletion strain 
To further investigate the function and substrate range of Cid1 in vivo, we purified 
mRNA from wildtype and Δcid1 S. pombe strains and amplified several mRNA species 
to sequence their 3′-end by cRACE. Surprisingly, uridylation of RNAs was found in both 
the wildtype and the deletion strain. The small subunit ribosomal RNA, ScpofMR12 is, as 
typical for ribosomal RNA, not adenylated, and most samples also did not contain 
additional uridyl residues at the 3′-end (Figure 4.3). In S. pombe wildtype cells, one 
sequence was retrieved with multiple uridines added to the RNA 3′-end (Figure 4.3A) 
and in the cid1 deletion strain, monouridylated RNA was found (Figure 4.3B). Since 
uridylations are rare and only few sequences were retrieved, no conclusions as to the 
general uridylation pattern can be drawn from this data. SPBC215.11c, a protein coding 
RNA, was polyadenylated in both strains, with no 3′-end uridylated RNAs recovered. 
Interestingly, a uridylation/adenylation pattern was found in several samples of dak2, a 
protein coding RNA, where a poly(A) tail of differing length was interceded by two 
uridyl residues, followed by an additional four adenines (5′-NxAUUAAAA-3′). This 
pattern was found only in dak2 RNA, in eight out of nine sequenced RNA samples, and is 
not derived from the dak2 5′- or 3′-UTRs (Figure 4.3C). For another protein coding 
mRNA, SPAC19G12.09, samples encoding poly(A) tails without uridines were most 
prevalent. One polyuridylated sample was recovered from the cid1 deletion strain and 
two monouridylated RNAs from wildtype S. pombe RNA. Again, due to sample size, no 
conclusions can be drawn whether this represents a general uridylation pattern. Though it 
appears that uridylation is slightly less prevalent in the cid1 deletion strain, the small 
sample size and methodology of cRACE does not allow for a quantification of 
uridylation, but rather the qualitative observation that mono- and polyuridylation occurs 
in both wildtype and cid1 deletion strains, and that dak2 RNA is prone to an unusual 
pattern of RNA uridylation and adenylation. 
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Figure 4.3: RNA uridylation of diverse RNA transcripts is found in wildtype and 
cid1 deletion strains. 
RNA was extracted from wildtype and cid1 deletion strain, and 3′-ends of selected 
mRNAs were analyzed by cRACE. In both A) wildtype and B) Δcid1 S. pombe cells 
transcripts containing terminal uridyl residues, and residues incorporated into the poly(A) 
tail were detected. A slight decrease in uridylated transcripts was detected 
upon cid1 deletion. (C) Sequence of the dak2 mRNA 3′-UTR (red) and 5′-UTR (blue). 
The protein coding sequence was omitted and is indicated as dak2 coding sequence.   
 
4.3.3 Deletion of the Dis3L2 exonuclease elicits changes in the 
transcriptome 
To further probe the prevalence of uridylation-dependent RNA decay in S. pombe, we 
isolated total RNA from wildtype, Δcid1, and Δdis3L2 strains, depleted ribosomal RNA 
and analyzed the RNA content using deep sequencing. Reads were mapped to the S. 
pombe genome, and differentially expressed genes (effect size >1.5) with more than a 
1.5-fold change in expression between wildtype and Δcid1 or wildtype and Δdis3L2 were 
 
101 
 
considered for the data analysis (Figure 4.4A and B, Appendix B Tables B2-B6). Gene 
expression changes in Δcid1 and Δdis3L2 deletion strains followed a similar trend, as 
outlined in Figure 4.5A, B and Appendix B Figure B1 and Tables B2-B6. Overall, 72 
genes were found differentially expressed >1.5-fold between wildtype and Δcid1, and 
214 genes were differentially expressed >1.5-fold between wildtype and Δdis3L2 (Table 
B2). 24 of the genes were differentially regulated more than 1.5-fold in both deletion 
strains (Figure 4.5B). While changes in the transcriptome of >1.5-fold were more 
noticeable in Δdis3L2, many of the same genes were similarly up- or down-regulated in 
Δcid1 (Figure 4.5A), albeit to a lesser extent. To verify the results obtained by RNA 
sequencing, we performed Northern Blotting on several RNAs found to be differentially 
expressed in the deletion strains. ecl1 was shown to be 1.4-fold up-regulated in 
the cid1 deletion strain, which was confirmed by Northern Blot (Figure 4.6A), and little 
to no expression changes were seen in spac19g12.09, spac27e2.11c, thf1 and tdh1, which 
confirms our sequencing results (Table 4.1). We further used RT-qPCR to confirm our 
sequencing results (Figure 4.6B), and all data confirmed the data observed in our Next 
Generation Sequencing data. The qPCR data confirmed no significant change in the 
expression of pex22 (Wt/dis3L2: qPCR 0.73-fold change, Sequencing 1.0-fold change). 
Four genes, hsp104 (Wt/dis3L2: qPCR 2.8-fold change, Sequencing 3.9-fold 
change), hsp78 (Wt/dis3L2: qPCR 1.8-fold change, Sequencing 2.7-fold 
change), ssa2 (Wt/dis3L2: qPCR 1.8-fold change, Sequencing 2.9-fold change) 
and tcg1 (Wt/dis3L2: qPCR 1.24-fold change, Sequencing 2.3-fold change) were more 
abundant in Δdis3L2, confirming our sequencing results (Table 4.1). As observed in our 
next generation sequencing data, the changes in mRNA abundance as measured by RT-
qPCR are less pronounced in the cid1 deletion strain than in the dis3L2 deletion strain 
(Figure 4.6B). 
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Figure 4.4: Changes in relative abundance of mRNAs in WT, Δcid1, and Δdis3L2 
cells. 
Expression plot comparing relative abundance (log2 centered log ratio, clr) of transcripts 
from a WT (x-axis) and A) Δcid1 or B) Δdis3L2 strain (y-axis). Differentially expressed 
genes (ALDEx2 effect size >1.5) are indicated in red, and dotted lines indicated a 2-fold 
change in expression from the line of best fit for the data (Pearson's r = 0.9805). 
 
 
Figure 4.5: Genes differentially expressed in S. pombe deletion strains compared to 
wildtype. 
A) Heat map showing fold-change for significantly different genes with hits for both 
WT S. pombe and Δcid1 and WT and Δdis3L2 strains. A histogram is included in the 
colour key to show the gene fold-change distribution. B) Venn diagram of genes 
differentially expressed in Δcid1 and Δdis3L2 deletion strains versus wildtype. 
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Figure 4.6: Northern blot and RT-qPCR showing differential expression of genes in 
wildtype versus Δcid1 or Δdis3L2 S. pombe. 
A) Northern blots of total RNA extracted from WT and Δcid1 S. pombe was run on a 1% 
agarose gel in 1 x MOPS and capillary blotted onto a Nylon membrane overnight at 4°C. 
RNA was UV-crosslinked to the membrane and probed with gene-specific 
oligonucleotides labelled on the 5′-end with 32P. The blot was exposed to a 
phosphorimaging screen for two days at −80°C. tdh1 (GAPDH) was used as loading 
control. Expected sizes are as following: ecl1 with UTRs, 3597 nts; spac19G12.09 with 
UTRs, 1213 nts; spac27E2.11c with UTRs, 2140 nts; thf1 with UTRs, 3449 nts, with 
UTRs and introns, 3777 nts; tdh1 with UTRs, 1518 nts. B) RT-qPCR was performed on 
WT, Δcid1, or Δdis3L2 S. pombe cells to assess the gene expression changes in the 
absence of cid1 or dis3L2. Cultures were grown to exponential phase (OD600 = 0.6), 
harvested, and RNA isolated. Expression of each gene was normalized to the WT strain 
grown to early-exponential phase. Internal control used was rpp0. Error bars show the 
standard error on the mean (n = 6). 
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Table 4.1: Select genes up- or down-regulated in either S. pombe ∆cid1 deletion 
strain or S. pombe ∆dis3L2 deletion compared to wildtype S. pombe. 
Genes targeted in the Northern blot or RT-qPCR are listed. 
 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
SPAC19D5.02c 
peroxisomal membrane protein 
Pex22 (predicted) 2.56 31.96 1.01 1.03 
SPAC27E2.11C 
Schizosaccharomyces specific 
protein 2.00 3.49 1.82 3.57 
SPBC16D10.08c heat shock protein Hsp104 1.60 2.85 3.96 5.18 
SPBC4F6.17c 
mitochondrial heatshock protein 
Hsp78 (predicted) 1.21 2.01 2.69 10.07 
SPBC839.16 
C1-5,6,7,8-tetrahydrofolate (THF) 
synthase, trifunctional enzyme Thf1 0.80 0.25 0.90 0.48 
ssa2 heat shock protein Ssa2 1.63 2.13 2.88 4.96 
tcg1 
single-stranded telomeric binding 
protein Tgc1 1.30 2.34 1.76 3.60 
tdh1 
glyceraldehyde-3-phosphate 
dehydrogenase Tdh1 1.57 1.68 2.62 2.88 
 
For genes >1.8-fold up- or down-regulated, we performed STRING analysis for 
enrichment of specific pathways38 (Figure 4.7). In the Δdis3L2 strain, we found 
significant enrichment in genes up-regulated in protein folding and protein degradation 
pathways (false discovery rate <0.001, Table 4.2). Differential expression for genes 
involved in stress response, especially heat shock proteins, chaperones, and protein 
degradation were most prominent, but enrichment was also observed in sugar and 
nucleotide metabolism (false discovery rate <0.01, Table 4.2), specifically in galactose 
metabolism (false discovery rate <0.02, Table 4.2). No significant enrichment was found 
for genes up- or down-regulated in the cid1 deletion strain (Appendix B Figure B2A and 
B). Similarly, few genes were down-regulated in Δdis3L2, and the gene products did not 
show enrichment in specific pathways according to our STRING analysis (Appendix B 
Figure B2C). 
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Figure 4.7: Search tool for the retrieval of interacting genes/proteins (STRING) 
diagram of RNAs with altered expression levels in a dis3L2 deletion strain compared 
to wildtype. 
Respective proteins displayed are up-regulated (>1.5-fold) in the Δdis3L2 strain. The 
diagram was generated using the STRING database. Functional associations between 
proteins are shown, with confidence of the proposed association denoted by line 
thickness. 
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Table 4.2: Functional enrichments in genes >1.8-fold up-regulated in S. pombe 
Δdis3L2 compared to wildtype. 
Gene ontology processes enriched with a false discovery rate <0.01 are listed. 
Gene ontology 
biological process 
observed 
gene count 
false 
discovery rate 
matching proteins in S. pombe 
network 
protein folding 12 0.000414 
SPBC1711.08.1, bip1, cdc37, 
hsp104, hsp78, hsp90, psi1, ssa1, 
ssa2, ssc1, sti1, trx1 
galactose 
catabolic process 4 0.0021 
SPBC32F12.10.1, gal1, gal10, 
gal7 
single-organism 
catabolic process 15 0.00848 
SPAC26F1.07.1, 
SPBC32F12.10.1, SPBC3B9.01, 
SPCC5E4.05c.1, bip1, cdc48, 
gal1, gal10, gal7, glo1, pgi1, 
plg7, rpt1, rpt3, trx1 
monosaccharide 
catabolic process 6 0.00848 
SPAC26F1.07.1, 
SPBC32F12.10.1, gal1, gal10, 
gal7, pgi1 
 
4.3.4 Deletion of dis3L2 confers resistance to hydroxyurea, whereas 
deletion of cid1 increases sensitivity to protein misfolding stress 
Since our sequencing analysis revealed major changes to the transcriptome of stress 
related genes in the dis3L2 deletion strain, we assessed phenotypic effects on S. pombe in 
response to chemical stress (Figure 4.8). Cid1 was first identified as a protein involved in 
S-M checkpoint control and cid1 deletion strains were found to be sensitive to caffeine 
stress12. For phenotypic analysis, cells were grown on EMM containing 10 mM caffeine, 
10 mM hydroxyurea (HU), or a combination of 2.5 mM caffeine and 10 mM HU as 
described previously12. Our data shows that the cid1 deletion strain is sensitive to caffeine 
and HU (Figure 4.8). Since Cid1 and Dis3L2 function in the same pathway, we next 
tested the impact of these chemical stressors on the dis3L2 deletion strain. Surprisingly, 
Δdis3L2 cells were more resistant to HU and caffeine, and a combination of caffeine and 
HU than wildtype cells (Figure 4.8). In addition, we tested the sensitivity of strains 
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bearing a deletion of dis3L2 or cid1 to conditions of protein misfolding stress for growth 
in media containing hydrogen peroxide, which causes oxidative damage. Deletion 
of dis3L2 did not cause significant changes in sensitivity to hydrogen peroxide compared 
to wildtype (Figure 4.8). By contrast, deletion of cid1 resulted in increased sensitivity to 
oxidative stress. 
 
 
Figure 4.8: Growth assay of S. pombe WT, Δdis3L2, and Δcid1. 
Cells were grown on EMM with required nutrients and with or without drug treatment at 
30C. A) Cells were grown overnight in EMM media with Ura, Leu, and Ade and then 
spotted on media plates. B) Quantification of standardized growth differences between 
wildtype and deletion strains. WT growth was normalized to 1 and compared against 
deletion strains. The p values were calculated using a two-tailed t-test. A p value < 0.05 is 
indicated by an asterisk (*) and < 0.01 by (**). 
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4.3.5 Deletion of dis3L2 and cid1 causes the accumulation of misfolded 
proteins 
To test whether the up-regulation of stress response genes in the deletion strains was a 
transcriptional response to cellular stress, we tested WT and deletion strains for the 
accumulation of misfolded proteins in the cell. Indeed, the overall protein abundance in 
the insoluble protein fraction was significantly higher in both deletion strains (Figure 
4.9A, C, and D). PGK1 (Phosphoglycerate kinase 1) was blotted for in total cell lysates 
as a loading control (Figure 4.9B). To investigate whether dis3L2 or cid1 expression is 
up-regulated under stress conditions, we performed a Northern blot on RNAs extracted 
from WT cells grown under heat, cold, caffeine and hydroxyurea stress (Figure 4.9E). No 
changes in abundance were observed. 
 
Figure 4.9: Sedimentation assay of aggregated proteins in WT, Δcid1, and Δdis3L2 
deletion strains. 
A) Representative SDS gel of a sedimentation assay showing total, soluble, and insoluble 
protein of WT S. pombe cells in triplicate. B) Western Blot showing similar amount of 
PGK1 of total cell lysate of WT, Δcid1, and Δdis3L2 deletion strains were used for 
sedimentation assays. R, replicate. C) Quantification of total amount of protein in the 
supernatant and pellet fractions of three biological replicates from the wildtype, Δcid1, 
and Δdis3L2 strains. D) The ratio between the supernatant and pellet for each strain was 
calculated and plotted on a bar graph. The p values were calculated using a two-tailed t-
test (0.03 between WT and Δcid1, 0.05 between WT and Δdis3L2). A p value <0.05 is 
indicated by an asterisk (*). E) Northern blot showing no change in expression 
of cid1 or dis3L2 RNA in response to different growth conditions. 
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4.4 Discussion 
4.4.1 mRNA uridylation does not exclusively depend on Cid1 
Uridylation-dependent RNA decay is now well established as an alternative RNA 
degradation pathway9. Despite growing knowledge on the biochemical and structural 
properties of the responsible enzymes Cid1 and Dis3L2 in S. pombe, little is known about 
the prevalence and substrate-specificity of uridylation-dependent mRNA decay. A 
truncated Cid1, lacking amino acids 1–31 of the N-terminal domain was previously 
shown to be highly processive in vitro15,21, yet only a few U residues are added in vivo 
(Figure 4.3 and 15). By contrast, our full-length protein is significantly less processive and 
its uridylation activity is restricted to few residues (Figure 4.2). It is therefore possible 
that the N-terminal domain of Cid1 serves as an auto-inhibitory domain to prevent 
excessive RNA uridylation. 
In the cellular context, our data shows that mRNA uridylation in S. pombe is not 
exclusive to the founder Tutase Cid1 but is likely also executed by a partially redundant 
Tutase. We found evidence of mRNA uridylation in a cid1 deletion strain (Figure 4.3), 
indicating the activity of an alternate Tutase in this pathway. In addition, less drastic 
changes were observed in the transcriptome upon cid1 deletion (Figures 4.4, 4.5 and 
Appendix B Figure B2). It remains to be elucidated which TENTs are responsible for 
RNA uridylation in the absence of Cid1. S. pombe encodes several TENT homologs 
besides Cid1, namely Cid11, Cid12, Cid13, Cid14, and Cid16. Interestingly, 
transcriptional levels of the TENT Cid14 are 2-fold down-regulated in the cid1 deletion 
strain. Cid14 is thought to be a poly(A) polymerase and lacks the histidine residue 
specifying uridine over adenine specificity (Figure 4.1A). Furthermore, Cid14 has been 
shown to act as a poly(A) polymerase in ribosomal RNA processing39, and is thus 
unlikely to also act as a Tutase. Similarly, Cid11, Cid12 and Cid13 are thought to be 
adenylyltransferases rather that Tutases9,40. The most likely candidate for mRNA 
uridylation appears to be Cid16, an enzyme previously shown to act as a Tutase on small 
RNAs, targeting Argonaute-bound RNAs to promote their degradation41. In a recent 
study, spatially separated activities of the nuclear adenylyltransferase Cid14 and the 
cytoplasmic Tutase Cid16 were shown to regulate small RNA stability41. While Cid1 
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does not compensate for small RNA uridylation in the absence of Cid1641, it is possible 
that Cid16 uridylates mRNAs in the absence of Cid1, or generally functions as a 
redundant Tutase acting on mRNA. 
 
4.4.2 Mixed mRNA A/U tails 
While adenylyltransferases and Tutases have previously been shown to act on the 
same set of RNAs on separate instances41, we show here a previously unreported 
combined 3′ A/U modification in S. pombe. The observed combination of A/U addition 
suggests that in contrast to the uridylation and adenylation of sRNAs catalyzed by the 
spatially separate Cid14/Cid16, the dak2 mRNA 5′-NxAUUAAAA-3′ tail most likely 
occurs in the cytoplasm as a cooperative effort between uridylyl- and 
adenylyltransferases. The Tutases Cid1 and Cid16, as well as the adenylyltransferases 
Cid11 and Cid13, localize to the cytoplasm42 and could interact to form this unusual 3′-
end RNA motif. Whether the 5′-NxAUUAAAA-3′ motif serves as a specific signal for 
downstream RNA processing, RNA localization, or degradation remains to be 
determined. We observed the 5′-NxAUUAAAA-3′ motif on dak2 mRNA, which encodes 
a dihydroxyacetone kinase. Whether the 5′-NxAUUAAAA-3′ motif is unique to this 
mRNA species is speculative, as we only tested a small sample number of mRNAs. 
Excitingly, guanylyl- and adenylyltransferases were shown to generate mixed-tails in 
human cells, and mixed tails were shown to shield mRNA from rapid deadenylation43. 
Future research will have to explore the biological function and prevalence of combined 
A/U tailored transcripts in S. pombe in vivo. 
 
4.4.3 Uridylation-dependent RNA decay is linked to stress response and 
telomere maintenance 
While Cid1 is not essential for the uridylation-dependent RNA decay pathway under 
non-stress conditions, Dis3L2 appears to represent more of a bottleneck in RNA 
degradation. Our data shows that the deletion of dis3L2 leads to an accumulation of 
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transcripts predominantly in protein folding and degradation pathways, as well as sugar 
catabolic processes. While Cid1 does not contain specific RNA recognition motifs, such 
as Zinc fingers, its crystal structure revealed a positively charged surface area thought to 
facilitate general, sequence-independent RNA binding19,20. It has been suggested that 
RNA binding proteins interact with Cid1 to direct the TENT to substrate RNAs, but these 
proteins remain to be identified21. 
As previously described for chemical stress, the transcriptome of S. pombe undergoes 
global changes in response to stress conditions44 (Appendix B Tables B2-B6). We found 
most significant changes in the transcriptome in genes related to protein folding, such as 
heat shock protein genes hsp90 and hsp70, co-chaperones cdc37 and wos2, protein 
remodeling factor hsp104, and chaperone activators aha1 and sti1 with an effect change 
between 2- and 10-fold in the dis3L2 deletion strain (Appendix B Tables B2, B5, B6). 
Changes to the Δcid1 transcriptome generally followed the same trend, albeit to a lesser 
extent, indicating that a partially redundant Tutase reduces the effect of the cid1 deletion 
(Appendix B Tables B2, B3, B4). Furthermore, protein catabolic processes and protein 
degradation pathways, including AAA-type ATPase cdc48, and 19S proteasome 
regulatory subunits rpt1, rpt3 and rpt6, and the ubiquitin C-terminal hydrolase ubp15, 
were up-regulated between 2- and 5.4-fold in Δdis3L2, and up to 2.2-fold in Δcid1. Other 
accumulated transcripts include RNAs of genes from a variety of metabolic pathways, 
transcriptional regulators, cell cycle, and the cytoskeleton (Figure 4.7). 
Galactose metabolism genes gal1, gal7, and gal10 are required for using galactose as 
a carbon or energy source and are usually repressed in wildtype fission yeast in the 
absence of galactose45. We found these genes significantly up-regulated in the 
Δdis3L2 strain with effect changes between 3.5 and 8.5 (Appendix B Tables B2, B5, B6). 
Expression of gal genes is regulated by telomeric silencing45. We observed an increased 
expression of genes involved in telomere organization in the dis3L2 deletion strain, 
namely DNA replication factor A subunit Ssb1 (effect change = 6.5), and single-stranded 
telomeric binding protein Tgc1 (effect change = 3.6). Overexpression of proteins 
involved in telomere organization may be compensatory effects in an effort to counteract 
a disruption of telomere organization, which is evident from the de-repression 
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of gal genes. Cid1 was initially characterized as a protein involved in S-M checkpoint 
control, and it may well be that disruption of uridylation-dependent RNA decay interferes 
with telomere maintenance and repair. 
Previous studies in frog oocytes show that uridylation-dependent decay is crucial for 
clearance of the maternal transcriptome, indicating that this decay pathway plays a role in 
the degradation of transcripts that are no longer required46. Similarly, in humans, Dis3L2 
depletion is associated with the accumulation of damaged RNA transcripts6. Furthermore, 
Dis3L2 depletion inhibits global apoptotic mRNA decay and cell death47. These and 
other studies indicate that uridylation-dependent RNA decay is part of a global mRNA 
surveillance, aiding in the clearance of unneeded or damaged RNAs. Our data show that 
perturbation in uridylation-dependent RNA decay elicits a stress response as evidenced 
by increased abundance of transcripts enriched in protein folding and degradation 
pathways. It is possible that some of the other transcriptional changes beyond stress 
response result in a higher expression rate of those genes. We hypothesize that excess 
protein production may overwhelm the cellular protein quality control, leading to the 
accumulation of unfolded proteins and consequently elicit the unfolded protein response. 
In addition, since the TUT/Dis3L2 pathway in humans functions in damaged transcript 
decay6, these transcripts may also be accumulating in S. pombe, but not be detected as a 
significant change in abundance rates. Stress response genes are likely up-regulated as a 
response to accumulated proteins in the deletion strains (Figure 4.9). 
 
4.4.4 Dis3L2 depletion increases resistance to hydroxyurea-induced 
stress 
Taking into account that both Cid1 and Dis3L2 are dispensable under normal growth 
conditions7,9,12, it is likely that uridylation-dependent RNA decay targets damaged or 
incomplete RNA transcripts as part of a stress response, similar to the Cid14/16 small 
RNA surveillance pathway41. Cid1 was first described as a protein involved in the S-M 
cell cycle checkpoint12. A cid1 deletion strain displays a growth retarded phenotype 
under stress conditions when exposed to caffeine, HU, or a combination of caffeine and 
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HU (Figure 4.8) and overexpression of Cid1 increases resistance to this stress-inducing 
combination12,48. Our data shows that a dis3L2 deletion on the other hand increases 
viability when exposed to HU and caffeine (Figure 4.8). Both HU and caffeine are known 
for their interference with the cell cycle49. HU inhibits the enzyme ribonucleotide 
reductase, which is essential for DNA synthesis, and its depletion impairs DNA 
replication and subsequently arrests cells in S phase50. Interestingly, the RNAs up-
regulated in the dis3L2 deletion strain included ribonucleotide reductase small 
subunit suc22 (1.9-fold) and ribonucleoside reductase large subunit cdc22 (3.4-fold), 
which were previously shown to be up-regulated in response to HU51. The increased 
expression of ribonucleotide reductase subunits, in combination with an already activated 
stress response may give Dis3L2 depleted cells the growth advantage over wildtype cells. 
While overexpression or depletion of enzymes in the uridylation-dependent RNA decay 
pathway can alter cell viability, we found no evidence that expression of cid1 or dis3L2is 
altered at the transcriptional level (Figure 4.9E). Both cid1 and dis3L2 show similar 
abundance independent of growth temperature or chemical stress (Figure 4.8). However, 
protein production may instead serve as the point of control on the translational level, or 
enzyme activity could be modulated by post-translational modification, as described for 
other nucleotidyltransferases52,53. It is plausible that enzymes involved in RNA 
uridylation and decay are constitutively active and degrade damaged RNA transcripts on 
demand. 
We also tested the effect of the deletion of dis3L2 or cid1 on protein quality control. 
When grown on hydrogen peroxide to induce protein misfolding, the cid1 deletion, but 
not the dis3L2 deletion strain showed a significant increase in sensitivity (Figure 4.8). It 
is possible that the up-regulation of the cellular stress responses (e.g. the heat shock 
response) that we observed in the dis3L2 deletion exerts a protective function compared 
to the cid1 deletion strain. We further found that both deletion strains accumulated higher 
proportions of misfolded and insoluble proteins compared to wildtype (Figure 4.9). These 
results indicate that the defects in RNA processing in these strains leads to an 
accumulation of misfolded protein, which in turn appears to induce the expression of 
many protein quality control genes possibly by activation of the heat shock response. 
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We conclude that uridylation-dependent RNA decay is part of an RNA surveillance 
system, and RNA transcripts are not efficiently disposed of in the absence of Dis3L2 or 
to a lesser extent Cid1. Translation of these potentially damaged or unwanted RNA 
transcripts leads to the accumulation of misfolded proteins, eliciting the cellular stress 
response and the increased expression of chaperones and enzymes involved in protein 
degradation. 
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Chapter 5 
5 Summary and Perspectives  
RNAs are a fundamental part of cellular homeostasis and are regulated throughout 
their life cycle1–11. The addition of non-templated 3’-end nucleotides plays a key role in 
RNA regulation12. The enzymes that these reactions are known as terminal RNA 
nucleotidyltransferases (TENTs) and are divided into two functional groups, 
adenylyltransferases and uridylyltransferases, based on their nucleotide preference.  
Adenylation is associated with stabilization while uridylation leads to silencing and 
degradation of RNAs, with the exception of a role for uridylation in Group II pre-miRNA 
maturation7,12. The first uridylyltransferase discovered was Cid1 in Schizosaccharomyces 
pombe. Cid1 was initially assumed to be an adenylyltransferase shown to play a role in 
the S-M cell cycle checkpoint13. The unexpected uridylation activity was later identified 
through in vitro assays with recombinant Cid1 and in vivo assays in S. pombe14–16. This 
uridylation activity is thought to be part of a uridylation-dependent RNA decay pathway 
where polyuridylated RNAs are recognized and degraded by the U-specific 3′-5′ 
exonuclease Dis3L217. The discovery of Cid1 as an uridylyltransferase sparked new 
investigations resulting in many adenylyltransferases to be re-classified as 
uridylyltransferases10–12,18–20. One human homolog of Cid1 is Gld2, which has been 
associated with both adenylation and uridylation in different reports7,9,21,22.  
Both Cid1 and Gld2 encode two domains necessary for catalytic activity but lack 
recognizable RNA binding domains23. Therefore, their catalytic activity and RNA 
specificity are thought to be regulated by interacting proteins. In humans, some of those 
interacting proteins were identified and characterized, but remain uncharacterized in S. 
pombe22,24,25. The fact that Cid1 and Gld2 likely require accessory proteins to determine 
their substrate specificity makes it challenging to identify what RNAs are targeted by 
these enzymes. In addition, their similar domain structure and high amino acid 
conservation, but seemingly different nucleotide preferences, suggest that 
uridylyltransferases and adenylyltransferases are closely related despite having opposing 
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roles. The work in this thesis provides insights into the regulation and cellular impact of 
TENT-catalyzed nucleotide additions to RNAs. 
 
5.1 The evolution of adenylyl- and uridylyltransferase nucleotide 
specificities 
In previous studies, Gld2 has been reported to both adenylate and uridylate the 3’-end 
of RNAs7,9,21,22,25,26. As adenylation (stabilizing) and uridylation (silencing and/or 
degradation) have opposing effects on RNA stability12, the cellular roles of Gld2 were not 
clear. Through extensive enzyme kinetic analysis, I showed that Gld2 is a true 
adenylyltransferase with an 83-fold preference for ATP over UTP. As the cellular 
concentrations of ATP vastly exceeds that of UTP27, it is most likely that Gld2 acts as an 
adenylyltransferase in vivo to stabilize RNAs.  
The high amino acid conservation and structural similarity between 
adenylyltransferases and uridylyltransferases suggests these enzymes are homologous 
and evolved from a common ancestor. A detailed phylogenetic analysis showed that 
uridylyl- and adenylyltransferases do not separate into two distinct groups according to 
nucleotide specificity. Rather the phylogeny (see Figure 2.6 in Chapter 2) showed that 
nucleotide specificity evolved multiple times, suggesting a simple mechanism governing 
ATP versus UTP selectivity in the TENT family. My experiments revealed that UTP 
specificity is accomplished through insertion of a crucial histidine residue in the active 
site. This histidine is absent in adenylyltransferases and present in uridylyltransferases, 
where it sterically blocks the larger ATP from the active site. Insertion of the histidine 
into the coding sequence of Gld2 did indeed switch the nucleotide preference from ATP 
to UTP. This simple insertion/deletion of a histidine residue could explain how uridylyl- 
and adenylyltransferases appeared multiple times throughout evolution of the TENT 
family.           
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5.2 Regulation of Gld2 activity by post-translational 
phosphorylation 
The activity and RNA specificity of Gld2 is regulated through interactions with other 
proteins such as the Hepatitis C (HepC) core protein28 and the RNA binding proteins 
QKI-724 and CPEB25,29,30. No other modes of regulation, such as regulation of protein 
stability, have been described in the literature. Large scale proteomic studies using mass 
spectrometry revealed five phosphorylated serine residues in the predicted disordered N-
terminal domain of Gld231–33, suggesting the possibility of Gld2 regulation through 
phosphorylation. I showed that phosphomimetic substitutions at each of the five serine 
positions lead to changes in Gld2 activity and RNA binding that were dependent on the 
position as well as the RNA substrate. Two sites of interest were identified where one site 
(S62) increased enzymatic activity by ~5-fold while another site (S116) severely 
inhibited Gld2’s adenylation activity up to 111-fold. When both sites were combined, the 
inhibiting ability of S116E overwhelmed the activating function of S62E. This was the 
first evidence that phosphorylation at these sites may regulate Gld2 activity. 
Using kinase activity assays and mass spectrometry, I identified the first known 
kinases of Gld2: protein kinase A (PKA) and protein kinase B (Akt1). Both kinases were 
found to specifically and exclusively phosphorylate Gld2 at S116 and reduced Gld2 
activity to an even greater extent than the phosphomimetic. The data suggest that these 
kinases may play a role in inactivating Gld2. Gld2 promotes the stability and maturation 
of the miRNAs miR-122 and let-7a, respectively7,9,21. Both miRNAs function as tumor 
suppressors and reduced levels of these miRNAs lead to dysregulation of their target 
genes, some of which are involved in cell growth, metastasis, and apoptosis34,35. As Akt1 
and PKA are commonly over-activated in many cancers36,37, their ability to inhibit Gld2 
may promote tumorigenesis by decreasing the levels of miRNA tumor suppressors. Thus, 
the data reveal a possible novel link between oncogenic kinases signaling and miRNA 
regulation.    
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5.3 The role of the Cid1/Dis3L2 pathway in global RNA decay 
The Cid1/Dis3L2 RNA decay pathway in S. pombe plays a major role in mRNA 
homeostasis17,19,38–42. However, the contribution of the Cid1/Dis3L2 pathway to total 
RNA decay is unknown. Deletion of cid1 did not display any major changes in the 
uridylation status compared to wildtype S. pombe. However, an interesting 
uridylation/adenylation pattern (5′-NxAUUAAAA-3′) was found on the 3′-ends of dak2, a 
protein coding RNA. Such mixed RNA ends were previously shown to alter RNA 
stability in human cells43. The role of the mixed RNA tail in S. pombe remains to be 
investigated.  Deep sequencing revealed that deleting cid1 or dis3L2 elicited similar 
changes to the transcriptome. However, the changes in gene expression were much 
greater in the dis3L2 deletion strain. Genes involved in protein folding and degradation 
were up-regulated with the greatest change, indicating an up-regulated stress response. 
The transcriptome of both deletion strains showed similar accumulation of transcripts 
related to stress response, yet larger and more significant changes were observed in the 
dis3L2 deletion strain. The greater transcriptional response as well as the presence of 
somewhat redundant uridylyltransferase activity in the cid1 deletion strain indicates that 
Dis3L2 represents a bottleneck in the RNA decay pathway.  
The data suggests that the increase of mRNA transcripts of stress response genes 
could be due to the accumulation of misfolded proteins. As the Cid1/Dis3L2 RNA decay 
pathway was compromised in the deletion strains, we expect accumulation of RNA 
transcripts that would usually be decayed in the Cid1/Dis3L2 pathway. These transcripts 
could be translated into proteins, resulting in a dysregulated proteome, which may then 
overwhelm the protein control machinery. The accumulation of misfolded proteins, 
which we observed experimentally, may trigger the cellular stress response. Our data 
suggests that the uridylation-dependent RNA decay pathway mediated by Cid1 and 
Dis3L2 plays an important role in maintaining mRNA and proteome homeostasis. 
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5.4 Future Directions and Perspectives  
5.4.1 The role of post-translational modifications in regulating Gld2 
Post-translational modifications (PTMs) are an efficient means for the cell to regulate 
proteins44. In Chapter 3, phosphomimetic substitutions at specific serine residues in the 
predicted disordered N-terminal domain of Gld2 demonstrated that the activity and RNA 
binding of Gld2 is affected and that two different oncogenic kinases were able to 
phosphorylate and inhibit Gld2 activity through one site (S116). Confirming these results 
in human cell lines and animal models would be the next steps in connecting the kinases 
to miRNA regulation. As PKA and Akt1 are hyperactive is many cancers36,37, mass 
spectrometry of tumor samples that show hyperactivity of either kinase would be a 
valuable tool to determine if Gld2 pS116 is present in those samples. In addition, 
determining additional upstream kinases for Gld2 would reveal different pathways that 
regulate Gld2 activity. 
The majority of PTMs were shown to be in the predicted disordered N-terminal 
domain of Gld245. Disordered regions are known as protein docking areas due to their 
ability to adopt different conformations46. In fact, the RNA binding protein QKI-7 was 
shown to bind to the predicted disordered N-terminal domain of Gld224. As Gld2 lacks 
known RNA binding motifs, it seems the enzyme depends on RNA binding proteins to 
promote recognition with specific RNA substrates and regulate Gld2 activity12,22–25. It is 
possible that these interacting proteins bind the N-terminal domain of Gld2 and PTMs in 
this region may regulate Gld2 binding to specific proteins at specific times.  
Although PTMs may affect the binding of interacting proteins, phosphorylation of 
five serine sites were shown to directly affect Gld2 activity and RNA binding in Chapter 
3. It would be interesting to extend the study to include different RNAs such as a wider 
range of miRNA forms, poly(A) tail mimics of different lengths, and poly(A) tail mimics 
that include different sequence motifs. In addition, testing the effect that serine 
phosphorylation may have on nucleotide specificity may be worthwhile as Gld2 can 
accept and use ATP and UTP7,9,21,47. As Gld2 is currently viewed as an enzyme involved 
in promoting RNA stability through adenylation, this would significantly change the 
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biological function of Gld2 as a RNA regulating enzyme. The ability to switch between 
either nucleotide based on the phosphorylation status would allow Gld2 to take part in 
stabilizing (adenylation) and silencing/degrading (uridylation) RNAs, two opposing roles 
thought to be carried out by different enzymes.  
The Gld2 N-terminal domain constitutes approximately one third of the protein and it 
is possible that the domain can act as a regulatory element for the two catalytic domains. 
This was observed for Cid1, where the full-length enzyme was less processive than an 
enzyme lacking the first 31 amino acids15,48. I have unpublished data revealing that Gld2 
lacking the N-terminal domain is approximately 20-fold more active than wildtype Gld2. 
Besides the five serine positions that were studied, other phosphorylation sites throughout 
Gld2 and modifications such as methylation and ubiquitination were also reported in 
mass proteomic studies of various samples31,32,49–53. Future studies will probe the function 
of these other modifications. 
In a disease context, determining if there are different PTMs on Gld2 in diseases such 
as cancer or cardiovascular diseases would be of great interest as a diagnostic tool. The 
HepC core protein has been shown to inhibit Gld2 activity without affecting protein 
expression levels28, leading to decreased miR-122 levels. The reported PTMs of 
Gld231,32,45,49–53 were identified in a variety of tumors, tissues, and immortalized human 
cells, making it difficult to determine what modifications are a result of healthy 
conditions or cellular dysregulation. As miR-122 is a known substrate of Gld29,21 and 
miR-122 is highly expressed in the liver54, immunoprecipitation and mass spectrometry 
of Gld2 from healthy livers of animal models such as mice would reveal PTMs on Gld2 
in healthy tissue. These can be compared to PTMs reported in the literature31,32,45,49–53 or 
disease mouse models. Immunoprecipitation and mass spectrometry of Gld2 from a 
variety of liver cells lines, such as the HepG2 liver hepatocellular carcinoma cell line and 
the PLC/PRF/5 hepatoma cell line, would also give an overview of PTMs that are 
associated with specific conditions. 
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5.4.2 Regulating miR-122 through Gld2 in health and disease 
The miRNA miR-122 is the most abundant miRNA in the liver, comprising 70% of 
the total miRNA population in human livers54. It is a naturally unstable miRNA that 
requires the post-transcriptional addition of a 3′-end adenine residue to enhance its 
stability9,21. Gld2 was identified as the nucleotidyltransferase responsible for stabilizing 
miR-1229,21. Not only does miR-122 play important roles in liver development and 
homeostasis, but also in viral infections and liver diseases34. The levels of miR-122 in 
viral infections vary. HepC infected livers have moderate levels of miR-122 as the virus 
requires miR-122 for replication. On the other hand, Hepatitis B (HepB) infected livers 
have non-detectable miR-122 levels. HepB actively reduces miR-122 as miR-122 was 
shown to exert an inhibitory effect on the replicative ability of the virus28,34,55. Both HepC 
and HepB regulate miR-122 stability. The HepC core protein binds to Gld2 and inhibits 
its activity28 while the HepB virus X protein (HBx) impairs Gld2 gene expression55. 
Although miR-122 has been a target for HepC therapeutic intervention, patients require 
constant dosages to reduce miR-122 levels due to the instability of the therapeutic 
RNAs56–58. Thus, inhibiting Gld2 with a small molecule is a potentially more desirable 
route to deplete miR-122 levels.  
Investigating how Gld2 is regulated during viral infection or in cancers may reveal 
specific post-translational modifications that are not present in healthy cells. The 
resulting data would enable downstream development of drugs, such as antibodies, 
against those different modifications or protein conformations. However, inhibiting Gld2 
to reduce miR-122 levels would be counterproductive in treating diseases such as HepB 
that require therapies to increase miR-122 levels. Therefore, drugs that could lock Gld2 
in a catalytically-active conformation or inhibitors of kinases that inactivate Gld2, such as 
Akt1 and PKA, would be preferred in this situation. 
 
5.4.3 Identifying new cellular roles of Gld2  
In studies, C. elegans Gld2 has been shown to play an important role in 
development26,59,60. Here, Gld2 is involved in extending the poly(A) tails of genes 
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associated with meiosis to increase protein expression and promote entry into 
meiosis26,59,60. In humans, Gld2 plays a role in controlling mRNA stability, in addition to 
miRNA maturation and stability7,9,12,21,61. However, whether Gld2 has the same function 
in different tissues and if Gld2 regulation is tissue-specific remains to be answered.  
As Gld2 lacks recognizable RNA binding domains, studies have shown that it 
interacts with RNA binding proteins to recognize specific substrates22,24,25. In addition, 
these RNA binding proteins may also modulate Gld2 processivity by allowing Gld2 to 
stay in contact with the RNA longer22,24,25. Thus, Gld2 could be regulated through RNA 
binding proteins that are differentially expressed in different cell types or tissues. As cell 
lines are commonly used to study proteins in a cellular context, co-immunoprecipitation 
assays can be used to identify interacting proteins that can then be verified through 
biochemical approaches and further in vivo experiments such as protein expression 
knockdowns with siRNAs and co-localization studies.  
Although the studies in Chapter 3 showed that phosphomimetics at specific serine 
residues on Gld2 changed the activity and RNA binding, the experiments were performed 
in vitro and further studies in cells and ultimately animal models should be pursued. As 
Gld2 has been shown to stabilize the liver-specific miRNA miR-1229,21, liver cell lines 
are the standard used by the field to study miR-122. The phosphomimetic variants and a 
non-phosphorylatable variant as a control could be expressed through transient 
transfections and their activity can be measured through miR-122 levels either indirectly 
using a GFP reporter construct developed in the Heinemann lab62 or directly using 
miRNA RT-qPCR. Since we found glutamate substitutions provided an accurate mimic 
of phosphorylation at Ser116, a systems level analysis of the impact of phosphomimetic 
variants on mRNA levels can also be studied through deep sequencing. 
 
5.4.4 Impact of Cid1 and Dis3L2 on Schizosaccharomyces pombe RNA 
metabolism 
Deep sequencing of S. pombe cid1 and dis3L2 deletion strains revealed changes 
across the transcriptome. Although both deletion strains showed similar changes in RNA 
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expression, the dis3L2 deletion strain showed gene expression changes of far greater 
magnitude. This is potentially due to a partially redundant uridylyltransferase such as 
Cid16 in S. pombe that can take on Cid1’s role. Deep sequencing of a cid1/dis3L2 double 
deletion strain would provide additional information on what genes are specifically 
affected through the Cid1/Dis3L2 decay pathway. Other deletion strains to study would 
be a cid16 single deletion strain and double deletion strains of cid1/cid16 and 
cid16/dis3L2. 
Select genes from different pathways that were differentially expressed were further 
verified in Chapter 4 but many others involved in pathways such as telomere and 
mitochondria organization were identified in the analysis. Genes that were affected in 
both deletion strains, such as ubiquitin-protein ligase E3 Dbl5 and acetyl-CoA C-
acetyltransferase Erg10, would be a good starting point for further studies. Chapter 4 
discussed how the dis3L2 deletion disrupted telomere organization which led to an up-
regulation in galactose metabolism genes and telomere organization genes. As many 
genes were up- or down-regulated, it is possible that not all of them are a direct result 
from the cid1 or dis3L2 deletion and are a downstream effect of other dysregulated genes. 
A possible experiment to determine what RNAs Cid1 uridylate would be to crosslink 
Cid1 with interacting RNA in S. pombe cells, pull-down Cid1 through 
immunoprecipitation, and identify the RNAs through RNA sequencing. 
Terminal nucleotidyltransferases that exhibit different nucleotide preferences have 
been reported to act on the same RNA substrates at different times63. In S. pombe, a 
unique pattern was found at the end of the dak2 mRNA tail where 2 uridine residues were 
added before the terminal four adenine residues. Such U/A mixed 3’-terminal RNA tails 
were also observed in human cells where uridine residues were found on short poly(A) 
tails (<25 nucleotides) and guanine residues on long tails (>40 nucleotides)64. 
Polyuridylation at the 3′-end of mRNAs is commonly associated with degradation10,18 but 
the addition of single guanine residues within the poly(A) tail was shown to prevent rapid 
deadenylation43. As the U/A pattern was observed on short and long poly(A) tails and 
consists of only 2 uridine residues, the poly(A) tail interspaced with two uridine residues 
potentially have the same protective function in S. pombe as the single guanine residues 
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do in human cells43. This can be studied by determining the half-lives of RNAs with and 
without the mixed tails transfected into human cells. As the guanylation was found on 
multiple mRNA tails64, determining if the uridine/adenine pattern also exists on other S. 
pombe mRNA tails would indicate that mixed tails is an evolutionarily conserved 
mechanism to prevent rapid deadenylation of RNAs. 
 
5.5 Conclusion 
RNAs play an essential role in many cellular processes and RNA homeostasis is thus 
highly regulated. The discovery of RNA regulation through non-templated 3′-end 
nucleotide additions by terminal nucleotidyltransferases added an additional layer of 
complexity to the network regulating RNA metabolism. The work presented in this thesis 
aimed to elucidate the impact of these nucleotide additions on RNA homeostasis and the 
regulatory mechanisms controlling terminal nucleotidyltransferases. The included data 
broadens our understanding of the enzymes and pathways regulating cellular RNAs. 
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Appendices 
Appendix A 
Table A1: Primers for cloning of Gld2 into pGEX-6P-2 and mutagenesis of Gld2. 
Primer Name Primer Sequence 
Gld2BamHIfor 5′-ATGCGGATCCGAAAATCTGTACTTC-3′ 
Gld2XhoIrev 5′-TAATCTCGAGTTAACGTTTTAACACGG-3′  
Gld2Glu62for 5′-CATACGGTAACGTGGAACCGATCCAGACCAGCGC-3′ 
Gld2Glu62rev 5′-GCGCTGGTCTGGATCGGTTCCACGTTACCGTATG-3′ 
Gld2Glu69for 5′-GATCCAGACCAGCGCCGAACCTCTGTTCCGTGG-3′ 
Gld2Glu69rev 5′-CCACGGAACAGAGGTTCGGCGCTGGTCTGGATC-3′ 
Gld2Glu95for 5′-CGCCAGCGTTTTCATGAACCGCACCAAGAACCG-3′ 
Gld2Glu95rev 5′-CGGTTCTTGGTGCGGTTCATGAAAACGCTGGCG-3′ 
Gld2Glu110for 5′-GAACCAGATTGTGCCGTTAGAAGGTGAACGTCGCTATAGC-3′ 
Gld2Glu110rev 5′-GCTATAGCGACGTTCACCTTCTAACGGCACAATCTGGTTC-3′ 
Gld2Glu116for 5′-CGGTGAACGTCGCTATGAAATGCCTCCGCTGTTTC-3′ 
Gld2Glu116rev 5′-GAAACAGCGGAGGCATTTCATAGCGACGTTCACCG-3′ 
Gld2Ala116for 5′-CGGTGAACGTCGCTATGCCATGCCTCCGCTGTTTC-3′ 
Gld2Ala116rev 5′-GAAACAGCGGAGGCATGGCATAGCGACGTTCACCG-3′ 
 
Table A2: Kinases predicted to phosphorylate Gld2 at residues S62, S69, S95, S110 
and S116. 
Position in Gld2 Gld2 Sequence* Predicted Kinases 
62 NVSP GSK-3, ERK1, ERK2, CDK5 
62 SPIQT MAPKAPK2 
62 QLTYGNVSPIQTSAS PKA, PIKK, CDK, MAPK, ERK1, ERK2 
69 SASP GSK-3, ERK1, ERK2, CDK5 
69 SPIQTSASPLFRGRK PKA, PKC 
95 RQRFHS Akt2, MAPKAPK 
95 RFHS PKA, PKC 
95 FHSP GSK-3, ERK1, ERK2, CDK5 
95 GKRQRFHSPHQEPTV Akt, Akt2, AGC, CDK5 
110 SGE CK2 
116 LSGERRYSMPPLFHT PKA, PKC, Akt, AGC, CAMK 
*Serine residue predicted to be phosphorylated is bolded and underlined 
 
 
132 
 
 
Figure A1: Purified Gld2 constructs. 
Purified GST-Gld2 constructs were visualized on a 10% polyacrylamide SDS gel stained 
with Coomassie Brilliant Blue G-250 and Western blotted using an anti-Gld2 antibody. 
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Figure A2: Catalytic activity and RNA binding of Gld2 phosphomimetic variants. 
The activity plots show the amount of product formed at 1 µM ATP plotted over time 
with A) miR-122 (22 nts) or B) oligo(A) tail mimic 15A RNA (15 nts). Insets of Gld2 
S116E and the no enzyme control are for better visualization of the data. Wildtype Gld2 
(WT) and no enzyme reactions are plotted on all graphs for comparison and the insets 
show the low activity Gld2 variants. Error bars represent the standard error. The binding 
assay plots show the binding of wildtype Gld2 and Gld2 mutants to C) miR-122 or D) 
oligo(A) tail mimic 15A RNA. WT reaction is plotted on all graphs for comparison. Gld2 
mutants are graphed separately for better visualization of the data. Each Gld2 variant was 
incubated with 1 µM unlabelled and [α-32P]-labelled ATP and 2 µM RNA substrate. 
Samples were taken every 2 minutes and stopped with the addition of 2 x RNA loading 
dye. Reactions were analyzed via electrophoretic separation and subsequent 
phosphorimaging. Specific activity was calculated from the linear slope of the curve. 
Fluorescence anisotropy was used to determine the Kd. Each Gld2 enzyme was incubated 
with a RNA substrate fluorescently labelled on the 5′-end with 6-FAM and incubated at 
room temperature for 20 minutes. Fluorescence polarization was measured at Ex. 492nm 
and Em. 535/20 nm and the Kd was calculated using SigmaPlot. Error bars represent the 
standard error from triplicate reactions. ΔmP, change in fluorescence polarization in 
millipolarization units. 
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Figure A3: PKA and Akt1 produce phosphorylated Gld2. 
The activity plot shows the amount of phosphorylated Gld2 (nM) produced over time 
when incubated with PKA or Akt1. A no kinase control is also plotted. Gld2 WT and a 
kinase were incubated with [γ-32P]-ATP and samples were taken every 5 minutes and 
stopped with the addition of 2 x SDS loading dye. Reactions were analyzed on a 10% 
polyacrylamide SDS gel and subsequent phosphorimaging and product quantification. 
Error bars are one standard error calculated from triplicate reactions. 
 
 
Figure A4: PKA-mediated phosphorylation down-regulates Gld2 catalytic activity. 
The activity plots show the amount of product formed at 1 µM ATP plotted against time 
with miR-122 (22 nts) or oligo(A) tail mimic 15A RNA (15 nts). Gld2 was incubated 
with PKA and purified before activity assay. Phosphorylated Gld2 was incubated with 1 
µM unlabelled and [α-32P]-labelled ATP and 2 µM RNA substrate. Samples were taken 
every 2 minutes and stopped with the addition of 2 x RNA loading dye. Reactions were 
analyzed via electrophoretic separation and subsequent phosphorimaging. Wildtype Gld2 
treated in the same way without kinase (treated wildtype, tWT) and no enzyme reactions 
are plotted on all graphs for comparison. Insets of Gld2 phosphorylated by PKA and the 
no enzyme control are for better visualization of the data. Error bars are one standard 
error calculated from triplicate reactions. 
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Figure A5: Gld2 S116A does not mimic wildtype activity and binding. 
A) The activity plots show the amount of product formed at 1 µM ATP plotted over time 
with miR-122 (22 nts) or oligo(A) tail mimic 15A RNA (15 nts). Insets of Gld2 S116E, 
Gld2 S116A, and the no enzyme control are for better visualization of the data. Wildtype 
Gld2 (WT) and no enzyme reactions are plotted on all graphs for comparison. Each Gld2 
variant was incubated with 1 µM unlabelled and [α-32P]-labelled ATP and 2 µM RNA 
substrate. Samples were taken every 2 minutes and stopped with the addition of 2 x RNA 
loading dye. Reactions were analyzed via electrophoretic separation and subsequent 
phosphorimaging. Specific activity was calculated from the linear slope of the curve. 
Error bars represent the standard error. B) The binding assay plots generated through 
fluorescence anisotropy show the binding of wildtype Gld2 and Gld2 S116E and S116A 
mutants to miR-122 or oligo(A) tail mimic 15A RNA. WT reaction is plotted on all 
graphs for comparison. Each Gld2 enzyme was incubated with a RNA substrate 
fluorescently labelled on the 5′-end with 6-FAM and incubated at room temperature for 
20 minutes. Fluorescence polarization was measured at Ex. 492nm and Em. 535/20 nm 
and the binding affinity (Kd) was calculated using SigmaPlot. Error bars represent the 
standard error from triplicate reactions. C) Bar graphs showing the fold change in 
specific activity at 1 µM ATP and Kd between wildtype Gld2, S116E, and S116A with 
miR-122 or oligo(A) tail mimic 15A RNA calculated from A) and B). ΔmP, change in 
fluorescence polarization in millipolarization units. 
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Appendix B 
Table B1: Oligonucleotide primers.  
Target Method Forward Primer 5′-3′ Reverse Primer 5′-3′ 
Thf1 
Northern 
Blot 
CGAAGGTCAACCCTTGTTTAC
CG 
CCAACATCAATAGCGACAAC
G 
ECl1 
GGAGACATACATTTACAAAG
CG 
GAGCAGTCATGATTTCTTCCT
GTC 
SPAC19G12.09 
GGTACAGCTTTGTTTAAGAA
AG 
GGAATAGGACTATGCAAAAG
G 
Tdh1 
GGTGCTGACTACGTTATCGA
G 
CTTGGAGGGACCGTCAACG 
SPAC27E2.11c 
GCCATGATTGCTGTCGCTTGC
TCTGTC 
CGACACCACACAGAATAATA
TAGTTGAATGG 
Cid1 TCACGTTATCAAGCCTCCCG 
AAGCGGCCATAAATTCCCCT
C 
Dis3L2 AGGAGTCATCGGGAGCAACT AGACTGGCACCATTACGCTC 
ScpofMr12                    
cRACE 
GAAGGAGGAATTGCGAG GATTACGATTTGAGCTTG 
SPBC215.11c CAGTCCGGTTATGCTACC GCAAGCCTCTTTGTC 
dak2 GGCATATCATGTAACCTG GTTTAGTAGAGGGAGAAGC 
SPAC19G12.09 GCGTTATACCTATCACTAC CAACATGCTTATCGCTGC 
Pex22 
RT-qPCR 
GTCTTTTCCTCAGGTTCGGAC
T 
TCCGACTCAGAAAGTGCTGT 
Hsp104 CTTCGTCCTTCTCACGCTCT TGGTTACTGCTGCCCATCTC 
Hsp78 GCTCCTTCCAGGTCACTCAG ATCCTGCGTTAGTTGGTCCG 
Ssa2 GGTGACGCTGCTAAGAACCA CGGGGGTAAAGGTCTTGGTC 
Tcg1 CCGCTGAGGAAACTGTAACC 
CCGTTTCAAACAATGAACGG
ATT 
Rpp0 GTTACCGGCAGGGACAAAGA GATTCGTCGTGCTATGCGTG 
 
Table B2: Genes up- or down-regulated in either S. pombe ∆cid1 deletion strain or S. 
pombe ∆dis3L2 deletion compared to wildtype S. pombe. 
Actin cytoskeleton organization 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
adf1 actin depolymerizing factor, cofilin 1.21 2.05 1.34 3.80 
arp2 
ARP2/3 actin-organizing complex 
subunit Arp2 0.98 0.89 1.27 5.65 
arp3 
Arp2/3 protein complex, actin-like 
protein subunit Arp3 1.49 2.40 1.83 3.76 
myo1 myosin type I 0.98 0.89 1.33 6.11 
SPAC637.13c 
cytoskeletal signaling protein Slm1 
(predicted) 0.98 0.95 1.54 3.46 
Antisense RNA Fold Effect Fold Effect 
 
137 
 
change 
in Δcid1 
change 
in Δcid1 
change in 
Δdis3L2 
change in 
Δdis3L2 
SPNCRNA.1036 antisense RNA (predicted) 1.37 2.59 2.29 14.8 
SPNCRNA.1132 antisense RNA (predicted) 3.02 2.91 1.65 1.56 
SPNCRNA.1138 antisense RNA (predicted) 0.86 0.86 0.19 0.16 
SPNCRNA.1170 antisense RNA (predicted) 2.49 3.06 1.24 1.24 
SPNCRNA.1204 antisense RNA (predicted) 0.88 0.87 0.38 0.22 
SPNCRNA.1212 antisense RNA (predicted) 0.39 0.26 1.00 1.00 
SPNCRNA.1235 antisense RNA (predicted) 1.10 1.34 1.82 2.89 
SPNCRNA.1447 antisense RNA (predicted) 1.14 1.58 1.72 8.58 
SPNCRNA.1451 antisense RNA (predicted) 0.87 0.68 0.61 0.13 
SPNCRNA.1467 
antisense RNA (predicted), possible 
alternative UTR 0.94 0.78 0.58 0.14 
SPNCRNA.1548 antisense RNA (predicted) 0.39 0.25 0.27 0.16 
SPNCRNA.1563 antisense RNA (predicted) 2.01 1.61 2.85 2.89 
SPNCRNA.1626 antisense RNA (predicted) 0.88 0.76 2.66 7.15 
SPNCRNA.1665 antisense RNA (predicted) 1.27 2.07 1.42 2.83 
SPNCRNA.579 antisense RNA (predicted) 0.79 0.74 0.51 0.23 
SPNCRNA.606 antisense RNA (predicted) 0.68 0.55 0.33 0.25 
SPNCRNA.636 antisense RNA (predicted) 1.50 4.30 1.73 2.95 
SPNCRNA.706 antisense RNA (predicted) 1.26 1.15 4.98 3.15 
SPNCRNA.857 antisense RNA (predicted) 1.00 1.00 1.79 3.07 
SPNCRNA.886 antisense RNA (predicted) 0.78 0.64 0.48 0.34 
SPNCRNA.949 antisense RNA (predicted) 1.20 1.46 0.67 0.30 
SPNCRNA.967 antisense RNA (predicted) 0.59 0.34 0.69 0.38 
Carbohydrate metabolic process 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
adh4 alcohol dehydrogenase Adh4 0.90 0.73 0.46 0.16 
dak1 dihydroxyacetone kinase Dak1 1.02 1.05 1.81 3.41 
gal1 galactokinase Gal1 1.35 1.65 3.78 8.51 
gal10 
UDP-glucose 4-epimerase/aldose 1-
epimerase Gal10 0.83 0.82 2.63 6.07 
gal7 
galactose-1-phosphate 
uridylyltransferase Gal7 0.84 0.78 1.67 3.52 
gpd2 
glycerol-3-phosphate 
dehydrogenase Gpd2 0.93 0.69 0.63 0.12 
mal1 maltase alpha-glucosidase Mal1 0.74 0.34 0.88 0.73 
pgi1 
glucose-6-phosphate isomerase 
(predicted) 1.16 2.49 1.87 4.75 
SPAC26F1.07 
glucose 1-dehydrogenase (NADP+) 
(predicted) 0.87 0.78 2.36 4.63 
SPACUNK4.16c 
alpha,alpha-trehalose-phosphate 
synthase (predicted) 0.99 0.99 2.45 5.29 
SPBC1683.04 
glycosyl hydrolase family 3 
(predicted) 0.77 0.26 1.17 1.59 
SPBC2G2.17c beta-glucosidase Psu2 (predicted) 0.53 0.54 0.33 0.28 
SPBC32F12.10 phosphoglucomutase (predicted) 1.11 1.44 1.93 3.75 
SPCC306.06c ER membrane protein, BIG1 family 0.80 0.32 0.81 0.23 
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(predicted) 
tdh1 
glyceraldehyde-3-phosphate 
dehydrogenase Tdh1 1.57 1.68 2.62 2.88 
tps1 
alpha,alpha-trehalose-phosphate 
synthase [UDP-forming] 1.18 1.28 2.75 4.08 
Carbohydrate derived metabolic process 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
SPCC1322.04 
UTP-glucose-1-phosphate 
uridylyltransferase Fyu1 1.19 1.38 2.25 4.67 
Cell adhesion 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
SPBPJ4664.02 
cell surface glycoprotein, flocculin, 
related to Gsf2 0.63 0.34 1.07 1.24 
Cell wall organization or biogenesis 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
omh5 
alpha-1,2-mannosyltransferase 
Omh5 (predicted) 1.36 3.14 1.04 1.15 
Cellular amino acid metabolic process 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
arg1 acetylornithine aminotransferase 0.86 0.29 0.82 0.20 
arg11 
N-acetyl-gamma-glutamyl-
phosphate reductase/acetylglutamate 
kinase 0.86 0.32 0.86 0.29 
gdh1 
NADP-specific glutamate 
dehydrogenase Gdh1 (predicted) 1.28 3.27 1.35 7.05 
leu2 3-isopropylmalate dehydratase Leu2 0.94 0.61 0.61 0.10 
SPBC19F5.04 aspartate kinase (predicted) 0.89 0.35 0.77 0.10 
SPBC776.03 
homoserine dehydrogenase 
(predicted) 1.09 1.46 1.28 3.01 
SPBPB2B2.05 peptidase family C26 protein 1.57 1.54 3.80 5.73 
SPCC70.03c 
proline dehydrogenase Put1 
(predicted) 0.84 0.24 0.90 0.36 
trx1 cytosolic thioredoxin Trx1 1.02 1.10 1.51 6.99 
Chromatin organization 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
ams2 
cell cycle regulated GATA-type 
transcription factor Ams2 1.20 1.62 1.54 4.09 
asa1 Astra associated protein 1 Asa1 0.78 0.50 0.64 0.29 
SPBC582.04c RNAi protein, Dsh1 0.72 0.29 0.72 0.28 
swc3 Swr1 complex subunit Swc3 1.12 1.28 1.52 2.93 
swd3 WD repeat protein Swd3 0.81 0.42 0.73 0.26 
tel2 
Tel2/Rad-5/Clk-2 family protein 
Tel2 0.72 0.32 0.86 0.58 
Cofactor metabolic process 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
coq3 
hexaprenyldihydroxybenzoate 
methyltransferase Coq3 1.44 1.73 2.15 3.15 
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pdx1 
pyruvate dehydrogenase protein x 
component, Pdx1 (predicted) 0.95 0.81 0.69 0.29 
SPAC806.06c 
nicotinamide mononucleotide 
(NMN) adenylyltransferase 
(predicted) 2.21 4.15 2.02 6.54 
SPBC1709.19c 
mitochondrial iron-sulfur cluster 
assembly protein Nfu1 (predicted) 0.82 0.48 0.70 0.23 
SPBC4B4.01c 
fumble family pantothenate kinase 
(predicted) 1.39 2.38 1.44 2.85 
SPBC947.15c 
mitochondrial NADH 
dehydrogenase (ubiquinone) Nde1 
(predicted) 1.14 1.56 1.71 10.56 
Cytoplasmic translation 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
dph2 
diphthamide biosynthesis protein 
(predicted) 0.91 0.78 0.69 0.28 
hri2 eIF2 alpha kinase Hri1 0.96 0.87 1.42 4.06 
psi1 DNAJ domain protein Psi1 1.07 1.24 2.60 7.32 
SPBC3B9.01 
Hsp70 nucleotide exchange factor 
Fes1 (predicted) 1.33 2.59 2.74 4.35 
tif212 
translation initiation factor eIF2 beta 
subunit (predicted) 1.31 3.53 0.99 0.94 
Detoxification 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
glo1 glyoxalase I 1.27 2.44 1.83 4.86 
SPAC869.02c nitric oxide dioxygenase Yhb1 0.55 0.11 1.12 1.37 
DNA-templated transcription 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
nut2 mediator complex subunit Med10 0.84 0.58 0.69 0.33 
rad24 14-3-3 protein Rad24 1.19 1.68 1.49 3.55 
rpc53 
DNA-directed RNA polymerase III 
complex subunit Rpc53 (predicted) 0.74 0.50 0.70 0.33 
rrn3 
ribosomal DNA (rDNA) 
transcription factor Rrn3 0.90 0.66 0.66 0.17 
SPBC2G5.02c 
CK2 family regulatory subunit 
Ckb2 (predicted) 0.91 0.60 0.76 0.22 
SPBC83.17 
transcriptional coactivator, 
multiprotein bridging factor Mbf1 
(predicted) 1.28 2.34 1.51 3.78 
SPCC548.05c ubiquitin-protein ligase E3 Dbl5 0.36 0.27 0.37 0.26 
DNA recombination 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
mcp7 
meiosis specific coiled-coil protein 
Mcp7 0.83 0.60 0.64 0.19 
rec10 
meiotic recombination protein 
Rec10 0.54 0.32 0.87 0.75 
Tf2-1 
(NC_003424 
1465326.14702
52) 
retrotransposable 
element/transposon Tf2-type 2.58 2.90 1.70 1.60 
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DNA repair 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
lub1 WD repeat protein Lub1 0.98 0.91 1.47 2.97 
msh6 MutS protein homolog 1.18 1.61 1.49 5.18 
nse4 
Smc5-6 complex non-SMC delta-
kleisin subunit Nse4 0.90 0.70 0.71 0.35 
nth1 DNA endonuclease III 0.89 0.71 0.70 0.34 
pnk1 DNA kinase/phosphatase Pnk1 0.95 0.85 0.76 0.34 
pso2 DNA 5' exonuclease (predicted) 0.70 0.39 0.67 0.26 
rik1 silencing protein Rik1 5.07 3.52 3.65 2.61 
SPBC23E6.02 
ATP-dependent DNA helicase, 
ubiquitin-protein ligase E3 
(predicted) 2.45 4.46 1.39 1.69 
tdp1 
tyrosyl-DNA phosphodiesterase 
Tdp1 0.74 0.34 0.93 0.83 
tra2 
NuA4 complex phosphatidylinositol 
pseudokinase complex subunit Tra2 0.80 0.34 0.88 0.64 
DNA replication 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
cdc23 MCM-associated protein Mcm10 0.52 0.33 0.50 0.26 
cdt2 WD repeat protein Cdt2 1.38 1.97 1.78 4.01 
dna2 
DNA replication endonuclease-
helicase Dna2 0.81 0.39 0.80 0.25 
Establishment or maintenance of cell polarity 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
paa1 
protein phosphatase regulatory 
subunit Paa1 1.19 2.41 1.38 4.45 
tea3 cell end marker Tea3 0.84 0.38 0.77 0.19 
Generation of precursor metabolites and energy 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
cob cytochrome b, Cob1 (predicted) 0.89 0.61 0.65 0.25 
cox1 cytochrome c oxidase 1 (predicted) 0.97 0.92 0.66 0.35 
idp1 
isocitrate dehydrogenase Idp1 
(predicted) 0.81 0.64 1.35 4.33 
SPBC660.16 
phosphogluconate dehydrogenase, 
decarboxylating 1.15 1.98 1.80 4.88 
SPCC1620.08 
succinate-CoA ligase beta subunit 
Lsc2 (predicted) 0.82 0.32 1.15 1.81 
Intergenic RNA 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
SPNCRNA.1115 
intergenic RNA (predicted), 
possible alternative UTR 1.12 1.40 1.37 3.04 
SPNCRNA.1164 intergenic RNA (predicted) 1.76 3.34 1.13 1.24 
SPNCRNA.1297 
intergenic RNA (predicted), 
possible alternative UTR 0.80 0.67 0.31 0.16 
SPNCRNA.1325 
intergenic RNA (predicted), 
possible alternative UTR 2.28 2.05 3.05 2.93 
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SPNCRNA.1474 intergenic RNA (predicted) 0.50 0.60 0.40 0.35 
SPNCRNA.1657 
intergenic RNA (predicted), 
possible alternative UTR 2.14 2.96 0.62 0.54 
SPNCRNA.1673 intergenic RNA (predicted) 2.05 3.19 0.84 0.83 
SPNCRNA.671 intergenic RNA (predicted) 1.00 1.00 0.53 0.29 
SPNCRNA.672 intergenic RNA (predicted) 2.24 3.23 1.26 1.52 
SPNCRNA.737 intergenic RNA (predicted) 1.14 1.08 0.49 0.34 
SPNCRNA.781 intergenic RNA (predicted) 1.63 2.69 0.48 0.30 
SPNCRNA.877 intergenic RNA (predicted) 2.05 1.94 2.98 3.26 
SPNCRNA.935 
intergenic RNA (predicted), 
possible alternative UTR 1.06 1.16 0.70 0.19 
SPNCRNA.968 
intergenic RNA (predicted), 
possible alternative UTR 1.13 1.28 0.62 0.35 
Lipid metabolic process 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
aim22 lipoate-protein ligase A (predicted) 0.74 0.34 0.72 0.31 
erg10 
acetyl-CoA C-acetyltransferase 
Erg10 (predicted) 1.39 3.93 1.47 4.34 
plg7 
phospholipase A2, PAF family 
homolog 1.02 1.10 1.36 3.89 
SPAC4A8.10 acylglycerol lipase (predicted) 0.77 0.43 0.64 0.31 
SPAC977.09c phospholipase (predicted) 1.14 1.33 2.92 10.71 
SPBC36.10 
mitochondrial intermembrane space 
protein; involved in phospholipid 
metabolism Ups2 (predicted) 0.97 0.93 0.68 0.35 
SPCC5E4.05c 
mitochondrial acylglycerol lipase 
Mgl1 (predicted) 1.28 2.36 1.48 3.69 
Microtubule cytoskeleton organization 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
sad1 
spindle pole body SUN domain 
protein Sad1 1.07 1.26 1.32 3.30 
Mitochondrion organization 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
exo5 
mitochondrial single stranded DNA 
specific 5'-3' exodeoxyribonuclease 
Exo5 (predicted) 0.54 0.33 0.71 0.50 
mdj1 
mitochondrial DNAJ domain 
protein Mdj1 (predicted) 1.11 1.32 1.62 3.01 
phb1 prohibitin Phb1 (predicted) 0.97 0.89 1.23 2.94 
SPCC1442.05c 
MICOS complex subunit Mic26/27 
(predicted) 1.25 1.81 1.40 3.72 
SPCC4B3.03c 
CBS domain protein implicated in 
magnesium homeostasis (predicted) 0.85 0.46 0.77 0.33 
Mitotic cytokinesis 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
fim1 fimbrin 1.03 1.15 1.62 4.60 
mid2 medial ring protein Mid2 1.95 2.96 2.05 4.30 
rng2 IQGAP 0.75 0.49 0.80 0.33 
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Mitotic sister chromatid segregation 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
cnp3 
kinetochore protein, CENP-C 
ortholog Cnp3 0.89 0.71 0.57 0.28 
rpn2 
19S proteasome regulatory subunit 
Rpn2 (predicted) 1.04 1.34 1.31 5.02 
rpn7 
19S proteasome regulatory subunit 
Rpn7 1.01 1.06 1.25 3.78 
SPBC2G2.14 
mitotic centromere-SPB clustering 
protein Csi1 0.88 0.72 0.79 0.26 
ssl3 cohesin loading factor Ssl3 0.93 0.71 0.79 0.34 
mRNA metabolic process 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
cdc28 
ATP-dependent RNA helicase 
Cdc28 1.67 1.91 1.83 2.85 
cft2 
cleavage factor two 
Cft2/polyadenylation factor CPSF-
73 (predicted) 1.32 2.54 1.75 5.59 
cwf21 
complexed with Cdc5 protein 
Cwf21 0.88 0.64 0.72 0.35 
edc3 enhancer of mRNA decapping Edc3 0.74 0.25 0.98 0.93 
frg1 
FRG1 family protein, involved in 
mRNA splicing (predicted) 0.89 0.68 0.51 0.08 
mug161 
CwfJ family protein, splicing factor 
(predicted) 1.05 1.13 1.80 4.33 
prp10 
U2 snRNP-associated protein 
Sap155 0.82 0.35 0.92 0.61 
SPAC2C4.07c Dis3L2 0.87 0.75 0.09 0.04 
SPBC56F2.08c 
pumilio family RNA-binding 
protein Puf1 (predicted) 0.92 0.76 0.61 0.13 
Nucleobase-containing small molecule metabolic 
process 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
ade3 
phosphoribosylformylglycinamidine 
synthase Ade3 0.90 0.47 0.87 0.32 
adk1 adenylate kinase activity 2.53 3.19 2.73 2.73 
cdc22 
ribonucleoside reductase large 
subunit Cdc22 1.19 1.89 1.68 3.29 
SPACUNK4.15 
2',3'-cyclic-nucleotide 3'-
phosphodiesterase (predicted) 1.13 1.53 1.47 3.65 
SPBC839.16 
C1-5,6,7,8-tetrahydrofolate (THF) 
synthase, trifunctional enzyme Thf1 0.80 0.25 0.90 0.48 
suc22 
ribonucleotide reductase small 
subunit Suc22 1.10 3.72 1.12 1.87 
Nucleocytoplasmic transport 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
SPCC550.15c 
ribosome biogenesis protein Rei1 
(predicted) 0.93 0.71 0.80 0.12 
Other 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
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abp2 ARS binding protein Abp2 0.97 0.95 0.54 0.30 
cnt6 
centaurin ADOP ribosylation factor 
GTPase activating protein family 
(predicted) 0.76 0.31 0.76 0.25 
meu31 
Schizosaccharomyces specific 
protein Meu31 1.08 1.12 0.39 0.31 
mug74 
Schizosaccharomyces specific 
protein Mug74 4.02 3.53 1.91 2.14 
ppr3 
mitochondrial PPR repeat protein 
Ppr3 0.82 0.49 0.74 0.34 
ppr5 
mitochondrial PPR repeat protein 
Ppr5 0.76 0.46 0.70 0.32 
slt1 
Schizosaccharomyces specific 
protein Slt1 1.05 1.15 2.47 4.87 
SPAC11E3.12 
mitochondrial thioredoxin family 
protein 1.27 1.87 1.42 4.05 
SPAC17G6.15c 
MTC tricarboxylate transmembrane 
transporter Fsf1 (predicted) 0.99 0.96 0.77 0.35 
SPAC22A12.06c serine hydrolase-like 0.69 0.61 0.36 0.16 
SPAC22A12.14c 
BSD domain protein, unknown 
biological role 1.39 2.02 1.63 3.71 
SPAC22A12.17c 
short chain dehydrogenase 
(predicted) 1.25 3.23 1.75 12.70 
SPAC27D7.09c But2 family protein 1.24 1.18 5.12 3.15 
SPAC27E2.11c 
Schizosaccharomyces specific 
protein 2.00 3.49 1.82 3.57 
SPAC2E1P3.05
c 
fungal cellulose binding domain 
protein 0.90 0.68 1.85 8.22 
SPAC30C2.03 
Schizosaccharomyces specific 
protein 1.25 1.18 2.80 4.45 
SPAC513.02 phosphoglycerate mutase family 0.58 0.69 5.34 3.46 
SPAC513.07 
flavonol reductase/cinnamoyl-CoA 
reductase family 1.00 1.00 1.66 3.13 
SPAC750.05c 
S. pombe specific 5Tm protein 
family 1.25 1.23 4.26 3.91 
SPAC750.06c 
S. pombe specific DUF999 protein 
family 4 1.56 1.59 2.44 3.77 
SPAC7D4.05 hydrolase (predicted) 0.88 0.76 0.68 0.27 
SPAC977.15 dienelactone hydrolase family 0.78 0.68 1.83 3.03 
SPAPB18E9.05
c 
Schizosaccharomyces pombe 
specific protein 0.61 0.34 1.11 1.33 
SPAPB2B4.07 
ubiquitin family protein, human 
UBTD1 homolog 0.73 0.43 0.60 0.31 
SPBC216.01c 
protein phosphatase PP4 complex 
regulatory subunit 3 Psy2 
(predicted) 0.85 0.35 0.81 0.34 
SPBC21B10.08c 
antibiotic biosynthesis 
monooxygenase-like domain 
(predicted) 1.11 1.59 1.86 4.38 
SPBC21C3.19 
SBDS family protein Rtc3 
(predicted) 1.02 1.04 1.87 3.13 
SPBC29A10.17 
Schizosaccharomyces specific 
protein 0.77 0.27 0.82 0.37 
SPBC30D10.14 dienelactone hydrolase family 1.09 1.20 2.71 4.76 
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(predicted) 
SPBC3B8.06 conserved fungal protein 1.17 1.78 1.33 2.91 
SPBC651.04 
Schizosaccharomyces specific 
protein 0.99 0.97 1.50 4.80 
SPBC8E4.05c 
fumarate lyase superfamily, 
bacterial 3-carboxy-cis,cis-
muconate cycloisomerase related 1.02 1.02 1.86 3.98 
SPBP8B7.32 dubious 1.22 1.45 0.54 0.20 
SPBPB21E7.08 Unassigned 1.07 1.08 2.95 4.70 
SPBPB2B2.08 conserved fungal protein 1.42 1.10 7.42 3.20 
SPCC1235.01 
Schizosaccharomyces specific 
protein 0.94 0.82 1.94 3.70 
SPCC1322.09 conserved fungal protein 1.06 1.30 1.36 3.77 
SPCC1682.08c 
pumilio family RNA-binding 
protein Mcp2 0.83 0.54 0.64 0.33 
SPCC569.03 mug2/mug135/meu2 family 0.95 0.86 1.87 5.54 
SPCC663.09c 
short chain dehydrogenase 
(predicted) 1.06 1.26 1.67 4.04 
SPNCRNA.1436 
box H/ACA small nucleolar RNA 
snR95 1.16 2.92 1.02 1.10 
vps901 
guanyl-nucleotide exchange factor 
Vps902 0.99 0.93 0.85 0.28 
Protein catabolic process 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
bip1 ER heat shock protein BiP 1.10 2.21 1.40 5.70 
cdc48 
AAA family ATPase involved in 
ubiquitin-mediated protein 
degradation Cdc48 1.10 2.11 1.81 5.03 
fub2 
PI31 proteasome regulator Fub2 
(predicted) 0.86 0.47 0.78 0.24 
nta1 
protein N-terminal amidase Nta1 
(predicted) 0.34 0.25 0.83 0.75 
rpt1 
19S proteasome regulatory subunit 
Rpt1 (predicted) 1.15 1.99 1.34 3.78 
rpt3 
19S proteasome regulatory subunit 
Rpt3 (predicted) 1.14 1.61 1.42 3.89 
rpt6 
19S proteasome regulatory subunit 
Rpt6 (predicted) 1.00 0.97 1.23 3.37 
ubp15 
ubiquitin C-terminal hydrolase 
Ubp15 1.08 1.19 1.62 3.24 
Protein complex assembly 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
SPCC18.17c 
proteasome assembly chaperone 
(predicted) 0.77 0.36 0.66 0.24 
Protein folding 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
cct5 
chaperonin-containing T-complex 
epsilon subunit Cct5 1.50 1.76 2.13 3.20 
cdc37 Hsp90 co-chaperone Cdc37 0.95 0.95 2.04 3.73 
cnx1 calnexin Cnx1 1.18 1.85 1.58 3.28 
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hsp90 Hsp90 chaperone 1.64 2.58 2.29 6.48 
mcp60 
mitochondrial heat shock protein 
Hsp60/Mcp60 1.40 2.02 1.67 3.17 
SPBC16D10.08
c heat shock protein Hsp104 1.60 2.85 3.96 5.18 
SPBC1711.08 chaperone activator Aha1 1.63 3.50 2.20 7.46 
SPBC4F6.17c 
mitochondrial heatshock protein 
Hsp78 (predicted) 1.21 2.01 2.69 10.07 
ssa1 heat shock protein Ssa1 (predicted) 1.36 1.84 3.08 5.16 
ssa2 heat shock protein Ssa2 1.63 2.13 2.88 4.96 
ssc1 
mitochondrial heat shock protein 
Hsp70 1.38 2.34 1.88 5.15 
sti1 chaperone activator Sti1 (predicted) 1.46 2.51 2.78 5.34 
wos2 
p23 homolog, predicted co-
chaperone Wos2 1.22 1.62 1.74 3.15 
Protein glycosylation 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
gma12 
alpha-1,2-galactosyltransferase 
Gma12 1.05 1.16 0.78 0.30 
Protein maturation 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
grx5 monothiol glutaredoxin Grx5 0.85 0.57 0.73 0.32 
SPAC2G11.05c 
BRO1 domain protein Rim20 
(predicted) 0.80 0.68 0.64 0.35 
Protein modification by small protein conjugation or 
removal 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
ubc4 
ubiquitin conjugating enzyme E2 
Ubc4/UbcP1 1.44 2.98 1.14 1.39 
ulp2 
SUMO deconjugating cysteine 
peptidase Ulp2 (predicted) 0.80 0.34 0.74 0.23 
Protein targeting 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
kap109 karyopherin Kap109 0.98 0.94 1.30 3.38 
qcr1 
mitochondrial processing peptidase 
(MPP) complex beta subunit Mas1 
(predicted) 0.85 0.25 1.08 1.39 
SPAC19D5.02c 
peroxisomal membrane protein 
Pex22 (predicted) 2.56 31.96 1.01 1.03 
tim21 
TIM23 translocase complex subunit 
Tim21 (predicted) 1.19 1.96 1.39 6.63 
tlh2 RecQ type DNA helicase Tlh1 1.18 1.16 0.21 0.29 
Regulation of mitotic cell cycle phase transition 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
wee1 
M phase inhibitor protein kinase 
Wee1 0.60 0.35 0.74 0.47 
Ribosome biogenesis 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
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fib1 fibrillarin, rRNA methyltransferase 2.70 2.59 2.40 3.06 
mrm2 
mitochondrial 2' O-ribose 
methyltransferase Mrm2 (predicted) 2.48 3.22 1.30 1.29 
SPAPB8E5.07c 
rRNA processing protein Rrp12 
(predicted) 0.92 0.56 0.66 0.08 
SPBC13G1.09 
bystin family U3 and U14 snoRNA 
associated protein Enp1 (predicted) 0.88 0.41 0.65 0.05 
SPBP8B7.10c 
U3 snoRNP-associated protein 
Utp16 (predicted) 0.86 0.71 0.61 0.33 
SPCC830.09c 
RNase P and RNase MRP subunit 
(predicted) 1.00 0.99 0.75 0.27 
SPCP1E11.08 
ribosome biogenesis protein Nsa2 
(predicted) 1.06 1.32 0.73 0.33 
utp20 
U3 snoRNP protein Utp20 
(predicted) 0.89 0.40 0.78 0.11 
Signaling 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
efc25 
Ras1 guanyl-nucleotide exchange 
factor Efc25 0.81 0.83 0.64 0.34 
gap1 GTPase activating protein Gap1 0.90 0.75 0.61 0.12 
ncs1 
neuronal calcium sensor related 
protein Ncs1 0.59 0.20 0.67 0.35 
ptc2 protein phosphatase 2C Ptc2 0.97 0.85 0.77 0.24 
ric1 
Ypt/Rab-specific guanyl-nucleotide 
exchange factor (GEF) subunit Ric1 0.53 0.23 1.26 1.28 
snoRNA metabolic process 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
cid14 
TRAMP complex poly(A) 
polymerase subunit Cid14 0.89 0.58 0.74 0.26 
Telomere organization 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
ssb1 
DNA replication factor A subunit 
Ssb1 1.09 1.64 1.48 6.48 
tcg1 
single-stranded telomeric binding 
protein Tgc1 1.30 2.34 1.76 3.60 
Transmembrane transport 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
amt2 
ammonium transmembrane 
transporter Amt2 0.98 0.94 0.78 0.25 
atp2 F1-ATPase beta subunit Atp2 0.97 0.55 1.29 4.29 
cch1 calcium ion channel Cch1 0.86 0.53 0.83 0.30 
mrs2 
magnesium ion transmembrane 
transporter Mrs2 (predicted) 0.82 0.53 0.66 0.29 
per1 
plasma membrane amino acid 
permease Per1 0.73 0.50 0.63 0.31 
SPAC12G12.07
c conserved fungal protein 1.20 3.03 1.42 4.71 
SPAC23H3.12c 
mitochondrial hydrogen/potassium 
transport system protein (predicted) 0.75 0.58 0.58 0.25 
SPAC24H6.11c sulfate transmembrane transporter 0.86 0.64 0.68 0.30 
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(predicted) 
SPAC30D11.06
c 
Lazarus1 family transmembrane 
transporter 0.76 0.56 0.64 0.34 
SPAC323.07c 
MatE family transmembrane 
transporter (predicted) 0.74 0.58 0.58 0.24 
SPAC328.09 
mitochondrial 2-oxoadipate and 2-
oxoglutarate transmembrane 
transporter (predicted) 0.79 0.44 0.68 0.26 
SPBPB2B2.01 
amino acid transmembrane 
transporter (predicted) 0.78 0.73 2.44 2.92 
SPCC1235.11 
mitochondrial pyruvate 
transmembrane transporter subunit 
Mpc1 (predicted) 0.73 0.50 0.54 0.21 
SPCC320.08 
transmembrane transporter 
(predicted) 1.03 1.13 0.73 0.31 
SPCC4B3.13 
MatE family transmembrane 
transporter (predicted) 1.12 1.44 1.51 3.52 
SPCC965.11c 
amino acid transmembrane 
transporter (predicted) 0.81 0.70 0.69 0.29 
str1 
siderophore-iron transmembrane 
transporter Str1 1.09 1.16 2.41 4.77 
vma6 
V-type ATPase V0 subunit d 
(predicted) 0.84 0.30 0.94 0.66 
tRNA metabolic process 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
pgp1 
mitochondrial metallopeptidase, 
tRNA N6-threonyl-carbamoyl-
adenosine (t6A), a modification 
protein Pgp1 0.65 0.34 0.66 0.38 
SPBC16A3.06 
tRNA specific adenosine-37 
deaminase Tad1 (predicted) 1.57 2.35 1.74 3.30 
SPCC63.07 
tRNA guanylyltransferase Thg1 
(predicted) 1.53 2.94 1.28 2.11 
vrs2 
mitochondrial valine-tRNA ligase 
Vrs2/Vas2 0.77 0.33 0.84 0.47 
Vesicle-mediated transport 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
chc1 
clathrin heavy chain Chc1 
(predicted) 0.91 0.61 1.24 5.08 
cog1 
Golgi transport complex subunit 
Cog1 (predicted) 0.77 0.29 0.91 0.48 
end4 
Huntingtin-interacting protein 
homolog 0.92 0.57 1.15 3.07 
sec26 coatomer beta subunit (predicted) 1.08 1.43 1.29 3.39 
SPBC18H10.20
c 
arrestin-related endocytic adaptor 
Any1 1.00 1.02 0.74 0.15 
SPBC4.03c 
COPII-coated vesicle component 
Sfb3 (predicted) 1.19 1.73 1.32 2.83 
SPBPJ4664.04 
coatomer alpha subunit Cop1 
(predicted) 1.03 1.34 1.22 7.41 
SPCC18.15 
WD repeat protein, involved in 
diphthamide biosynthesis Dph7 
(predicted) 1.87 1.74 2.60 6.65 
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SPCC970.06 COP II adaptor Erv29 (predicted) 1.18 2.36 1.23 3.33 
Vitamin metabolic process 
Fold 
change 
in Δcid1 
Effect 
change 
in Δcid1 
Fold 
change in 
Δdis3L2 
Effect 
change in 
Δdis3L2 
SPCC4G3.16 
CMP deaminase family/ 
methyltransferase bifunctional 
enzyme involved in riboflavin 
biosynthesis and tRNA 
pseudouridine biosynthesis Rib2 
(predicted) 0.63 0.30 0.66 0.30 
 
Table B3: Genes up-regulated at least 1.8-fold in the S. pombe ∆cid1 deletion strain 
compared to wildtype S. pombe. 
Gene  Protein name Fold up in Δcid1 
SPAC19D5.02c peroxisomal membrane protein Pex22 5.00 
rps1101 40S ribosomal protein S11  2.57 
SPBC23E6.02 ATP-dependent DNA helicase 2.16 
SPNCRNA.636 antisense RNA (predicted) 2.10 
SPAC806.06c 
nicotinamide mononucleotide (NMN) 
adenylyltransferase 
2.05 
erg10 acetylCoA Cacetyltransferase Erg10 1.97 
suc22 ribonucleotide reductase small subunit Suc22 1.90 
tif212 translation initiation factor eIF2 beta subunit 1.82 
mug74 sequence orphan; with a role in meiosis  1.82 
rik1 
Silencing protein Rik1, component of the 
rik1-associated E3 ubiquitin ligase complex  
1.82 
SPBC1711.08 chaperone activator Aha1 1.81 
SPAC27E2.11c sequence orphan 1.80 
 
Table B4: Genes down-regulated at least 1.8-fold in the S. pombe ∆cid1 deletion 
strain compared to wildtype S. pombe. 
Gene  Protein name 
Fold Down in 
Δcid1 
SPAC869.02c nitric oxide dioxygenase Yhb1 3.15 
ncs1 neuronal calcium sensor related protein Ncs1 2.30 
ric1 
Ypt/Rabspecific guanylnucleotide exchange 
factor (GEF) subunit Ric1 2.13 
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SPCC70.03c proline dehydrogenase  2.04 
SPNCRNA.1548 SPBC336.13c-antisense-1 2.03 
nta1 protein Nterminal amidase Nta1  2.02 
qcr1 
mitochondrial processing peptidase (MPP) 
complex beta subunit Mas1 2.02 
SPBC839.16 
C15,6,7,8tetrahydrofolate (THF) synthase, 
trifunctional enzyme Thf1 2.01 
edc3 enhancer of mRNA decapping Edc3 2.00 
SPNCRNA.1212 antisense RNA (predicted) 1.97 
SPBC1683.04 glycosyl hydrolase family 3 1.93 
SPCC548.05c ubiquitinprotein ligase E3 Dbl5 1.88 
SPBC29A10.17 Schizosaccharomyces specific protein 1.86 
 
Table B5: Genes down-regulated at least 1.8-fold in the S. pombe ∆dis3L2 deletion 
strain compared to wildtype S. pombe. 
Gene Protein name 
Fold Down in 
Δdis3L2 
SPBC13G1.09 
bystin family U3 and U14 snoRNA 
associated protein Enp1 4.29 
frg1 
FRG1 family protein, involved in mRNA 
splicing  3.63 
SPAPB8E5.07c rRNA processing protein Rrp12 3.63 
leu2 3-isopropylmalate dehydratase Leu2 3.31 
SPBC19F5.04 aspartate kinase  3.30 
utp20 U3 snoRNP protein Utp20 3.16 
gpd2 glycerol-3-phosphate dehydrogenase Gpd2 3.10 
gap1 GTPase activating protein Gap1 3.08 
SPCC550.15c ribosome biogenesis protein Rei1 3.02 
SPNCRNA.1451  cdc28-antisense-1 RNA 2.93 
SPBC56F2.08c pumilio family RNA-binding protein Puf1  2.91 
SPNCRNA.1467 mdl1-antisense-1 RNA 2.86 
SPBC18H10.20c arrestin-related endocytic adaptor Any1 2.78 
adh4 alcohol dehydrogenase Adh4 2.68 
SPNCRNA.1138 antisense RNA (predicted) 2.64 
SPNCRNA.1297 
intergenic RNA (predicted), possible 
alternative UTR 2.64 
SPNCRNA.1548 SPBC336.13c-antisense-1 RNA 2.62 
SPAC22A12.06c serine hydrolase-like 2.61 
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rrn3 
ribosomal DNA (rDNA) transcription factor 
Rrn3 2.60 
SPNCRNA.935 
intergenic RNA (predicted), possible 
alternative UTR 2.41 
tea3 cell end marker Tea3 2.40 
mcp7 meiosis specific coiled-coil protein Mcp7 2.40 
arg1 acetylornithine aminotransferase 2.34 
SPBP8B7.32 Unassigned 2.34 
SPCC1235.11 
mitochondrial pyruvate transmembrane 
transporter subunit Mpc1 2.24 
SPNCRNA.1204 rsm1-antisense-1 RNA 2.21 
SPBC2G5.02c CK2 family regulatory subunit Ckb2 2.17 
SPNCRNA.579 ggc1-antisense-1 RNA 2.13 
ulp2 
SUMO deconjugating cysteine peptidase 
Ulp2 2.12 
SPCC306.06c ER membrane protein, BIG1 family 2.11 
SPBC1709.19c 
mitochondrial iron-sulfur cluster assembly 
protein Nfu1 2.10 
fub2 PI31 proteasome regulator Fub2 2.09 
SPAC323.07c MatE family transmembrane transporter 2.07 
ptc2 protein phosphatase 2C Ptc2 2.05 
SPCC18.17c proteasome assembly chaperone 2.04 
SPNCRNA.606 isp3-antisense-1 RNA 2.01 
amt2 ammonium transmembrane transporter Amt2 2.00 
cob cytochrome b 2.00 
cnt6 
centaurin ADOP ribosylation factor GTPase 
activating protein family 2.00 
dna2 
DNA replication endonuclease-helicase 
Dna2 1.98 
SPAC23H3.12c 
mitochondrial hydrogen/potassium transport 
system protein  1.98 
cid14 
TRAMP complex poly(A) polymerase 
subunit Cid14 1.97 
SPAC328.09 
mitochondrial 2-oxoadipate and 2-
oxoglutarate transmembrane transporter 1.96 
SPBC2G2.14 
mitotic centromere-SPB clustering protein 
Csi1 1.95 
SPCC548.05c ubiquitin-protein ligase E3 Dbl5 1.95 
swd3 WD repeat protein Swd3 1.93 
pso2 DNA 5' exonuclease  1.92 
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cdc23 MCM-associated protein Mcm10 1.92 
SPCC830.09c RNase P and RNase MRP subunit  1.90 
SPAC7D4.05 hydrolase  1.88 
vps901 guanyl-nucleotide exchange factor Vps902 1.86 
SPBC2G2.17c beta-glucosidase Psu2 1.85 
cnp3 kinetochore protein, CENP-C ortholog Cnp3 1.84 
SPBC582.04c RNAi protein, Dsh1 1.83 
dph2 diphthamide biosynthesis protein 1.82 
 
Table B6: Genes up-regulated at least 1.8-fold in the S. pombe ∆dis3L2 deletion 
strain compared to wildtype S. pombe. 
 Fold up in 
Δdis3L2 Heat shock proteins/chaperones 
SPBC4F6.17c mitochondrial heatshock protein Hsp78 3.33 
SPBC1711.08 chaperone activator Aha1 2.90 
psi1 DNAJ domain protein Psi1 2.87 
tim21 TIM23 translocase complex subunit Tim21 2.73 
hsp90 Hsp90 chaperone 2.70 
bip1 ER heat shock protein BiP 2.51 
SPCC569.03 mug2/mug135/meu2 family 2.47 
sti1 chaperone activator Sti1  2.42 
SPBC16D10.08c heat shock protein Hsp104 2.37 
ssa1 heat shock protein Ssa1 2.37 
ssc1 mitochondrial heat shock protein Hsp70 2.36 
ssa2 heat shock protein Ssa2 2.31 
cdc37 Hsp90 co-chaperone Cdc37 1.90 
SPBC3B9.01 Hsp70 nucleotide exchange factor Fes1 2.12 
    
Metabolism Fold change 
SPAC22A12.17c short chain dehydrogenase 3.67 
SPAC977.09c phospholipase 3.42 
SPBC947.15c 
mitochondrial NADH dehydrogenase 
(ubiquinone) Nde1 3.40 
gal1 galactokinase Gal1 3.09 
SPAC2E1P3.05c fungal cellulose binding domain protein 3.04 
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gdh1 NADP-specific glutamate dehydrogenase Gdh1 2.82 
SPCC18.15 
WD repeat protein, involved in diphthamide 
biosynthesis Dph7 2.73 
SPAC806.06c 
nicotinamide mononucleotide (NMN) 
adenylyltransferase  2.71 
gal10 
UDP-glucose 4-epimerase/aldose 1-epimerase 
Gal10 2.60 
SPACUNK4.16c alpha,alpha-trehalose-phosphate synthase 2.40 
SPBC660.16 
phosphogluconate dehydrogenase, 
decarboxylating 2.29 
glo1 glyoxalase I 2.28 
SPBC30D10.14 dienelactone hydrolase family 2.25 
pgi1 glucose-6-phosphate isomerase 2.25 
SPCC1322.04  UTP-glucose-1-phosphate uridylyltransferase 2.22 
SPAC26F1.07 glucose 1-dehydrogenase (NADP+)  2.21 
SPBC21B10.08c 
antibiotic biosynthesis monooxygenase-like 
domain 2.13 
erg10 acetyl-CoA C-acetyltransferase Erg10 2.12 
idp1 isocitrate dehydrogenase Idp1 2.11 
atp2 F1-ATPase beta subunit Atp2 2.10 
tps1 
alpha,alpha-trehalose-phosphate synthase 
[UDP-forming] 2.03 
SPCC663.09c short chain dehydrogenase (predicted) 2.02 
SPBC8E4.05c 
fumarate lyase superfamily, bacterial 3-
carboxy-cis,cis-muconate cycloisomerase 
related 1.99 
plg7 phospholipase A2, PAF family homolog 1.96 
SPBC32F12.10 phosphoglucomutase 1.91 
SPCC5E4.05c mitochondrial acylglycerol lipase Mgl1 1.88 
SPACUNK4.15 2',3'-cyclic-nucleotide 3'-phosphodiesterase 1.87 
gal7 galactose-1-phosphate uridylyltransferase Gal7 1.81 
    
Oxidative Stress Fold change 
trx1 cytosolic thioredoxin Trx1 2.81 
SPAC11E3.12 mitochondrial thioredoxin family protein 2.02 
    
Protein degradation Fold change 
cdc48 
AAA family ATPase involved in ubiquitin-
mediated protein degradation Cdc48 2.33 
rpn2 19S proteasome regulatory subunit Rpn2  2.33 
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rpt3 19S proteasome regulatory subunit Rpt3  1.96 
rpt1 19S proteasome regulatory subunit Rpt1 1.92 
rpn7 19S proteasome regulatory subunit Rpn7 1.92 
    
Vesicles Fold change 
SPBPJ4664.04 coatomer alpha subunit Cop1 (predicted) 2.89 
chc1 clathrin heavy chain Chc1 2.35 
    
Antisense RNA Fold change 
SPNCRNA.1036 wis2-antisense-1 RNA 3.89 
SPNCRNA.1447 uds1- antisense RNA 3.10 
SPNCRNA.1626 antisense RNA 2.84 
    
Cell cycle Fold change 
ssb1 DNA replication factor A subunit Ssb1 2.69 
cft2 
cleavage factor two Cft2/polyadenylation factor 
CPSF-73  2.48 
msh6 MutS protein homolog 2.37 
SPBC651.04 Schizosaccharomyces specific protein 2.26 
paa1 protein phosphatase regulatory subunit Paa1 2.15 
mid2 medial ring protein Mid2 2.11 
ams2 
cell cycle regulated GATA-type transcription 
factor Ams2 2.03 
cdt2 WD repeat protein Cdt2 2.00 
tcg1 single-stranded telomeric binding protein Tgc1 1.85 
rad24 14-3-3 protein Rad24 1.83 
    
Cytoskeleton Fold change 
myo1 myosin type I 2.61 
arp2 ARP2/3 actin-organizing complex subunit Arp2 2.50 
fim1 fimbrin 2.20 
adf1 actin depolymerizing factor, cofilin 1.92 
arp3 
Arp2/3 protein complex, actin-like protein 
subunit Arp3 1.91 
    
Other Fold change 
SPBPB2B2.05 peptidase family C26 protein 2.52 
slt1 Schizosaccharomyces specific protein Slt1 2.28 
 
154 
 
str1 
siderophore-iron transmembrane transporter 
Str1 2.25 
SPAC12G12.07c conserved fungal protein 2.24 
SPBPB21E7.08 Unassigned 2.23 
SPAC30C2.03 Schizosaccharomyces specific protein 2.15 
mug161 CwfJ family protein, splicing factor 2.11 
hri2 eIF2 alpha kinase Hri2  2.02 
SPAC750.05c S. pombe specific 5Tm protein family 1.97 
SPBC83.17 
transcriptional coactivator, multiprotein 
bridging factor Mbf1 1.92 
SPAC750.06c S. pombe specific DUF999 protein family 4 1.92 
SPCC1322.09 conserved fungal protein 1.91 
SPCC1442.05c MICOS complex subunit Mic26/27 1.90 
SPAC22A12.14c BSD domain protein, unknown biological role 1.89 
SPCC1235.01 Unassigned 1.89 
SPAC27E2.11c Schizosaccharomyces specific protein 1.84 
SPCC4B3.13 MatE family transmembrane transporter 1.81 
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Figure B1: Colour map of gene expression changes between wildtype S. pombe and 
Δcid1 or Δdis3L2 strains. 
Rank-ordered false colour map showing the fold-change in gene expression (relative to 
the WT strain) for all genes identified as differentially expressed in either Δcid1 or 
Δdis3L2 strains. An effect size cut off of 1.5 was applied to identify differentially 
expressed genes in each mutant strain. 
cid1 disL32 cid1 disL32 cid1 disL32 cid1 disL32
SPRRNA.42 cft2 SPCC1620.08 SPNCRNA.967
SPRRNA.45 SPBC16A3.06 ubc4 nut2
SPRRNA.43 wos2 SPNCRNA.1164 SPCC965.11c
SPRRNA.46 SPNCRNA.636 suc22 dph2
SPRRNA.44 SPNCRNA.1447 SPAC869.02c SPAC328.09
SPBPB2B2.08 SPBC947.15c SPAPB18E9.05c SPBC36.10
SPAC513.02 Tf2-1 rps1101 SPAC24H6.11c
SPAC27D7.09c cdc22 qcr1 SPAC7D4.05
SPNCRNA.706 rps2 SPBPJ4664.02 SPNCRNA.949
SPAC750.05c mcp60 omh5 pso2
SPBC16D10.08c gal7 SPNCRNA.1436 ncs1
SPBPB2B2.05 SPCC663.09c SPAC19D5.02c cox1
gal1 SPAC513.07 SPNCRNA.1212 rrn3
rik1 SPNCRNA.1132 tif212 mrs2
ssa1 SPAC22A12.14c edc3 SPCC4G3.16
SPNCRNA.1325 ubp15 vma6 pgp1
SPNCRNA.877 fim1 tdp1 SPCC18.17c
SPBPB21E7.08 mdj1 prp10 SPAPB8E5.07c
SPAC977.09c cnx1 cog1 cob
ssa2 ams2 SPBC839.16 SPBC13G1.09
SPNCRNA.1563 SPAC637.13c SPCC70.03c SPAC2G11.05c
SPAC30C2.03 swc3 tra2 SPCC1682.08c
sti1 SPBC83.17 mal1 efc25
tps1 trx1 rec10 SPAC4A8.10
SPBC3B9.01 SPCC4B3.13 ade3 asa1
adk1 SPBC651.04 arg11 mcp7
SPBC30D10.14 rad24 tel2 SPAC30D11.06c
SPBC4F6.17c msh6 vps901 per1
SPNCRNA.1626 ssb1 vrs2 gpd2
gal10 SPCC5E4.05c SPNCRNA.1673 SPNCRNA.968
tdh1 SPACUNK4.15 nta1 SPNCRNA.1657
SPCC18.15 lub1 cch1 SPNCRNA.1451
psi1 erg10 arg1 SPBC56F2.08c
slt1 SPBC4B4.01c SPBC29A10.17 SPBP8B7.10c
SPACUNK4.16c SPAC11E3.12 SPCC306.06c leu2
SPBPB2B2.01 SPAC12G12.07c SPBC216.01c gap1
SPAC750.06c hri2 dna2 SPAPB2B4.07
str1 rpt3 SPCC550.15c SPNCRNA.1467
fib1 SPNCRNA.1665 rng2 SPAC23H3.12c
SPAC26F1.07 bip1 SPBC2G2.14 SPAC323.07c
hsp90 SPCC1442.05c ssl3 cnp3
SPNCRNA.1036 SPBC23E6.02 fub2 abp2
SPCC1322.04 tim21 gma12 SPBP8B7.32
SPBC1711.08 paa1 amt2 SPCC1235.11
coq3 SPNCRNA.1115 utp20 SPNCRNA.671
rpp101 SPCC1322.09 ptc2 frg1
cct5 plg7 SPAC17G6.15c SPNCRNA.579
mid2 idp1 SPCC4B3.03c cdc23
cdc37 gdh1 tea3 SPNCRNA.737
SPAC806.06c rpt1 SPBC19F5.04 SPNCRNA.886
SPCC1235.01 adf1 SPBC2G5.02c SPNCRNA.781
SPBC32F12.10 myo1 pnk1 adh4
mug74 SPBC3B8.06 cnt6 SPNCRNA.1474
ssc1 SPBC4.03c SPCC830.09c meu31
SPBC21C3.19 sad1 ulp2 SPNCRNA.1204
pgi1 rpn2 wee1 SPCC548.05c
SPCC569.03 mrm2 cid14 SPAC22A12.06c
SPBC21B10.08c kap109 SPBC18H10.20c SPNCRNA.606
SPBC8E4.05c atp2 ppr3 SPBC2G2.17c
SPAC2E1P3.05c sec26 SPCC320.08 SPNCRNA.1297
glo1 SPCC63.07 SPCP1E11.08 SPNCRNA.1548
arp3 SPBC776.03 swd3 tlh2
SPAC977.15 arp2 grx5 SPNCRNA.1138
cdc28 SPNCRNA.672 aim22 SPAC2C4.07c
SPNCRNA.1235 ric1 cwf21
SPAC27E2.11c rpn7 SPBC582.04c
cdc48 chc1 nse4
dak1 SPNCRNA.1170 exo5
mug161 SPCC970.06 ppr5
SPBC660.16 rpt6 SPBC1709.19c
SPNCRNA.857 phb1 SPNCRNA.935
cdt2 SPBPJ4664.04 rpc53
tcg1 SPBC1683.04 nth1
SPAC22A12.17c end4 pdx1
4 -4
Log2 Fold-Change
cid1   dis3L2 cid1   dis3L2 cid1   dis3L2 cid1   dis3L2 
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Figure B2: Search tool for the retrieval of interacting genes/proteins (STRING) 
diagram of RNAs with altered expression levels in cid1 and dis3L2 deletion strains 
compared to wildtype. 
Expression of genes encoding respective proteins displayed are down-regulated more 
than 1.5-fold. The diagram was generated using the STRING database. Functional 
associations between proteins are shown, with confidence of the proposed association 
denoted by line thickness. A) RNAs up-regulated in a Δcid1 strain compared to wildtype 
S. pombe cells. B) RNAs down-regulated in a Δcid1 strain compared to wildtype S. 
pombe cells. C) RNAs down-regulated in a Δdis3L2 strain compared to wildtype S. 
pombe cells. No significant functional enrichments were detected. 
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